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Abstract 
Atypical Chemokine Receptor 3 (ACKR3) is a seven-transmembrane spanning receptor 
with pleiotropic functions in development, homeostasis and pathophysiology. The 
spatiotemporal expression of ACKR3 is tightly regulated, a fact that highlights its 
importance in several biological processes. ACKR3, similar to the other atypical 
chemokine receptors, does not signal through G proteins. ACKR3 exerts its functions by 
a) recruiting the β arrestins and b) scavenging its ligands thus shaping their 
concentration in the extracellular milieu. 
ACKR3 expression is often dysregulated in pathophysiological conditions, including 
cancer. There is a growing body of evidence that implicates ACKR3 in certain types of 
human cancers. 
In the present study, we interrogated publicly available databases of cancer patients in 
order to assess ACKR3 expression in different types of human cancers. These analyses 
revealed that ACKR3 is upregulated in several types of human cancers, including lung 
cancer. To this end, we investigated the role of ACKR3 in cancer progression with a 
particular focus on lung cancer. 
In order to overcome the lack of specific ACKR3 antibodies, we used a GFP fluorescent 
reporter mouse to assess ACKR3 expression in the different stromal cell populations in 
the lung. Our approach revealed that ACKR3 is expressed in the fibroblasts, blood and 
lymphatic endothelial cells in the resting lung. Furthermore, in this study, we tried to 
address the discrepancies in the literature about  ACKR3 expression that is a result of 
the nonspecific nature of commercially available antibodies. More specifically, we tested 
commercially available flow cytometry anti-ACKR3 antibodies in the GFP/ACKR3 
reporter mouse. Our approach revealed that both of the ACKR3 antibodies that were 
tested were inefficient in staining but also nonspecific in all the cell populations that were 
tested. 
Subsequently, we employed the CRISPR/Cas9 genome editing technologies to generate 
ACKR3 null cancer cell lines that we used subsequently in vivo in different mouse 
models. Our study identified ACKR3 as a positive regulator in lung cancer progression. 
Furthermore, ACKR3 was also identified as a crucial player at the early steps of 
metastasis and colonisation of metastatic circulating tumour cells in the lung. 
Collectively our data suggest that ACKR3 is a promising candidate for drug targeting in 
certain types of human lung cancer.   
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1.1 Inflammation and cancer  
  
   
Inflammation is a complex biological response and one of the essential mechanisms 
of the immune response of our body against microbial and viral infections but also 
against specific injuries. Inflammation can be classified as acute or chronic.    
 
Acute inflammation is a rapid response that occurs within minutes or hours after injury 
or infection. It is a non-specific first line of defence and includes processes such as 
the recruitment of white blood cells at the inflamed site. Some of the common 
symptoms of acute inflammation include redness, swelling, increased temperature 
and pain, which are the result of increased blood flow in the inflamed tissue. Acute 
inflammation is characterised by two phases: initiation and resolution. Initially, the first 
cells attracted to a site of injury or infection are neutrophils, followed by eosinophils,  
monocytes and macrophages. These cells belong to the white blood cells, commonly 
named as leukocytes and are recruited to the inflamed site following chemotactic 
gradients in a process that is called chemotaxis1,2.   
 
During the initiation phase, “patrolling” polymorphonuclear neutrophils which are 
abundant in the blood circulation, migrate to the area of infection or injury, attracted 
by pro-inflammatory mediators such as leukotrienes and chemokines. Neutrophils 
leave the blood circulation and enter the inflamed tissues in a multistep process that 
involves rolling activation, firm adhesion, and extravasation to the inflamed tissue. 
Neutrophils are phagocytes, and they can engulf and digest harmful foreign particles, 
bacteria, and dead cells.    
 
Subsequently, during the resolution phase, circulating blood monocytes are attracted 
to the site of inflammation and infiltrate the inflamed tissue. There, they differentiate 
into macrophages or dendritic cells that act as phagocytes engulfing pathogens but 
also apoptotic cells, thus signalling the resolution phase of inflammation3.     
Acute inflammation resolution is a prerequisite for tissue repair and homeostasis 
restoration, and is achieved through apoptosis and clearance of the cell debris and 
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immune cells. Acute inflammation is a short-term process that lasts a few days, and 
it is usually self-resolving. However, in some cases, it can progress to unresolved 
chronic inflammation contributing to a variety of chronic inflammatory diseases.  
Chronic inflammation, unlike acute inflammation, is the aberrant and persistent 
inflammation. Chronic inflammation is also characterised by the simultaneous 
destruction and repair of the tissue due to the prolonged inflammatory 
microenvironment4,5.   
 
The first observation that linked inflammation and cancer is placed back in the 19th 
century when Rudolf Virchow noticed the presence of leukocytes within tumours. He 
introduced the hypothesis that the sites of chronic inflammation are the sites of origin 
for cancer. Despite this, only over the last two decades, cancer inflammation and 
tumour immune microenvironment have become the intense subject of study. The 
tumour immune microenvironment includes macrophages, neutrophils, mast cells, 
myeloid-derived suppressor cells, dendritic cells, natural killer cells, T and B 
lymphocytes. Besides the inflammatory cells, the tumour microenvironment is rich in 
pro-inflammatory cytokines and chemokines that can be secreted by tumour cells 
themselves but also from tumour- associated leukocytes, fibroblasts and other 
stromal cells. This network of inflammatory cells and pro-inflammatory mediators can 
contribute to the tumour progression6.  
 
It is now generally accepted that prolonged inflammation is linked with DNA damage, 
which can lead to the development of cancer. Inflammatory cells such as leukocytes 
can induce DNA damage in cells, through the production and release of reactive 
oxygen and nitrogen species that are typically produced by these cells to fight 
infections. In chronic inflammatory conditions, repeated tissue damage and 
regeneration of tissue lead to a highly proliferative epithelium. In these proliferative 
epithelial cells, the highly reactive nitrogen and oxygen species can oxidise the DNA, 
resulting in permanent genomic alterations such as point mutations, deletions, or 
genomic rearrangements7. One observation that supports the positive correlation 
between chronic inflammation and cancer is the fact that the frequency of mutations 
in the p53 tumour suppressor gene (TP53) in tumours, is observed at similar rates in 
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chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel 
disease8.  
 
The study of particular subsets of human inflammatory diseases has brought an 
invaluable insight into the correlation between inflammation and cancer. 
Epidemiological and clinical studies have revealed that chronic inflammation that can 
be caused by infections, autoimmune diseases or irritants is associated with 15%- 
20% of human cancers. Some examples of chronic inflammation-associated cancers 
include Helicobacter pylori infections in the gastric mucosa that are linked with 
lymphoid tissue lymphoma, Hepatitis B or C infections that can lead to hepatocellular 
carcinoma (HCC) and inflammatory bowel disease that is associated with colorectal 
cancer (CRC)9.  
 
1.1.1 Inflammatory cells  
   
One of the most crucial and well-organised mechanisms of inflammation includes the 
recruitment of white blood cells to the inflamed site. The essential subsets of white 
blood cells (also known as leukocytes) that play a crucial role in cancer inflammatory 
responses are briefly introduced below. 
 
Neutrophils   
Neutrophils are the most abundant leukocyte population in the circulation and are 
considered to be the first line of defence mechanism after infection or injury. 
Neutrophils exhibit high mobility; they have a short life span and are densely packed 
with secretory granules. Neutrophils are produced in the bone marrow and 
differentiate from hematopoietic stem cells to common myeloid progenitor cells to 
lineage-committed progenitors that subsequently mature into neutrophils10. 
 
Neutrophils have three mechanisms to kill microbes: phagocytosis, degranulation 
and neutrophil extracellular trap (NET) formation. Neutrophils are considered 
phagocytes because of their ability to engulf and digest harmful foreign particles, 
bacteria, and dead cells. Neutrophils are also referred to as granulocytes because 
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they have characteristic granules in their cytoplasm.  Molecules that are stored in 
certain types of these intracellular granules have antimicrobial properties and can 
regulate the rapid and accurate response to infections. Other granule proteins 
regulate adhesion, transendothelial migration, phagocytosis, and neutrophil 
extracellular trap (NET) formation. Neutrophils can modify their chromatin to trap and 
kill microbes. These structures are called NETs.  NETs are large, extracellular, 
structures composed of cytosolic and granule proteins that are assembled on a 
skeleton of chromatin. The use of modified chromatin as a host defence mechanism 
is evolutionarily conserved and appears in many organisms, including plants11.  
 
Neutrophils are ‘’patrolling’’ leukocytes in the blood circulation, and they are recruited 
to sites of inflammation responding to chemokine gradients. The most critical 
chemokine responsible for their recruitment is CXCL8, as neutrophils express the 
CXCL8-binding receptors CXCR1 and CXCR212.  
 
Dendritic cells   
Dendritic cells (DCs) are central players of the immune system, and they hold a key 
role linking innate and adaptive immunity. Dendritic cells are phagocytes and their 
role is to “screen” for pathogen at the tissues in which they reside. DCs utilise pattern 
recognition receptors (PRRs) to engage pathogen-associated molecular patterns 
(PAMPs). PAMPS can be nucleic acids of viral or bacterial pathogens or elements of 
the viral envelope or the bacterial cell wall. Upon recognition of a pathogen, DCs 
sequester the encountered pathogen through endocytosis or micropinocytosis, and 
the pathogen is processed and presented in the form of peptides on MHC class I and 
MHC class II  complexes on their surfaces to activate naïve T cells. The antigen 
presentation and T cell activation take place in the lymph nodes. To present antigens 
to naive T cells, dendritic cells migrate from inflamed or injured peripheral tissues to 
the closest draining lymph nodes through lymphatic vessels. More specifically, 
antigens that are presented on the MHC class I complex activate CD8+ cytotoxic T 
cells, while antigens presented  on the MHC class II complex activate CD4+ helper T 
cells. Antigen presentation process is the bridge between innate and adaptive 
immunity13. 
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Dendritic cell migration to lymph nodes   
During embryonic development, DC progenitors (pre-DCs) reside in the skin, the 
inner lining of the nose, lungs, stomach, intestines and other organs and give rise to 
immature DCs that act as sentinels of the immune system. DCs get activated and 
mature when they interact with pathogens. This activation leads to an increase in the 
expression of the CCR7 that is accompanied by increased mobility. CCR7 that is 
expressed on the surface of migrating DCs interacts with its ligand CCL21, which is 
constitutively produced by lymphatic vessels in peripheral tissues and directs the DCs 
into the lumen of afferent lymphatic vessels. Experiments with CCR7 knockout mouse 
models confirmed that CCR7 is essential for the migration of dendritic cells through 
the lymphatics to the lymph nodes. Following their entry to the afferent lymphatic 
vessels, DCs follow gradients of both CCL21/CCL19 to migrate into the lymph nodes 
although it has been shown that CCL21 alone is sufficient to drive their migration. 
When they reach the subcapsular sinus of lymph nodes, DCs following again a 
CCL21 gradient that leads to the lymph node paracortex (an area that is T- cell-rich), 
migrate and meet the naïve T cells to present the antigens and initiate the adaptative 
immune responses. ACKR4 is expressed by the lymphatic endothelial cells in the 
ceiling of the subcapsular sinus and shapes the CCL21 chemokine gradient guiding 
the DCs towards T cell-rich areas in the lymph node (also discussed in 1.10.3 
section)14,15,16. 
 
Macrophages   
Macrophages comprise a very heterogeneous cell population that plays a vital role in 
almost every biological function of an organism including development, homeostasis, 
tissue repair and immune responses to pathogens. Macrophages are specialised 
phagocytic cells and are characterised by high plasticity. Macrophages have distinct 
origins such as yolk sac, foetal liver and bone marrow. Inflammatory macrophages 
originate from bone marrow-derived monocytes. Tissue-resident macrophages can 
derive from yolk sac macrophages, foetal liver monocytes, or adult bone-marrow 
monocytes. Depending on the tissue in which they reside, macrophages can be 
categorised as alveolar macrophages (lung resident), Kupffer cells (liver resident), 
microglia (central nervous system resident), splenic macrophages (spleen resident), 
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peritoneal macrophages (peritoneal cavity resident) and osteoclasts (bone 
resident)17,18.    
 
Macrophages, as a response to extracellular signals, can be activated and adopt 
different functions in a process that is known as macrophage polarisation. Polarised 
macrophages can be classified as M1 (classically activated macrophages) and M2 
(alternatively activated macrophages). The classically activated M1 macrophages are 
aggressive against bacteria and produce high amounts of proinflammatory cytokines. 
The alternatively activated, anti-inflammatory M2 macrophages are involved in 
parasite control, tissue remodelling, immune regulation and also have tumour-
promoting properties19,20.  
 
T cells  
T cells are major components of the adaptive immune system. T lymphocytes 
originate from the bone marrow and they migrate to the thymus where, after 
maturation and selection, they enter the circulation. Peripheral T cells consist of 
different subsets, including naive T cells, memory T cells and regulatory T (Treg) 
cells. Memory T cells are essential for the maintenance of long-term immunity and 
regulatory T (Treg) cells for regulating immune responses. Regulatory T cells are 
critical immune suppressor cells. They play vital roles in the maintenance of 
peripheral immunological tolerance and preventing autoimmunity. Naive T cells 
circulate through the lymph nodes and peripheral tissues until they recognise 
antigens presented by antigen-presenting cells in the lymph nodes. Naïve T cells can 
be subdivided into helper T cells and cytotoxic T cells. Helper T cells express the 
CD4 protein on their surface. As indicated by their name, their main roles after they 
get activated, are to help B cells to secrete antibodies, to activate cytotoxic T cells, 
to kill target cells, but also to assist macrophages in destroying pathogens. There are 
different subsets of T helper cells, including Th1,Th2,Th9,Th17 and Th22. Helper T 
cells become activated when antigen-presenting cells present them with peptide 
antigens by MHC class II molecules. Cytotoxic T cells express CD8 protein on their 
surface and their primary  role is to kill virus-infected cells and malignant cells but 
they are also implicated in transplant rejection. Cytotoxic T cells become activated 
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when antigen-presenting cells present them with peptide antigens associated with 
MHC class I molecules21,22. 
 
T cell activation is a process that requires several signals. The first recognition signal 
includes antigen presentation where the T cell receptor (TCR) that is expressed on 
both CD4+ helper T cells and CD8+ cytotoxic T cells binds to the antigen-peptide that 
is  presented on the MHC complex, on the surface of the antigen presenting cells. 
Subsequently the CD4 and CD8 molecules bind to the MHC II and I molecules, 
stabilising the structure. The second signal for T cell activation occurs when the co-
stimulatory molecules CD80 and CD86, that are expressed on the surface of the 
antigen-presenting cells, bind to CD28 that is present on the T cell surface. This 
binding event induces the release of different cytokines from the T cell and promotes 
the proliferation and clonal expansion of T cells. The T cell subsets are distinguished 
by the cytokines that they release upon activation. CD8 cytotoxic T cells require a 
third cytokine signal produced by macrophages or dendritic cells, to get activated and 
elicit immune responses. CD8+ T cells that do not receive a third signal in addition to 
signal 1 and signal 2 fail to develop the cytotoxic function and become unresponsive. 
Recent studies identified  IL-12, type I IFN (IFNα/β) and possibly IL-21 as the major 
sources of signal 3 in a variety of responses, and are now considered to be the signal 
3 in T cell activation23,24. 
 
Natural Killer cells   
Natural Killers (NK) cells are large lymphocytes, derived from bone marrow. NK cells 
are mostly in the blood circulation, and they comprise of about 10% of human 
circulating lymphocytes. Apart from the blood circulation, NK cells can reside in 
organs such as the spleen, lung, lymph nodes, liver, and thymus. The role of NK cells 
is to recognise and kill virally infected cells, but also, they are responsible for tumour 
surveillance as they can recognise and kill malignant cells. The NK cells in the blood 
circulation, are usually inactive and they get activated by cytokines. In contrast to T 
cells, NK cells do not express clonotypic receptors. However, they initiate strong anti-
tumour cytotoxicity and generate significant quantities of pro-inflammatory cytokines. 
The absence of  clonotypic receptors is substituted by multiple NK cell activation 
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receptors such as NKG2D, NCR1, NCR2, NCR3, NKG2C, CD244, Ly49D, and 
Ly49H. The expression of a combination of these  activation receptors that recognize 
self or pathogen-derived ligands provides NK cells with inherent, innate abilities to 
initiate effector immune responses25.  
 
After activation, NK cells infiltrate to pathogen-infected or malignant tissues, to kill the 
infected cells or tumour cells depending on the pathophysiological context. 
Furthermore, during inflammation, NK cells enter the lymph nodes and can regulate 
the T cell immune response. NK cells can be activated by DCs in the lymph nodes 
and the spleen, and after activation, they secrete interferon γ, increasing the T cell -
mediated killing response. For instance, they can promote Th1 cells polarisation by 
releasing IFNγ. NK cells can also regulate T cells indirectly via modulation of antigen-
presenting cells. For example, the NK- dendritic cell crosstalk can stimulate the 
production of IFNγ from NK cells, which further promotes dendritic cells  activation. 
However, ΝΚ cells can, in some instances, restrict the expansion of activated T cell 
populations by directly killing them26. 
 
 
1.2 Cell migration     
Cell migration is a fundamental process in the development and maintenance of 
multicellular organisms. The main types of cellular migration are introduced below.  
 
Chemotaxis is the directed movement of cells in response to an extracellular chemical 
gradient27. Cell chemotaxis is a fundamental process in several physiological events 
such as leukocyte recruitment in inflamed tissues during immune responses and stem 
cells and specialised cell migration during development28. Although most of the 
chemotactic factors have dual roles in cell growth and survival, they can also mediate 
cytoskeletal rearrangements that result in chemotaxis29,30. Chemotaxis is also 
involved in pathophysiological conditions including autoimmune diseases and 
cancer, where metastatic tumour cells migrate through the blood circulation, and 
‘’colonise’’ distant secondary metastatic sites.  
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Eukaryotic cells can sense the presence of chemotactic stimuli in their 
microenvironment through seven-transmembrane spanning heterotrimeric G-protein-
coupled receptors (GPCRs), a class representing a significant portion of the 
genome31. The main classes of chemoattractants / chemotactic receptors are the 
following:  
   
• formyl peptides - formyl peptide receptors (FPR)  
• chemokines - chemokine receptors (CCR / CXCR)   
• leukotrienes - leukotriene receptors (LT)  
  
Haptotaxis is another type of cellular movement in which the cells move in a 
directional way in response to adhesive substrates such as the extracellular matrix 
(ECM). In haptotaxis, the gradient of the chemoattractant is expressed or is bound 
on a surface mostly commonly in the ECM. Haptotaxis is different from chemotaxis 
in which the chemoattractant gradient is in a soluble form. Finally, chemokinesis is 
the random, non-directional cellular movement in response to an external chemical 
stimulus32. 
 
1.3 Chemokine family    
 
The chemokine superfamily comprises of small (6-16 kDa) secreted proteins which 
play a fundamental role in a broad range of physiological processes including 
embryogenesis, haematopoiesis and immune system development. Initially, 
chemokines were mostly appreciated for their ability to orchestrate immune 
responses and maintain immune system homeostasis. Subsequently, chemokines 
were also linked to pathophysiological conditions like HIV infection, atherosclerosis, 
autoimmune diseases, cancer development and metastasis. Chemokines act as 
chemoattractants leading to directed migration of target cells towards increasing 
chemokine gradients33,34.   
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1.3.1 Evolution     
Chemokines and chemokine receptors arose in vertebrates. Chemokines and their 
receptors evolved rapidly through species-specific gene duplications that lead to the 
differences in chemokines between species. In the human genome,  the majority of 
the CC and CXC chemokine genes are located in two chromosomal regions, thus 
forming two large gene clusters, the CXC chemokines cluster (chromosome 4) and 
the CC chemokine cluster (chromosome 17). Apart from these two mega clusters, 
there are also mini clusters that consist of 2-3 chemokine genes and some 
chemokines genes that are not located in any gene cluster. This genomic 
organization of the chemokine genes is the result of evolutionary pressures and is 
linked to their functions (orchestrating the immune response, homeostatic 
regulation)35.  
 
Phylogenetic analyses indicate that only CXCL12 and CXCL14 have orthologues in 
fish. The remaining mammalian CXC chemokines do not have orthologues in any 
other vertebrate class. This supports the hypothesis that CXCL12 and CXCL14 
phylogenetically represent the most ancestral CXC chemokines. Furthermore, 
phylogenetic analyses revealed that one of the most evolutionarily conserved 
chemokine signalling axes is the CXCL12/CXCR4 axis, which has orthologs in 
vertebrate species ranging from fish to humans. Studies in zebrafish revealed that  
CXCL12 and CXCR4 are also crucial to the migration of primordial germ cells to the 
gonads. More specifically, it was shown that in Odysseus, a zebrafish homologue, 
CXCR4, is required for the chemotaxis of the germ cells and their proper spatial 
distribution. CXCR4 mutant germ cells were still able to migrate, but this migration 
lacked directionality towards the target tissue, resulting in randomly positioned germ 
cells. It was also shown that CXCL12, a ligand for CXCR4, was responsible for the 
germ cells proper migration and positioning in the tissue as CXCL12 mutant embryos 
phenocopied the CXCR4 null phenotype36. 
 
1.3.2 Nomenclature 
Previously, chemokines have been named arbitrarily, without following a defined 
system. Some chemokines were named according to their function (e.g. macrophage 
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chemotactic protein), others according to the cell type that produces the chemokine, 
(e.g. platelet factor 4), some were included in the interleukins (e. g. IL-8), and some 
were named using abbreviations (e.g. RANTES). To this end, there was an immediate 
need to agree on a universal and straightforward nomenclature system for 
chemokines. The systematic chemokine nomenclature system, names the 
chemokines according to the position of the cysteines in their structure, followed by 
a number that indicates the order in which the chemokine was discovered (e.g. 
CCL1). Chemokines exhibit a highly conserved primary structure regarding the 
position of their cysteine residues. Based on this primary characteristic, chemokines 
can be classified into four distinct subfamilies: CXC, CC, CX3C and XC (Figure 1.1). 
So far, in humans, there are more than 45 chemokines identified, that bind to 19 
chemokine receptors, triggering signalling cascades that generate various cellular 
responses such as chemotaxis, Ca+ influx, proliferation, cell adhesion and 
endocytosis (Figure 1.2). Although each receptor subtype typically binds multiple 
chemokines (redundancy), the specificity is restricted by chemokine subfamily in the 
inflammatory chemokine receptors37.   
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Figure 1.1 Chemokine subfamilies according to their cysteines’ residues 
position. Cysteine residues are linked by intramolecular disulfide bonds. The 
CX3C family members possess a transmembrane mucin-like domain. 
  
Functionally, chemokines can be classified into two distinct groups: homeostatic and 
inflammatory chemokines. Homeostatic chemokines such as CCL19, CCL20, 
CCL21, CCL25, CCL27, CXCL12 and CXCL13, are constitutively expressed and are 
responsible for the development and maintenance of the immune system. 
Inflammatory chemokines are inducible, in response to tissue damage or infection 
and play a crucial role in the inflammatory response, attracting immune cells to the 
site of inflammation38,39. Some examples of inflammatory chemokines are CXCL8, 
CCL2, CCL3, CCL4, CCL5, CCL11 and CXCL10.  
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1.3.3 Structure    
NMR and crystallography studies have revealed that chemokines (monomeric form) 
adopt the same folding architecture. Their generic structural pattern consists of a 
flexible disordered N-terminus, the ‘’signalling domain’’, followed by a structured core 
that consists of three-stranded antiparallel β-sheets, on which is folded a C-terminal 
α-helix. In chemokines, the highly conserved cysteine residues, form disulfide bridges 
that are crucial for maintaining the proper protein folding and structural integrity, which 
is essential for chemokine–receptor binding40. 
 
Chemokine monomers usually self-interact and usually form homodimers, but in 
some cases can also form tetramers and higher-order aggregates. CC chemokines 
dimerise through their N-terminal regions and they form a new antiparallel β-sheet. 
Instead CXC chemokines dimerise through their β-sheet regions. It has been reported 
that CXC chemokine dimers are active whereas CC chemokine dimers are not. This 
difference can be explained based on their different dimer structures. CXC 
chemokine dimerisation leaves the receptor-binding and activation regions exposed, 
whereas CC chemokine dimerisation involves the N-terminal region, which is crucial 
for receptor activation. Chemokine oligomerisation can be facilitated by interactions 
with glycosaminoglycans and can alter the chemokine functions. Chemokines bind to 
GAGs through high-order oligomer formation while chemokines bind and activate 
their respective receptors as monomers41.  
 
   
1.3.4 Interaction with GAGs    
Glycosaminoglycans (GAGs) are sulphated carbohydrates and their interactions with 
chemokines localise chemokines on and near cell surfaces and the extracellular 
matrix to provide direction to the cell movement. GAGs are present on endothelial 
cells and in the extracellular matrix. The interactions with GAGs can be crucial in 
many cases, for modulating chemokine functions such as leukocyte recruitment, 
chemokine oligomerisation, receptor binding and enhancement of stability 42,43.   
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The interactions between GAGs and chemokines can be predicted based on their 
structure since GAGs are acidic polysaccharides, and most chemokines are rich in 
basic amino acids like Lys, Arg and His. As a consequence, the acidic GAGs bind to 
basic residues within chemokines through electrostatic and H-bonding 
interactions44,45. 
One example of chemokine- GAGs interactions functions is Heparan Sulphate (HS). 
Heparan Sulphate is one of the most common GAGs and is present on the surface 
of endothelial cells. HS is an anionic GAG and part of the glycocalyx on the surface 
of the endothelial cells46. Experimental evidence of the importance of the interactions 
between chemokines and GAGs was provided  when chemokine mutants that were 
able to bind the chemokine receptors but failed to bind GAGs in vitro, failed to activate 
cell migration in vivo. This  paradigm highlights the importance of chemokine/GAG 
interactions for creating a chemokine gradient and modulating leukocyte migration 
and inflammatory responses47. 
 
 
1.4 Chemokine subfamilies  
   
1.4.1 CC chemokine subfamily  
The CC chemokines have as a common structural feature the presence of two 
adjacent cysteine residues located close to the N terminus. The CC chemokine 
subfamily contains at least 28 members, including CCL1- CCL28 chemokines. CC 
chemokines usually possess four cysteines, but a few of them possess six cysteine 
residues. CC chemokines bind to CCRs but also to members of the Atypical 
Chemokine Receptor (ACKR) family and more specifically to ACKR1, ACKR2 and 
ACKR4. Depending on their functions, CC chemokines can be characterised as 
allergenic, pro-inflammatory, developmental and homeostatic, but this 
characterisation is not exclusive as a chemokine can belong to more than one 
subgroup. The chemokines that belong to the allergenic and pro-inflammatory group 
are considered inducible, while the developmental and homeostatic are generally 
constitutively expressed48.  
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The allergenic subgroup includes the CCL1, CCL2, CCL7, CCL8, CCL11 and CCL13 
chemokines. They are potent eosinophil or basophil attractants and can lead to 
histamine release. CCL8-deficient mice exhibit markedly less eosinophilic 
inflammation than wildtype mice49. Members of the pro-inflammatory subgroup 
include CCL3, CCL4, CCL5, CCL6 and CCL18. CCL3, previously known as 
macrophage inflammatory protein (MIP) 1-α, is responsible for the recruitment of  
monocytes, macrophages, dendritic cells and both CD4+and CD8+ T cells during the 
acute immune response. Mice that are null for CC inflammatory chemokine receptors 
also exhibit defects in monocyte migration. For example the CCR5 and CCR2 
knockout mice appear to have a partial defect in macrophage function and exhibited 
a decreased Th1 immune response, as measured by a reduced production of Th1 
cytokines, such as IFN-γ50.   
 
CCL2, CCL7, CCL8 and CCL13 play a crucial role in the recruitment of monocytes to 
inflammatory sites. Finally, the subgroup of developmental and homeostatic CC 
chemokines includes the CCL17,CCL19,CCL20,CCL21,CCL22 and CCL25. CCL17 
is highly expressed in the thymus and shares similar roles with CCL22 as they both 
attract Th2 cells. CCL20 has been shown to recruit TH17 cells51. CCL19 and CCL21 
are produced constitutively by lymphoid tissues and organs and are responsible for 
the recruitment of mature dendritic cells and T cells in the lymph nodes for the antigen 
presentation process52.  
 
1.4.2 CX3C chemokine subfamily    
The CX3C subfamily consists of only one member: the CX3CL1 chemokine that has 
three amino acids between its first two cysteines. CX3CL1 binds specifically to its 
receptor CX3CR1. CX3CL1 is usually associated with cell membranes, via a mucin 
stalk linked to transmembrane and cytoplasmic domains. CX3CL1 is mostly present 
as a membrane-bound cytokine, but a soluble form (95 kDa) has also been detected. 
The soluble form acts as a potent chemoattractant for T cells and monocyte subsets.  
On the other hand, the membrane-bound form, that is detected in primary endothelial 
cells, promotes strong adhesion of leukocytes53,54 .  
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1.4.3 C chemokine subfamily    
The C chemokine subfamily members have only two cysteine residues, one N-
terminal cysteine and one cysteine downstream. This subfamily has only two 
members: XCL1 (lymphotactin-α) and XCL2 (lymphotactin-β), that are different from 
each other in two adjacent amino acids. XCL1 can induce the chemotaxis of 
lymphocytes but not monocytes or neutrophils, by binding to the receptor XCR155,56.   
 
1.4.4 CXC chemokine subfamily    
CXC chemokines display a plethora of effects regulating immunity, angiogenesis, and 
organ-specific metastasis in the context of cancer. The CXC chemokine subfamily 
consists of 17 members (CXCL1-CXCL17) which belong to the inflammatory 
chemokines, with the only exceptions being CXCL16, CXCL12 and CXCL13 that are 
homeostatic chemokines. The common characteristic of the CXC chemokines is that 
they have an amino acid between the first two cysteines. CXC chemokines are key 
players that can activate or inhibit angiogenesis through their interaction with cognate 
receptors that are expressed by endothelial cells. Regarding this, the CXC subfamily 
can be further divided into ELR+ and ELR- chemokines depending on the presence 
of an ELR (Glu-Leu-Arg) motif. ELR+ chemokines are considered angiogenic and 
mediate their angiogenic activity through binding and activating CXCR2 on the 
endothelium. ELR+ chemokines include the following members: CXCL1, CXCL2, 
CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8. ELR- chemokines include CXCL4, 
CXCL9, CXCL10, CXCL11 and CXCL17. ELR- chemokines in general, are inducible 
by interferon γ, are potent inhibitors of angiogenesis and (except CXCL17) bind to 
CXCR3 on the endothelium57.  
 
In wounding, CXC chemokines coordinate the interplay between  angiogenesis and 
inflammation, leading to tissue repair. At the wound site, platelets that are attracted, 
release vasoactive mediators that regulate the formation of the fibrin clot. 
Subsequently activated platelets release  CXCL1, CXCL5 and CXCL7 chemokines 
that initiate the recruitment of neutrophils. The cooperative expression of CXCL1 and 
CXCL8 in the superficial wound bed supports additional neutrophil recruitment to the 
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wound site. Neutrophils provide defence against contaminating microorganisms and 
they are involved in the phagocytosis of cell debris. CXCL8 secreted  by wounded 
epithelial cells induces massive angiogenesis, leading to the formation of new blood 
vessels that exhibit high CXCR2 expression. When the tissue repair is achieved, 
upregulation of the angiostatic chemokines CXCL9, CXCL10 and CXCL11 prevents 
unlimited vessel growth, arresting migration and growth of CXCR3+ proliferating 
endothelial cells58. 
 
CXCL12 is one of the most extensively studied chemokines. CXCL12 is a 
homeostatic chemokine and binds to CXCR4 and ACKR3. CXCL12 is constitutively 
expressed by stromal cells in the bone marrow, but during inflammation, CXCL12 can 
be secreted by most stromal cells, which leads to chemotaxis of lymphocytes towards 
the affected area. CXCL12 is also involved in the promotion of angiogenesis and the 
maintenance of tissues59.  
 
1.5 Chemokine Receptor Family   
 
Chemokine receptors belong to the superfamily of 7-transmembrane spanning G 
protein-coupled receptor (GPCRs).  They are usually around 350 amino acids long. 
They consist of a flexible extracellular N terminus that can be sulfated on tyrosine 
residues and contains N-linked glycosylation sites. The N terminus is essential for 
ligand binding. The N terminus is followed by a seven α-helical transmembrane region  
separated by three intracellular and three extracellular loops. Finally, there is a 
cytoplasmic C terminus responsible for G protein association and signalling cascade 
initiation. A disulfide bond links the highly conserved cysteines in extracellular loops 
one and two60.  Chemokine receptors are GPCRs that belong to the family of 
rhodopsin-like receptors, γ subgroup, chemokine receptor cluster. Genetically, these 
receptors are located in clusters on different chromosomes. This suggests a common 
ancestral origin which may have evolved through genome duplications61. Chemokine 
receptors are divided into “typical” and “atypical” chemokine receptors, based on their 
ability to elicit G protein-mediated responses. Furthermore, typical chemokine 
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receptors can be subcategorized based on the class of chemokines they bind: CCR 
bind CC chemokines, CXCR bind CXC chemokines, XCR1 binds XC chemokines, 
and CX3CR1 binds CX3CL1 chemokine.  Chemokine receptors follow the chemokine 
nomenclature and are named after the chemokines that they bind to. This has led to 
a logical chemokine receptor nomenclature system in which each receptor is 
designated by the chemokine subfamily name (C, CC, CXC, CX3C), followed by the 
letter R (stands for a receptor), and a number based on the chronological order in 
which the receptor was identified. So far, 45 chemokines and 19 chemokine receptors 
have been  identified in humans. The numerical mismatch between chemokines and 
receptors makes it apparent that ligand-receptor relationships are not always 
exclusive (more than one  chemokine can bind to one receptor and a single 
chemokine can bind to different receptors)  and in some cases responses can be 
elicited by as many as 10 individual ligands62. 
 
Chemokine receptors can be functionally characterised as either inflammatory or 
homeostatic. Constitutively expressed homeostatic chemokine receptors play a 
crucial role in developmental processes and basal leukocyte trafficking. Inflammatory 
chemokine receptors are characterised by inducible expression and their role is to 
orchestrate and fine-tune the immune response in acute but also chronic 
inflammatory conditions. Regarding this classification, the CXC chemokine receptors 
can be inflammatory (CXCR1-3) or homeostatic (CXCR4-6). CC chemokine 
receptors include ten members (CCR1-10). CCR1-5 are all associated with 
inflammation, although  CCR1,CCR2 and CCR5 are considered to be  the classical 
inflammatory receptors. The CC chemokine receptors are expressed on  immune 
cells including eosinophils, basophils, lymphocytes, macrophages, and dendritic 
cells, whereas the CXC receptors are expressed mainly on neutrophils and 
lymphocytes. CXCR1 and CXCR2 are expressed on neutrophils and are crucial as 
they regulate their migration of during inflammation63.  
 
CCR2 is expressed on a subset of inflammatory monocytes and plays an important 
role in their recruitment into the tissue. CCR6 is constitutively expressed on immature 
dendritic cells and in Th17 cells. CCR8 is constitutively expressed in the thymus and 
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is upregulated during T-cell activation and is a marker of TH2 cells. CCR7 is 
expressed in mature dendritic cells and T cells. Apart from leukocytes some 
chemokine receptors are upregulated in malignant cells. For example, CXCR4 is 
upregulated in tumour cells and drives metastasis to secondary sites that are rich in 
its ligand CXCL1264. 
 
The importance of the chemokine receptors in immune system regulation and 
development is highlighted by in vivo studies in which chemokine receptors or their 
respective ligands were ablated in animal models. For example, the deletion of 
CXCR4 or its ligand CXCL12 both result in a lethal embryonic phenotype65. Deletion 
of CCR7 or its ligand CCL21 results in mice that, although they are viable, lack the 
correct architecture of secondary lymphoid tissues66,67. Similarly, in mice deficient 
in CXCR5 the organization of primary splenic follicles is severely impaired68.  
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Figure 1.2  Schematic representation of the chemokine receptors and their 
respective chemokine ligands. Chemokines of the four subclasses (CCL, CXCL, 
CX 3 CL, and XCL) bind to more than one chemokine receptors(redundancy).  
 
  
  
 41 
1.6 Chemokine receptor signalling   
 
The typical chemokine receptors signal (but not exclusively) through G- proteins. In 
the cytoplasm, G proteins are protein complexes, that exist in trimeric form and 
consist of three different subunits Gα, Gβ and Gγ. They act as molecular switches 
and transmit signals from the surface of the cell downstream. 
G-proteins’ ability to transmit signals, lies in their ability to bind and hydrolyse 
guanosine triphosphate (GTP) to guanosine diphosphate (GDP). In their inactive 
state, G- proteins have GDP bound in their subunits. Upon binding of the chemokine, 
chemokine receptors associate with G-proteins, allowing the exchange of GDP for 
GTP. These events are followed by the dissociation of the three G protein subunits. 
The Gα subunit is responsible for the activation of an enzyme known as 
Phospholipase C (PLC) that is bound to the cell membrane. PLC cleaves 
Phosphatidylinositol (4,5)-bisphosphate (PIP2) to form two secondary messenger 
molecules called inositol triphosphate (IP3) and diacylglycerol (DAG). Subsequently, 
DAG activates another enzyme called protein kinase C (PKC), and inositol 1,4,5-
triphosphate (IP3) that triggers the release of calcium from intracellular stores. 
Calcium influx initiates many signalling cascades in the cell as a response to the 
original external stimuli69.  
 
1.7 Chemokines and receptors in diseases    
 
Chemokines and their respective receptors play a fundamental role in orchestrating 
the immune response in several inflammatory conditions that can be acute or chronic. 
The chemokine/ chemokine receptor involvement in some of the more significant 
inflammatory disorders is described below.  
   
1.7.1 Atherosclerosis     
Several studies have shown that CCL2 is highly expressed in atherosclerotic plaques, 
suggesting a role for monocyte extravasation in the formation of atherosclerotic 
plaques70. New evidence from studies using transgenic mice support this hypothesis. 
More specifically, CCL2/LDLR (low-density lipoprotein (LDL) receptor) double knock 
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out mice have significantly less lipid deposition than WT/LDLR mice in arteries 
following a high-fat diet71.  
 
Furthermore, CCR2 deficient mice that are also deficient in apolipoprotein E (double 
knock out mice) exhibited reduced atherosclerotic lesions compared to the control 
group after a high-fat diet72. These data strongly suggested that CCL2 is an essential 
player in the development of atherosclerotic plaques. Furthermore, monocyte subsets 
expressing CCR2 were increased in atherosclerotic lesions. This finding is consistent 
with the observation that hypercholesteraemic patients have elevated numbers of 
CCR2 positive monocytes73. Histological studies have also shown that activated T 
cells are present in atherosclerotic lesion development74.   
 
In the literature, several studies highlight the critical role of the CX3CL1/CX3CR1 axis 
in atherosclerosis. Two different mouse models of atherosclerosis support this role. 
More specifically, it has been shown that CX3CL1−/− ApoE−/− (Apolipoprotein E) 
mice exhibited decreased atherosclerotic lesion formation in the brachiocephalic 
artery but not the aortic root. In the second CX3CL1−/−LDLR−/− (low-density 
lipoprotein receptor) mouse model, atherosclerotic lesions were reduced both in the 
brachiocephalic artery and the aortic root75.   
 
In humans, it was found that two CX3CR1 polymorphisms and, more specifically, the 
V249I and T280M, were linked with coronary artery disease (CAD). The V249I 
polymorphism in CX3CR1, was associated with a lower risk of CAD. Another study 
revealed the cardioprotective effects of the T280M polymorphism in acute coronary 
syndromes76,77.   
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1.7.2 Human immunodeficiency virus (HIV)   
HIV can infect a variety of cells such as CD4+ helper T cells and macrophages that 
express the CD4 molecule on their surface. HIV-1 enters macrophages(M-tropic) and 
helper T cells(T-tropic) not only through the interaction of the viral envelope 
glycoproteins with the CD4 molecule but also with its chemokine co-receptors 
expressed on the surface of the target cells78.  
 
Maybe the most well-known paradigm and exciting discovery in the chemokine 
involvement in pathophysiology, is the involvement of CCR5 in HIV-1 infection. It was 
shown that M-tropic HIV-1 strains use both CD4 and CCR5 to infect the target cells. 
The HIV-1 envelope glycoprotein structure assists HIV-1 entry into the target cell. The 
HIV-1 envelope glycoprotein structure consists of two protein subunits: the gp120 
external subunit and the gp41 transmembrane subunit. CCR5 is the primary co-
receptor used by gp120 together with CD4 during HIV-1 infection. During HIV-1 
infection, gp120 binds both CD4 and CCR5 co-receptor in order for the viral/target 
cell membrane fusion to proceed. The tyrosine-sulphated amino terminus of CCR5 is 
crucial for binding to gp12079.  
 
In 1996, different research groups identified a 32-bp deletion(Δ32) of the CCR5 gene. 
This CCR5 deletion leads to a non-functional CCR5 receptor that degrades fast and 
does not support membrane fusion or infection by macrophage and dual tropic HIV-
1 strains. It is estimated that around one per cent of the population of northern Europe 
are homozygous for the CCR5Δ32 mutation and have no functional CCR5 receptor 
activity80. This deletion provides an advantage in certain diseases. Individuals that 
are homozygous for this mutation are resistant to infections by these HIV-1 strains. 
Furthermore, it has also been reported that CCR5Δ32 heterozygous HIV-positive 
individuals, take longer to develop acquired immunodeficiency syndrome (AIDS) 
symptoms81. Furthermore, this mutation provides protective effects in many 
inflammatory disorders. For example, CCR5Δ32 mutation seems to be protective 
against rheumatoid arthritis (RA), including extra-articular symptoms and joint 
erosions82.  
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However, in some cases, CCR5Δ32 is non-protective. More specifically,  CCR5Δ32 
carrier individuals are more susceptible to developing lethal encephalopathy after  
West Nile virus infection than  patients with wild-type CCR583. 
 
The knowledge of the mechanisms that HIV-1 uses to exploit CCR5 co-receptor to 
infect immune cells led to the development of CCR5 inhibitors. These CCR5 specific 
inhibitors can block HIV entry into the target cells. So far one CCR5 antagonist, 
Maraviroc, has been clinically approved in 2007 as an drug against HIV infections84.  
 
1.7.3 Psoriasis 
Immune-mediated inflammatory diseases (IMIDs), are a group of clinically unrelated 
disorders that are characterized by immune dysregulation and chronic non-resolving 
inflammation. IMIDs have been associated with cytokine dysregulation that is crucial 
for the pathophysiology of these diseases. There is evidence that leukocyte trafficking 
into peripherally inflamed tissues is altered in patients with IMIDs. Furthermore, 
genes associated with IMIDs are linked with leukocyte recruitment and migration85. 
Chemokines regulate the leukocyte migration into and out of tissues and play a vital 
role in the positioning of leukocytes within the inflamed site.  
 
High expression of members of the CC and CXC chemokine subfamilies has been 
associated with many inflammatory diseases including arthritis, psoriasis, multiple 
sclerosis and lung disorders. High expression of CXCL8 was detected in the 
epidermis of psoriatic patients86. A high number of neutrophils and T cells were also 
present in the epidermis of these patients. It was also shown, that CXCR1 and 
CXCR2 expression, was almost ten times higher in psoriatic epidermis compared to 
epidermis from healthy individuals87. These observations lead to the assumption that 
CXCL8 is responsible for the inflammatory phenotype observed in psoriatic 
epidermis. This inflammatory phenotype includes leukocyte infiltration,    increased 
HLA-DR (Human Leukocyte Antigen – DR isotype) expression in keratinocytes and 
epidermal hyperplasia88. Furthermore, psoriasis has been linked with T cell 
recruitment to the skin.  CCR6 and CCL20 are highly expressed in psoriasis. In 
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psoriatic lesions, keratinocytes express CCL20 and recruit CCR6 expressing Th17 
cells89. Keratinocytes in psoriasis also express CCL27 and attract T cells that 
express CCR1090. These paradigms indicate the vital role of chemokines and their 
receptors in the pathophysiology of this disease.  
 
 
1.7.4 Rheumatoid arthritis (RA)   
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by massive 
infiltration of synovial tissue and synovial fluid with immune cells, mediated by 
chemokines and adhesion molecules. It is well accepted that monocyte/macrophage 
numbers are increased in clinically affected joints and these numbers correlate with 
the clinical signs and symptoms. In RA, leukocytes extravasate through the vascular 
endothelium into the synovial tissue. Several chemokines and chemokines receptors 
are linked with this process. In rheumatoid arthritis, pro-inflammatory chemokines are 
present at high levels in the synovial tissue, resulting in accelerated inflammation. 
Chemokines are also involved in endothelial activation and angiogenesis, synovial 
fibroblast migration and proliferation91.  
 
Many CXCRs have been associated with the pathophysiology of rheumatoid arthritis. 
CXCR1 and CXCR2 are highly expressed by the neutrophils in the RA synovium and 
are associated with neutrophil recruitment to the inflamed joints. CXCR3 may be the 
most crucial receptor in leukocyte homing into the RA synovium and is associated 
with Th17 cell recruitment92. Among CC chemokine receptors, CCR1, CCR2, CCR3, 
CCR4, CCR5, CCR6, CCR7 and CCR10 are highly expressed in the synovium in RA. 
CCR6  is linked with Th1 cells infiltration. CCR1, CCR2 and CCR5 each bind multiple 
CC chemokines that have essential roles in the pathogenesis of RA93.  
 
Numerous antagonists to these receptors have been developed and tested in animal 
models. Data from in vivo studies have provided evidence about the role of 
chemokines in RA. In collagen-induced arthritis (CIA) mouse model study, CCR2 
knockout mice developed severe, aggressive CIA compared with wild-type mice. 
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Furthermore, it was shown that  when lethally irradiated wildtype mice received bone 
marrow transplants from CCR2 null mice, the transplanted mice developed CIA. In 
contrast, wildtype mice transplanted with wild-type bone marrow did not develop CIA. 
This supports the hypothesis that CCR2 expression in the hematopoietic 
compartment is a crucial element of CIA development94. In contrast, another study 
showed that CCR5 null mice developed CIA to the same level as wild-type mice95. 
Despite this,CCR5 is a promising candidate for drug targeting in RA. Pharmacological 
targeting of these receptors in clinical trials did not improve the clinical outcome in 
these diseases. There are several challenges in therapeutic targeting of chemokine 
receptors (discussed in section 1.9).  
  
 
1.8 Chemokines and cancer   
  
For a long time, chemokines, have been associated with cancer since they 
orchestrate the recruitment and spatial positioning of leukocyte subsets in tumours. 
It is also increasingly recognised that chemokines play an essential role in facilitating 
communication between cancer cells and non-malignant cells in the tumour 
microenvironment, including endothelial cells and fibroblasts, promoting the 
infiltration and activation of tumour-associated neutrophils (TANs) and tumour-
associated macrophages (TAMs). In the tumour microenvironment, chemokines are 
expressed and secreted from different cell types, including tumour cells, cancer-
associated fibroblasts (CAFs) endothelial cells, but also tumour-infiltrating 
leukocytes. Chemokines signal, through binding their respective chemokine 
receptors,  and mediate tumour proliferation, invasion, angiogenesis and immune 
evasion. Most tumours secrete chemokines that belong to the CXC or CC 
subfamilies. Usually, CXC chemokines are active on neutrophils and lymphocytes 
whereas CC chemokines act on several leukocyte subsets including monocytes, 
eosinophils, dendritic cells but also on lymphocytes and natural killer cells. The 
following synopsis summarises the most crucial processes that are regulated by 
chemokines within the tumour microenvironment96.     
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Leukocyte Recruitment   
Inflammation is one of the critical characteristics of the tumour microenvironment and 
one of the hallmarks of cancer97. Chemokines regulate immune cell attraction and 
infiltration within the tumour. It has been shown in several studies that inflammatory 
CC (CCL2, CCL5) and CXC (CXCL1, CXCL2, CXCL5, CXCL6, and CXCL8) 
chemokines are responsible for attracting to the tumour CCR2+ and CXCR2+ 
leukocytes. More specifically, it has been shown, that CC inflammatory chemokines 
that are secreted from the tumour, attract CCR2+ monocytes to the tumour. Those 
CCR2+ monocytes, after recruitment, infiltrate into the tumour and differentiate  into 
tumour-associated macrophages (TAMs). Correspondingly, CXC chemokines attract  
CXCR2+ neutrophils in the tumour that then subsequently transform into tumour-
associated neutrophils (TANs)98,99.    
 
Furthermore, other studies have shown that CCL21 and CCL19 attract CCR7+ 
dendritic cells but also regulatory T cells into tumours100. Also, CCL17 and CCL22 
attract CCR4+ Tregs and Th2 lymphocytes, that promote tumour growth101.CXCL9 
and CXCL10 can recruit NK cells, CD4+, Th1 and CD8+ cytotoxic lymphocytes, which 
can attack the tumour cells102,103.  
 
Metastasis   
Several studies have shown that cancer cells express chemokine receptors that can 
promote their metastasis and colonisation to secondary metastatic sites where there 
is a high concentration of their respective chemokine ligands104.   
 
 One appropriate paradigm of these receptors is CXCR4. CXCR4 is expressed in a 
variety of cancers. CXCR4 drives the metastasis of the cancer cells on which it is 
expressed, to secondary organs that produce and retain high concentrations of 
CXCL12105. In breast cancer metastasis, CXCL12 triggers recruitment of breast 
cancer cells to secondary sites (bone marrow, liver, lung and lymph nodes)  and this 
metastatic process can be inhibited by anti-CXCR4 antibodies.   
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One other paradigm of chemokine receptor involved in metastasis of cancer cells is 
CCR7, that drives cancer cells to lymph nodes where there are high concentrations 
of its ligands CCL19 and CCL21106. Furthermore, the CCR7 – CCL21 axis, regulates 
metastasis of tumour cells to the lymph nodes in many types of cancer including 
breast cancer, murine B16 melanoma, non-small cell lung cancer (NSCLC) and 
colorectal cancer107,108,109. In melanoma CCR10, and its ligand CCL27, are 
essential during metastasis as they increase the adhesion and survival of metastatic 
cancer cells110.    
 
Angiogenesis    
Angiogenesis is an essential process for the growth of tumours. Chemokines play a 
role in tumour-associated angiogenesis, and members of the CC and the CXC 
chemokine families have been shown to induce angiogenesis and tumour growth in 
the tumour microenvironment111.  
 
Members of the CXC chemokine family has been shown to play an essential role in 
different types of cancer, including lung, stomach, pancreas, prostate, colon and 
brain, among others. CXC chemokines that possess the three amino acids motif (Glu-
Leu-Arg) are ERL+ and are pro-angiogenic, whereas ELR− CXC chemokines are 
angiostatic. In human melanoma, the angiogenic chemokines, CXCL1, CXCL2, and 
CXCL3 are overexpressed. The chemokine receptor, CXCR2, is expressed in 
melanoma and is the receptor for these chemokines that mediates the angiogeneic 
response112. In lung cancer, the angiogenic CXC chemokines CXCL5 and CXCL8, 
play an essential role in cancer angiogenesis113. In pancreatic cancer, one study has 
shown that the CXC chemokines/CXCR2 axis promotes tumour angiogenesis both in 
vivo and in vitro114.    
 
Tumour growth and proliferation    
Chemokines, through binding to their receptors expressed in cancer cells, can 
activate signalling cascades that directly promote cancer cell proliferation such as 
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PI3K/Akt/NF-κB and MAPK/ERK pathways116,117.  Furthermore, they can promote 
the survival of cancer cells by preventing their apoptosis and regulating the 
equilibrium between apoptotic and antiapoptotic molecules118. In pancreatic 
carcinoma cells, CCL20 enhances the tumour growth of malignant cells and migration 
of TAMs that infiltrate the tumour119. In melanoma, inhibition of  CXCL1 or the 
CXCR2 receptor inhibits cell proliferation in vitro120.  
 
 
1.9 Pharmacological targeting of chemokine receptors    
 
Chemokine receptors belong to the G-protein-coupled receptor (GPCRs) 
superfamily. In the pharmaceutical industry, G-protein coupled receptors are the most 
frequently targeted of cell-membrane receptors, as they play a significant role in 
human pathophysiology. Even though they constitute only twelve percent of all 
human druggable targets, one-third of the small-molecule drugs on the market are 
designed to target them.  
 
Since 2007, two drugs targeting chemokine receptors have been clinically approved. 
More specifically, Maraviroc- a CCR5 inhibitor for preventing HIV infection and 
Mozobil (commercial name for Plerixafor) a CXCR4 inhibitor. Mozobil is used in the 
clinic to stimulate the release of hematopoietic stem cells from the bone marrow into 
the blood to stimulate the immune system in patients with non-Hodgkin lymphoma 
and multiple myeloma121.  
 
In the past, several pharmaceutical companies performed clinical trials for 
antagonists of chemokine receptors as antiretroviral agents and autoimmune and 
anti-inflammatory agents. Some clinical trial examples include CCR1 targeting for 
rheumatoid arthritis (Pfizer, CCR1 antagonist CP-481,715)122. Although this trial 
initially demonstrated promising results and entered the clinical phase II, eventually  
the  antagonist failed to demonstrate any signs of efficacy after six weeks of 
treatment. CCR1 targeting in multiple sclerosis had a similar outcome in the clinic 
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(Berlex  Laboratories, CCR1 antagonist BX471)123 . This clinical trial also entered 
phase II but was terminated after failing to provide any improvement in the clinical 
outcome of the patients.  
 
CCR2 was also a promising target for treating rheumatoid arthritis and multiple 
sclerosis (Merck,  CCR2 antagonist  MK-0812). The rheumatoid arthritis trial involved 
a 12-week protocol with 149 patients randomized to receive placebo treatment or 
MK-0812. MK-0812 failed to provide  any significant improvement for any of the end 
points studied and the trial was terminated early. Regarding the multiple sclerosis 
trial Merck removed the drug from its pipeline probably due to negative results, 
although they were never made publicly available124. 
 
Furthermore, CXCR3 was also a target for psoriasis treatment 
(ChemoCentryx/Amgen CXCR3 antagonist AMG-487).  Although the CXCR3 
antagonist showed positive results during clinical phase I and entered phase II, 
subsequently the trial was terminated due to lack of efficacy125. 
 
Despite all these efforts, all the clinical trials failed to provide a therapeutic benefit for 
the patients, and none of these antagonists were approved for clinical use. Several 
reasons could explain the clinical failures when targeting chemokine receptors. One 
reason is the fact that it is challenging to retain sufficient levels of drug/inhibitor in the 
plasma to efficiently inhibit the receptor target. Furthermore, clinical failure could be 
due to the differences between the immune system of humans versus animal models. 
Finally, several receptors may be involved in the pathophysiology of the disease, so 
pharmacological targeting one or two receptors is not sufficient to improve the clinical 
outcome of the disease.  
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1.10 Atypical Chemokine Receptors   
 
Atypical Chemokine Receptors belong to the chemokine receptor family, and they 
present many structural similarities. This chemokine receptor subfamily consists of at 
least four members: ACKR1, ACKR2, ACKR3 and ACKR4. These receptors, (except 
for ACKR1), although they exhibit high homology with several conventional 
chemokine receptors, are unable to initiate the classical signalling pathways upon 
ligand binding. These receptors, mostly serve as scavenger receptors that bind their 
respective chemokine ligands (Table 1) leading to their degradation, thus regulating 
the chemokine concentration in the local microenvironment126,127.   
 
 
RECEPTOR            LIGANDS       EXPRESSION  
ACKR1  CCL2, 5, 7, 11, 13, 14, 17,  
CXCL5 ,6, 8 ,11  
Erythrocytes,   
vascular endothelial cells,   
Purkinje cells  
ACKR2  CCL2, 3, 4, 5, 7, 8,  
11, 12, 13,14, 17, 18  
Lymphatic endothelial cells, 
leukocytes, keratinocytes, 
trophoblasts   
ACKR3  CXCL11, CXCL12, ADM,  
BAM22, MIF  
Hematopoietic cells, lymphatic 
endothelial cells, blood endothelial 
cells, mesenchymal cells and. 
neuronal cells   
ACKR4  CCL19, 21, 25  
 
Lymphatic endothelial cells and 
epithelial cells   
  
Table 1. Summary of ACKR ligands and their expression pattern in different cell 
types   
   
Regarding the aforementioned characteristics, in 2012, a committee of experts was 
formed in order to develop a new nomenclature/ classification for these receptors. 
They collectively agreed on the name Atypical Chemokine Receptors (ACKRs) that 
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is now approved by most of the scientific organisations and is used almost exclusively 
in the scientific literature128.  
 
All the ACKRs have alterations in the highly conserved DRYLAIV motif. This motif is 
located between the third transmembrane domain and the second intracellular loop 
and is the binding site of G proteins. Since the ACKRs exhibit altered DRYLAIV 
motifs, they fail to recruit and activate G proteins and subsequently trigger G protein-
dependent signalling pathways129.   
 
Although ACKRs were initially considered as non-signalling receptors, recently, 
evidence has emerged that members of the ACKR family  can signal through 
noncanonical pathways like β arrestins, mitogen-activated protein kinases (MAPKs) 
and heterodimerization with other signalling receptors130,131.  
 
1.10.1 ACKR1   
ACKR1 (previously named DARC), binds more than 20 inflammatory chemokines 
members of the CC and CXC subfamilies. It is expressed on endothelial cells and 
erythrocytes. During inflammation, ACKR1 binds chemokines with high affinity, thus 
regulating the concentration of bioavailable circulating chemokines132,133,134. In 
endothelial cells, ACKR1 has been linked with chemokine transcytosis by mediating 
the transportation of chemokine from the basal to the apical side of the endothelium. 
Furthermore, ACKR1 expression in endothelial cells has been linked to negative 
regulation of angiogenesis by scavenging the angiogenic ELR+ 
chemokines135,136,137.    
 
ACKR1 serves as a receptor for two human malarial parasites: Plasmodium vivax 
and Plasmodium knowlesi. These parasites use this receptor to invade erythrocytes. 
Some individuals belonging to certain ethnic groups (African, Yemenite Jews) exhibit 
resistance to malaria infections. These individuals carry natural polymorphisms that 
result in erythrocytes null for ACKR1138,139,140.  
 
 53 
Like all other ACKRs, ACKR1 lacks the typical DRYLAIV motif, so does not signal 
through G proteins. In contrast to other ACKRs, ACKR1 is not a constitutively 
internalising receptor, but it internalises only upon ligand binding. Another difference 
in this context, is that ACKR1, upon ligand binding and internalisation does not lead 
the ligand to degradation141.   
 
ACKR1 knock out mice, in acute and chronic inflammation models show reduced 
neutrophil recruitment. In atherogenesis models, ACKR1 KO mice exhibit a protective 
phenotype that is associated with reduced levels of inflammatory monocytes in the 
aorta142.  
 
1.10.2 ACKR2   
ACKR2 is one of the most well characterised of the atypical chemokine receptors 
(previously named D6). It is a scavenging receptor for a broad number of 
inflammatory CC chemokines such as CCL2, CCL3,CC4,CCL5 CCL7, CCL8, CCL11, 
CCL12, CCL13, CCL14 and CCL17 and CCL18. ACKR2 plays a pivotal role in 
orchestrating the inflammatory response and does not bind to any of the homeostatic 
chemokines143.  
 
ACKR2 is present in many organs tissues and cells. More specifically, in the immune 
cells, ACKR2 is expressed on B cells and some subsets of human dendritic cells and 
monocytes. In the non-immune compartment ACKR2 is expressed in hepatocytes in 
the liver, in the skin by keratinocytes and by trophoblasts in the placenta. ACKR2 is 
also expressed in lymphatic endothelial cells but not in blood endothelial cells 144,145.   
 
In the immune system, ACKR2 expression has been detected in some leukocyte 
subsets including T cells, B cells, neutrophils mast cells and macrophages146,147.  
ACKR2 has been shown to regulate lymphatic vessel density and function148. In the 
placenta, ACKR2 is expressed on trophoblasts. ACKR2 null mice exhibit abnormal 
embryo phenotypes like reduced foetal weight and increased neonatal death 
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rate149,150. In the skin, ACKR2 null mice exhibit a severe skin inflammatory 
phenotype that resembles psoriasis. ACKR2 also regulates the inflammatory 
response in the lung and the gut151,152,153,154. It has also shown to be important in 
infectious diseases like Mycobacterium tuberculosis. More specifically, ACKR2 null 
mice infected by Mycobacterium tuberculosis exhibited reduced survival, compared 
to WT mice. This lethal phenotype was attributed to an increased number of lung and 
lymph node-infiltrating mononuclear cells and an increase in pro-inflammatory 
cytokines and CC chemokines. ACKR2 is also involved in liver inflammation in 
chronic Hepatitis C. More specifically, genetic in silico and statistical analyses, 
proposed a correlation between  ACKR2 genetic variants with the grade of liver 
inflammation in  chronic Hepatitis C patients155 . 
 
In the context of cancer, ACKR2 in two different studies is involved in the early steps 
of metastasis by regulating the recruitment and infiltration of subsets of natural killer 
cells or neutrophils to the tumour156. Finally, ACKR2 is involved in skin cancer157 
and colorectal cancer by regulating the inflammatory environment and thus the 
progress of the disease158.  
 
1.10.3 ACKR4   
ACKR4 (previously named CCRL1) is a scavenger receptor for CCL19, CCL21 and 
CCL25 homeostatic chemokines. It is expressed in a wide variety of tissues and cells 
like lymphatic endothelial cells, blood endothelial cells, thymic epithelial cells, skin 
keratinocytes and brain. ACKR4 has a DRYWAVT motif, instead of the typical 
DRYLAIV, so it does not induce Ca2+ influx. ACKR4 functions as a chemokine 
scavenger receptor, causing ligand internalisation and subsequent lysosomal 
degradation159 . 
 
ACKR4 KO mice have increased levels of CCL21 in the plasma and increased levels 
of both CCL19 and CCL21 in lymph nodes but not in the spleen160. ACKR4 null mice 
have shown reduced dendritic cell (DC) lymph node homing. This phenotype might 
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be due to desensitisation of CCR7 (also binds CCL19 and CCL21) that is present on 
dendritic cells161. A recent study by Ulvmar et al. highlights the importance of ACKR4 
for shaping the CCL21 gradients in lymph nodes. The authors in this study have 
shown that the lymphatic endothelial cells lining the ceiling of the subscapular sinus, 
express ACKR4, which is responsible for scavenging CCL21.  ACKR4 scavenges 
CCL21, thus creating a  local gradient that guides the CCR7-expressing dendritic 
cells in the lymph node cortex162.  
 
 
1.11 Atypical Chemokine Receptor 3 (ACKR3)   
 
Atypical Chemokine Receptor 3 (formerly named CXCR7) is a seven transmembrane 
spanning receptor that like the other members of the ACKR family, cannot activate 
and signal through G proteins upon ligand binding.  
 
ACKR3 has two ligands that belong to the chemokine family: CXCL11 and CXCL12 
(Figure 1.4). Apart from these chemokine ligands, ACKR3 has been shown to interact 
with the following ligands: adrenomedullin (ADM), bovine adrenal medulla 22 
(BAM22) and macrophage inhibitory factor (MIF).  
 
The human ACKR3 gene is on chromosome 2 in genomic location 2q37.3. The 
human ACKR3 gene has two transcripts that encode two proteins 362 and 210 amino 
acids long (Ensembl genome database). However, there is no scientific  literature 
regarding the expression of the different ACKR3 isoforms in different tissues or 
different pathophysiological conditions. The ACKR3 protein sequence is 
evolutionarily conserved, a fact that highlights the importance of this receptor in 
fundamental biological processes. The high level of ACKR3 protein conservation 
among different species can be observed in protein sequence alignments obtained 
from UNIPROT protein database and compared using Clustal algorithm   as 
presented in Figure 1.3.   
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Figure 1.3 Multiple sequence alignment of ACKR3 protein sequences of 
different species were obtained from UNIPROT and generated with Clustal 
algorithm reveals the high level of conservation. The symbols are used to 
indicate amino acids aligned at the sites marked with the symbol. “*” indicates 
perfect alignment. “:” indicates a site belonging to group exhibiting strong 
similarity. “.” indicates a site belonging to a group exhibiting weak similarity. 
The species’ symbols that were used indicated the following: HUMAN(human), 
CANFL(canine), RAT(rat), MOUSE(mouse), MACMU(Rhesus macaque), 
BOVIN(bovine). 
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1.11.1 ACKR3 signalling and cellular properties   
Initially, ACKR3 was considered to be a scavenging receptor due to its inability to 
initiate G protein-mediated responses. This inability to signal through G proteins had 
initially been attributed to the fact that ACKR3 has a DRYLSIT motif instead of the 
classical DRYLAIV motif in the second intracellular loop that is essential for G protein 
interaction in other chemokine receptors. However, it has been shown in some 
studies that the replacement of DRYLSIT of ACKR3 with the DRYLAIV failed to 
induce G protein signalling cascades such as Ca2+ mobilisation, extracellular signal-
regulated kinase (ERK) phosphorylation or chemotaxis. This experiment suggests 
that the lack of the DRYLAIV motif in ACKR3 is not solely responsible for the ACKR3 
inability to signal through G proteins163,164.  
 
The interaction of ACKR3 with G proteins remains controversial, as there are studies 
that have reported ACKR3 and G protein interaction. In one study, the  ACKR3 and 
G protein interactions were reported using bioluminescence resonance energy 
transfer (BRET) in the absence of an agonist, but no G protein activation was reported 
in this case. In a subsequent study, it was reported that CXLC12 was able to initiate 
Gi/o activation upon binding to ACKR3 in primary rodent astrocytes. More 
specifically, the authors performed [35S]-GTPγS binding assays using membranes 
extracts of rodent astrocytes from CXCR4-/- mice. They noticed an increase in 
GTPγS binding after incubation of these membranes with CXCL12, an effect that was 
abrogated after silencing ACKR3 expression using siRNA. These observations 
contradict the general view that ACKR3 does not signal through G proteins and 
suggest that ACKR3  signalling responses upon ligand binding are context-
dependent165.   
 
Recent studies have shown that ACKR3 can initiate signalling cascades through β 
arrestins. It has been shown that ACKR3, upon CXCL12 binding, can recruit β-
arrestins that lead to Akt and ERK phosphorylation/activation, together with 
JAK2/STAT3 activation166. Furthermore, CXCL11 treatment in HEK293 cells 
overexpressing ACKR3 induces β-arrestin recruitment and ERK phosphorylation/ 
activation. However, stimulation with CXCL11 of rat vascular smooth muscle cells 
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expressing endogenous ACKR3 failed to show phosphorylation of ERKs. This 
highlights the importance of the cellular context in dictating signalling responses167.   
 
ACKR3 acts as a scavenger receptor for its ligands. When the ligands bind to ACKR3, 
then the complex of ligand-receptor is efficiently internalised, and the ligand gets 
degraded in the lysosomes. In the resting state, ACKR3 is mostly present on the 
membrane of endocytic vesicles. Truncations of the receptor’s C terminal tail resulted 
in a significant increase in the plasma membrane localisation. ACKR3 internalisation 
is β-arrestin-, clathrin- and dynamin-dependent, thus in the presence of a dominant-
negative dynamin mutant (K44A dynamin null), all ACKR3 is localised at the plasma 
membrane. This does not alter constitutive β-arrestin recruitment. In this case, upon 
CXCL12 stimulation of ACKR3, β-arrestin recruitment is significantly increased, and 
ERK phosphorylation is significantly prolonged. These observations suggest that 
ACKR3 can signal when it is located exclusively at the plasma membrane168.  
 
Several studies in zebrafish revealed the role of ACKR3 in cell migration during 
development. In zebrafish, the collective migration of cells during development, is 
CXCL12-CXCR4 axis-driven. The zebrafish lateral-line primordium is a cohesive 
cohort of over 100 cells that is guided through CXCR4-CXCL12 signals.  In zebrafish, 
knock out of CXCL12 resulted in a phenotype that  is stronger than the CXCR4 KD 
in the same model. This suggests that  other CXCL12  receptors play a role in the 
collective cell migration in zebrafish. Indeed, morpholino-mediated knockdown of 
both CXCR4 and ACKR3, results in a lateral-line- cell migration phenotype that is 
similar to the one observed in CXCL12 KO. In this study, it was shown that CXCL12, 
controls the cell migration during zebrafish development through two independent 
receptors, CXCR4 and ACKR3169.  
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1.11.2 ACKR3 expression   
ACKR3 spatial and temporal expression in tissue is tightly regulated, supporting the 
fundamental role of ACKR3 in developmental processes and immune surveillance. 
Human ACKR3 under homeostatic conditions has been detected in several tissues 
including heart, brain, spleen, kidney, lungs, thyroid and placenta as verified by RT- 
PCR and immunoistochemistry170,171,172. ACKR3 is also expressed in immune cells 
in homeostatic and pathophysiological conditions.  
  
ACKR3 expression in the immune system   
ACKR3 expression in lymphocyte and leukocyte subsets is controversial, partly 
because of differences in the techniques that were applied, but mostly due to the lack 
of specific antibodies for this receptor. ACKR3 has been detected in lymphocytes, 
granulocytes and some peripheral blood cells subsets in the bone marrow173. 
Several studies have reported ACKR3 expression in subsets of T cells, monocytes, 
B cells174 and natural killer (NK) cells175,176,177.  In most of these studies, ACKR3 
was mostly detected intracellularly using flow cytometry (after permeabilisation), and 
only a small amount was detected in the cell membrane fraction. It is proposed that 
ACKR3 internalises constitutively and this constitutive internalisation is independent 
of chemokine ligand binding. After ligand binding, the receptor-ligand complex 
internalises and goes to lysosomes for ligand degradation. After the chemokine -
ligand degradation, the receptor recycles back to the plasma membrane, available 
for the next round of chemokine binding and scavenging178.   
 
ACKR3 is implicated in B cell development179.  ACKR3 is proposed to be essential 
for B cell function and differentiation into plasma cells. This is based on the 
observation that during B cell development and differentiation, only the ACKR3+ 
subset of B cells, identified by flow cytometry analyses, is viable and can produce 
antibodies.   
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ACKR3 expression in non-immune cells   
ACKR3 has been detected during embryogenesis in foetal liver and is believed to be 
essential in vasculogenesis but not in haematopoiesis. ACKR3 is expressed in 
cardiac endothelial cells (as verified by immunofluorescence and RT-RCR analyses)  
and plays a role in angiogenesis180. The fact that ACKR3 is also expressed in 
endothelial and trophoblast cells in the placenta (verified by RT-PCR and 
immunohistochemistry) suggests additional functions during pregnancy and embryo 
development181,182. In neurobiology, several studies have shown ACKR3 
expression (verified by immunofluorescence and RT-PCR) in neurons and 
astrocytes, and it is important for proper migration and spatial distribution of cortical 
interneurons183,184,185. Furthermore, in astrocytes and Schwann cells, CXCL12 
binds to ACKR3 and activates Akt and ERK-mediated signalling responses186,187.   
In the kidneys, ACKR3 is expressed in renal blood and lymphatic vessels. It regulates 
the blood flow and contributes to vascular development through shaping the 
concentration of its ligands CXCL11, CXCL12 and ADM188,189.   
 
ACKR3 is also involved in reproductive processes through its ligands, CXCL12 and 
ADM. CXCL12 regulates the chemotaxis of immune cells to the uterus, the 
trophoblast invasion process and the synthesis of angiogenic factors during 
pregnancy190,191.  During the first weeks of pregnancy, trophoblast-derived  
CXCL12 leads to the recruitment of natural killer (ΝΚ) cells from peripheral blood to 
the uterus. These cells (peripheral blood NK), together with the NK cells that reside 
in the uterus, contribute to processes like spiral artery remodelling and development 
of immune tolerance of the foetus192,193,194.  Apart from CXCL12, it is also proposed 
that ADM regulation through ACKR3 scavenging, contributes to efficient embryo 
attachment to the maternal decidua. 
 
In addition to ACKR3 involvement in the regulation of reproductive processes in 
females, ACKR3 is also reported to be a player in male reproduction. ACKR3 during 
testis development is expressed in undifferentiated spermatogonia and contributes to 
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the fine-tuning of the CXCL12: CXCR4 signalling in this context195,196. However, the 
exact role of ACKR3 during spermatogenesis remains unclear.  
 
 
 1.12 ACKR3 ligands  
 
Major ligands  
1.12.1 CXCL12   
CXCL12 (previously named SDF-1) is a chemokine that has a fundamental role in 
several developmental processes and regulates immune surveillance. It is highly 
expressed in the lung, liver, lymph nodes, brain and bone marrow197,198. It is also 
expressed at lower levels in the skin, kidney and small intestine. CXCL12 expression 
in the aforementioned tissues defines secondary metastatic niches in several types 
of cancer199. CXCL12 has also been shown to be chemotactic for leukocytes, 
mesenchymal stem cells, endothelial progenitor cells and neural progenitor 
cells200,201,202. In pathophysiology, CXCL12 upregulation is associated with several 
conditions including ischemia, autoimmune diseases, inflammation and 
cancer203,204. CXCL12 binding to ACKR3 is not able to induce calcium mobilization 
or G protein activation but signals through β arrestin recruitment and ERK / AKT 
activation205,206.  CXCL12 binding to CXCR4 is able to induce G protein recruitment. 
G proteins are heterotrimeric and they consist of the Gα subunit and the tightly 
associated Gβγ subunits. There are many classes of Gα subunits such as  Gsα (G 
stimulatory), Giα (G inhibitory), Goα (G other), Gq/11α, and G12/13α. CXCL12 
binding promotes a CXCR4 conformation that favours mainly Giα subunit protein 
complexes. However, CXCR4 can also couple to other G proteins such as G12/13α 
and Gqα207. 
1.12.2 CXCL11   
CXCL11 (named I-TAC in the past), is expressed in peripheral blood cells (PBMCs), 
in the liver, thymus lung, spleen and pancreas208. CXCL11 binds to ACKR3 and the 
two isoforms of CXCR3 A and B. CXCL11 binding to ACKR3 or CXCR3–A is 
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associated with a more proliferative phenotype while binding to CXCR3-B has the 
opposite effect209. CXCL11 signals through Gi protein following the binding to 
CXCR3-A and Gs upon binding to CXCR3-B. CXCL11 interaction with ACKR3 results 
in β arrestin-2 recruitment but is unable to promote ERK or AKT mediated signalling 
cascades 210,211.   
 
Minor ligands 
1.12.3 Adrenomedullin (ADM)   
Adrenomedullin is a 52 amino acid hormone peptide with vasodilatory properties212. 
Adrenomedullin plays a key role in cardiac development and 
lymphangiogenesis213,214,215. Adrenomedullin binds and signals through a receptor 
complex that consists of a GPCR protein called CLR (calcitonin receptor like receptor) 
and a RAMP protein (receptor activity modifying protein). The interaction of 
adrenomedullin with its classical receptor complex can lead to cyclic AMP and nitric 
oxide production216,217. Recently it was shown that adrenomedullin binds ACKR3 
that acts as a scavenger receptor but cannot initiate G protein-mediated signalling. 
The signalling properties of adrenomedullin and ACKR3 remain uninvestigated, and 
further studies need to be done to fully understand the importance of this interaction 
in different biological contexts.  
  
1.12.4 Bovine Adrenal Medulla 22 (BAM 22)   
BAM22 was initially isolated from the adrenal medulla218,219 and acted like an opioid 
but also has other functions220. BAM22 is expressed in the central nervous system 
and acts through binding the opioid receptors μ-, δ- and κ221,222,223,224.  
A recent study revealed that BAM22 is a ligand for ACKR3 and binds with high affinity. 
This interaction leads to glucocorticoid secretion. It was also shown that binding to 
ACKR3 recruits β arrestin 1 and 2 but did not increase cAMP or lead to calcium 
mobilization225.  
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1.12.5 Macrophage Inhibitory Factor (MIF)   
Macrophage Inhibitory Factor is a cytokine that regulates the innate immune system 
and is expressed by a variety of cell types like endothelial cells, epithelial cells, 
eosinophils and macrophages226,227,228. Its main role is to inhibit macrophage 
migration229. MIF has been shown to bind to several receptors like the cluster of 
differentiation 74 (CD74)230, CXCR2 and CXCR4231. MIF has been recently linked 
to ACKR3 in pathological conditions such as Rhabdomyosarcoma, where it regulates 
tumour cell migration and in platelets where it prevents apoptosis via AKT dependent 
survival cascades232,233.  
 
   
Figure 1.4 Schematic representation of ACKR3 and its chemokine ligands. 
ACKR3 shares CXCL12 and CXCL11 with CXCR4 and CXCR3 chemokine receptors. 
ACKR3, in contrast with CXCR4, cannot elicit G protein-dependent signalling 
responses. Instead, ACKR3 can recruit and activate β arrestins- dependent signaling 
cascades.  
 
 64 
1.13 The role of ACKR3 in physiology   
 
The spatiotemporal distribution of chemokines during embryonic development has 
been shown to play a fundamental role in lineage commitment, organogenesis and 
chemotaxis. After the discovery that ACKR3 is another receptor for CXCL12 and due 
to the high importance of CXCL12 in various developmental processes and immune 
responses, the role of ACKR3 was also interrogated in this context.   
 
In one of the initial developmental studies on ACKR3, it was revealed that it is 
essential for primordial germ cell (PGCs) migration in zebrafish. The authors 
demonstrated that morpholino-mediated knockdown of ACKR3 resulted in aberrant 
PGC migration that impaired gonad development. To explain this phenotype, they 
proposed a mechanism in which ACKR3 is expressed in the somatic 
microenvironment of PGCs and scavenges CXCL12, thus creating a gradient for this 
chemokine. Migrating PGCs do not express ACKR3 but express CXCR4b chemokine 
receptor that binds to CXCL12 and leads their migration from areas with low CXCL12 
concentration to higher ones234.  
 
In 2007 Sierro et al. generated ACKR3 null mice that showed rapid postnatal death 
within 24 hours of birth. The few embryos that survived exhibited severe cardiac 
abnormalities and aortic valve defects, a phenotype that was also present in the 
ACKR3 +/- mice. In situ hybridization experiments revealed expression of ACKR3 in 
the brain and the endothelium of the embryonic heart. Specific ACKR3 depletion from 
the endothelium phenocopied the ACKR3 knockout cardiac abnormalities.  
Subsequently, gene expression analysis on ACKR3-/- embryonic valve leaflets 
revealed significant downregulation of Adrenomedullin and Heparin-binding EGF-like 
growth factor (HBEGF) genes, among others. Adrenomedullin expression in ACKR3 
null mice was also validated in other tissues with no apparent differences noticed235.   
 
In a subsequent study, Klein et al., using ADM overexpressing knock-in mice (ADM 
hi/hi), showed that these mice exhibit the ACKR3 null lethal phenotype. This 
observation supports the idea of ACKR3- ADM interaction being crucial in 
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angiogenesis and lymphangiogenesis during embryonic development. Furthermore, 
genetic reduction of ADM by crossing ACKR3 -/- and ADM +/- mice could reverse the 
ACKR3 null phenotype verifying that ACKR3 acts as a homeostatic regulator of ADM 
levels in the heart and dermal lymphatic system during development236.   
 
Besides these findings in the endothelial system, other studies have highlighted the 
importance of ACKR3 in mouse brain development. In the embryonic brain, ACKR3 
is expressed in the protrusions of cortical interneurons and seems to play a CXCR4- 
independent role in migration and spatial distribution of these cells. This phenotype 
is β arrestin/ MAPK mediated and does not follow the typical G protein recruitment 
signalling pathways237.  
 
Several studies highlight the involvement of ACKR3 in tissue regeneration after injury. 
Ding and et al. using an acute and a chronic liver injury model demonstrated the 
importance of ACKR3 and CXCR4 in liver regeneration. They demonstrated that after 
liver injury, accumulated CXCL12 on the site of injury leads to ACKR3 overexpression 
in liver endothelial cells. ACKR3, together with CXCR4, coordinates the start of the 
regeneration process through the activation of the transcription cofactor, inhibitor of 
DNA binding 1 (ID-1)238.  
 
In another study, the same research team revealed that the CXCL12 - 
CXCR4/ACKR3 axis is necessary for lung alveolar regeneration. They demonstrated 
that after surgical removal of the left lobe by pneumonectomy (PNX), accumulated 
platelets deposit CXCL12 in the pulmonary capillary endothelial cells. Using CXCR4 
and ACKR3 endothelial-specific knockouts, they proposed that platelet-derived 
CXCL12 triggers a CXCR4/ACKR3 signalling cascade that is fundamental for the 
initiation of the alveolar regeneration process239. 
 
In the lung, ACKR3 involvement in lung alveolar repair and fibrosis after chronic injury 
was demonstrated.  The authors proposed that a Notch ligand, Jagged1 (JAG1), is 
secreted by activated pulmonary capillary endothelial cells and induces the activation 
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of Notch signalling to the fibroblasts in the alveolar microenvironment after chronic 
bleomycin injury, promoting a fibrotic phenotype. In this model, they also observed 
that ACKR3 that is normally expressed in the capillary endothelial cells was 
significantly downregulated in the fibrotic environment. Administration of an ACKR3 
agonist reduced the levels of Jag1 and reversed the fibrotic phenotype suggesting a 
protective role of ACKR3 in alveolar epithelial damage240.  
 
1.14 ACKR3 in pathophysiology   
 
There is a substantial body of evidence that highlights the role of ACKR3 in the 
development and progression of several pathological conditions, including cancer.  
The implication of ACKR3 in several types of malignancies has been extensively 
reviewed in the recent past. ACKR3 is expressed in the tumour cells in the lung, in 
the brain, in the pancreas, in the prostate and the tumour vascular cells.  
 
In cardiovascular biology, ACKR3 is upregulated in arteries after injury and promotes 
ischemia-induced angiogenesis and endothelial cell proliferation after myocardial 
infarction. These findings highlight the role of ACKR3 as a homeostatic regulator of 
cardiac remodelling and repair after injury241. In diabetes mellitus ACKR3, expressed 
in endothelial progenitor cells, provides survival advantage and enhances the 
angiogenic capacity of these cells. The authors proposed a mechanism whereby 
CXCL12 binds ACKR3 and blocks GSK-3β that inhibits the nuclear factor (erythroid-
derived 2)-like 2 (NRF2), transcription factor, thus allowing NRF2 activation. 
Subsequently activated NRF2 target genes promote cell survival, angiogenesis and 
provide antioxidative protection against oxidative stress, a characteristic of the 
disease242.  
 
In atherosclerosis, ACKR3 is expressed in macrophage populations in atherosclerotic 
plaques. ACKR3 expression in these cells increases their phagocytic activity via MAP 
kinase mediated signalling. In another study, the authors propose the involvement of 
ACKR3 in thrombosis and inflammation. They showed that macrophage migration 
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inhibitory factor (MIF) interacts with ACKR3 expressing platelets, mediates 
antiapoptotic effects in these cells and also promotes antithrombotic effects after 
arterial injury both in vitro and in vivo243.  
  
1.15 ACKR3 role in cancer biology   
 
CXCR4 is one of the most studied chemokine receptors in the context of cancer 
because it is upregulated in more than 23 types of human cancers of epithelial, 
mesenchymal and haematopoietic origin. CXCL12 is the only ligand for CXCR4, and 
this interaction is extensively studied since CXCL12 has been detected in primary 
tumour sites in lymphomas, gliomas, ovarian and pancreatic cancer and at secondary 
metastatic sites in breast and thyroid cancer244,245,246.  
CXCL11 was believed to be the only binding partner of ACKR3. Recently, it was 
discovered that CXCL12 could also bind ACKR3 with higher affinity than CXCR4. 
The affinity of the CXCL12 – ACKR3 interaction is also higher than the affinity of 
CXCL11 – ACKR3 interaction but failed as well to induce Ca+  influx, chemotaxis or 
integrin activation, leaving the biological relevance of this interaction unclear247.  
   
There is a growing body of evidence that suggests the involvement of ACKR3 in 
cancer progression and metastasis, but our understanding of the exact mechanisms 
that ACKR3 uses to regulate these processes remains elusive. ACKR3 expression is 
elevated in several solid tumours and the tumour-associated vasculature. ACKR3 is 
overexpressed in a variety of cancers like astrocytoma and glioblastoma248, 
prostate249,250, breast251, pancreas252, lung253,254, colorectal255, bladder256,257 
and kidney258,259. These observations suggest that ACKR3, like CXCR4, plays a 
crucial role in cancer biology by regulating tumour immune microenvironment, tumour 
angiogenesis, stem cell trafficking, and metastasis (Figure 1.5) .   
 
ACKR3 is often reported to be co-expressed with CXCR4. Usually, these two 
receptors are clearly expressed in cancers such as glioma and breast cancer.  
Instead, in some other cancers, for example in pancreatic cancer, ACKR3 and 
 68 
CXCR4 are co-expressed. The co-expression of these two receptors on the same 
cells may suggest heterodimerization between them and the initiation of distinctive 
signalling pathways. Another hypothesis is that this co-expression is maybe crucial 
for tumour growth regulation in an autocrine manner. Apart from  CXCR4, ACKR3 
may also functionally interact with crucial other signalling receptors, such as estrogen 
and epidermal growth factor receptors (EGFRs) in breast cancer260.  
 
 
 
Figure 1.5 CXCR4 and ACKR3 (CXCR7) are expressed in primary   solid 
tumours and are involved in metastasis in organs that CXCL12 is highly 
expressed such as the bone marrow,  the lung, the liver and the  lymph 
nodes. 
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1.15.1 ACKR3 role in tumour-associated angiogenesis    
Apart from the expression of ACKR3 in tumour cells, it is also extensively reported 
that ACKR3 is highly expressed in tumour-associated vasculature. Hypoxia is a 
common characteristic in solid tumours. In this hypoxic microenvironment, VEGF and 
CXCL8 that are present in high concentrations, lead to the higher expression of 
ACKR3, creating a positive feedback loop261,262.  
 
ACKR3 is expressed in endothelial progenitor cells (EPCs) and is implicated in 
transendothelial migration, proliferation and tube formation of EPCs, that are 
essential steps in the angiogenic process263. Although ACKR3 can enhance the 
transendothelial migration of EPCs, its role in the migration of tumour cells is less 
clear, as it may either synergize with or impair CXCR4 action.  
 
In a study in human meningiomas, ACKR3 was detected in tumour endothelial cells. 
More specifically, the authors assessed the ACKR3 expression at both mRNA and 
protein level in human post-surgical human meningioma specimens. Using RT PCR, 
the authors observed an increase in the ACKR3 mRNA levels when comparing 
benign and aggressive meningioma specimens. Furthermore, immunohistochemistry 
and immunofluorescence analyses in these specimens revealed ACKR3  expression 
in tumour endothelial cells, but these observations are debatable due to the use of a 
new polyclonal anti ACKR3 antibody(Abcam) that has not used extensively in the 
literature or validated for its specificity264.  
 
In hepatocellular carcinoma(HCC), ACKR3 expression in human HCC tissues and 
cell lines was associated with tumour angiogenesis, verified by transwell co-cultures 
with primary human endothelial cells and tumour growth, assessed by xenografts in 
vivo265 . 
 
In colon cancer, transwell co-culture of human colorectal cell lines that overexpress 
ACKR3, with primary endothelial cells, enhanced angiogenesis via AKT/ERK 
pathway activation. This effect was abrogated when using cell lines that express 
 70 
shRNAs against ACKR3. The angiogenic contribution of ACKR3 in colon cancer was 
also validated in vivo in subcutaneous mouse models. In these models, ACKR3 
expressing cell lines exhibited increased expression of vascular endothelial growth 
factor (VEGF) as was revealed after immunohistochemistry analyses of the 
tumours266. Also, in patients with glioblastoma, ACKR3 expression by endothelial 
cells correlated with a better prognosis267.  
 
1.15.2 ACKR3 role in metastasis    
In the literature, there are contrasting conclusions about the role of ACKR3 in the 
metastatic process. In some cases, ACKR3 can reduce CXCR4 mediated effects. For 
example, in a breast cancer model ACKR3 inhibited tumour invasion by 
downregulating metalloproteinase-12, impaired CXCL12-stimulated matrix 
degradation and invasion, and decreased spontaneous lung metastasis268.   
 
In contrast with this study, another breast cancer study revealed a  positive correlation 
between ACKR3 overexpression and lymph node metastasis. More specifically, 
immunohistochemical analyses of human breast cancer tissues and tissue 
microarrays revealed that ACKR3 was upregulated in the cancerous tissues and 
associated with higher tumour aggressiveness and metastasis to the lymph nodes. 
Furthermore, using subcutaneous models of murine breast cancer cells, but also 
allograft experiments, the authors proposed that ACKR3 controls tumour growth but 
also lung metastasis in these models254,269. Another breast cancer study in mouse 
models proposes that glioma-associated oncogene 1 (GLI1) transcription factor 
enhances breast cancer cell lung metastasis by upregulating transcription from the 
CXCR4 and ACKR3 genes271. ACKR3 may also regulate CXCR4-mediated 
transendothelial migration (TEM) in a CXCL12-dependent manner. More specifically, 
human Burkitt's lymphoma cell line NC-37, which expresses CXCR4, CXCR5, 
ACKR3 and CCR7, was used as a model in TEM assays. These cells failed to migrate 
through HUVECs monolayers in increasing concentrations of CXCL13 (CXCR5 
ligand) or CCL19 (CCR7 ligand). Surprisingly the same cells could able to migrate 
towards CXCL13 or CCL19 after stimulation with CXCL12. The later phenotype was 
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abrogated after using the ACKR3 inhibitor CCX771 suggesting that ACKR3 mediates 
TEM in this system. However it is important to note that CCX771 inhibitor is not very 
specific for ACKR3 and can act as an agonist for CXCR4 (data not presented in this 
thesis). This in vitro setting may recapitulate the in vivo cancer cell migration towards 
the lymph nodes272.   
 
Finally, in rhabdomyosarcoma (RMS), ACKR3 is expressed in human 
rhabdomyosarcoma cell lines. Using an  intravenous injection model of human RMS 
cells that overexpressed ACKR3 in SCID mice, the authors assessed the effect of 
ACKR3 in metastasis to the bone marrow. They observed an increased seeding 
efficiency of tumour cells that  overexpress ACKR3  to the bone marrow 273. This 
suggests a positive correlation between ACKR3 expression and the seeding 
efficiency of tumour cells to secondary metastatic sites in this model. 
 
 
1.15.3 ACKR3 role in cell proliferation, adhesion and tumour growth   
In breast cancer, ACKR3 has been shown to enhance vascular cell-adhesion 
molecule-1 (VCAM-1) expression. This suggests a role for ACKR3 in tumour invasion 
to surrounding tissues as cell adhesion to the basement membrane is a crucial step 
in this process270.  
 
In the human glioblastoma cell line U373, ACKR3 induced proliferation upon CXCL12 
treatment, a phenotype that was abrogated after treatment with the ACKR3-specific 
inhibitor CCX733274. In bladder cancer, recent studies have identified ACKR3 as one 
of the chemokine receptors that is upregulated in several bladder cancer tissues and 
cell lines. In human bladder cancer cell lines, ACKR3 mediated proliferation through 
activation of AKT, ERK and STAT3 pathways. Furthermore, in allograft subcutaneous 
mouse models, J82 cancer cells that stably overexpressed ACKR3, showed 
enhanced tumour growth275.   
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In an endometrial carcinoma study, ACKR3 mRNA was detected in patient specimens 
but also cell lines. These observations were also verified at a protein level using 
immunohistochemical analyses. ACKR3 expression was associated with a 
proliferative phenotype in AN3CA cell line after treatment with CXCL12 ligand. The 
proliferation in these cells was inhibited after ACKR3 knockdown276.  
In lung cancer, ACKR3 expression was associated with tumour growth and a more 
aggressive phenotype. In subcutaneous  murine models, ACKR3 knockdown 
inhibited tumour growth. The use of ACKR3- specific inhibitors, phenocopied the 
ACKR3 silencing experiments. ACKR3 was detected using immunohistochemistry in 
lung cancer patient specimens using the 11G8 antibody253.  
 
In contrast with the previous studies, in oral lingual squamous cell carcinoma, ACKR3 
inhibited growth in in vitro invasion assays. ACKR3 expression in Tca8113 cells 
inhibited epithelial to mesenchymal transition (EMT) by downregulating crucial 
extracellular matrix proteins that are involved in cell migration277.  
 
Some viruses appear to be associated with ACKR3 receptor dysfunction. The role of 
ACKR3 in virus-related cancers has not been extensively studied; existing evidence 
suggests that these viruses commonly induce ACKR3 upregulation through the 
expression of viral oncogenes. In these cancers, ACKR3 expression seems to be 
associated with cell growth, transformation and survival278.   
 
1.15.4 Factors that regulate the ACKR3 expression in cancer 
Several factors have been linked with ACKR3 expression in tumours. In glioma cells, 
it has been shown that hypoxic conditions control the ACKR3 upregulation in the 
tumour-associated endothelial cells. More specifically, hypoxia inducible factor -1 
alpha (HIF-1 α) is associated with ACKR3 increase in the tumour microenvironment. 
Furthermore, hypermethylated in cancer 1 (HIC1) tumour suppressor has been 
proposed to regulate ACKR3 expression in the context of cancer279,280.  
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Several miRNAs have been linked to ACKR3 gene expression. For example, miRNA 
-430 is significantly downregulated in bladder cancer cells that exhibit high levels of 
ACKR3 expression.  In another study, overexpression of miRNA -101, that is 
considered a tumour suppressive miRNA, in hepatocellular carcinoma cells and 
xenograft mice models has led to reduced expression of ACKR3281.  
 
1.15.5 The role of  ACKR3 in lung  cancer 
ACKR3 expression is reported  in different  types of lung cancer. In a study using 
lung adenocarcinoma cell lines it was demonstrated that  TGFβ1 overexpression 
induced the upregulation of  ACKR3 gene as verified by qPCR analyses. Furthermore 
ACKR3 knockdown constrained the TGFβ1-mediated cell motility and epithelial to 
mesenchymal transition. Subsequently, the authors proposed that ACKR3 is involved 
in TGFβ1-promoted cancer stem cells’ (CSC) formation. The aforementioned 
observations were shown to be CXCR4- independent, since CXCR4 knockdown in 
the same lung cancer cell lines did not phenocopy the ACKR3-mediated 
phenotypes318. 
In another study, is was proposed that ACKR3 regulates tumour growth in lung 
adenocarcinoma among other types of cancer. More specifically, stable ACKR3 
knockdown Lewis lung carcinoma cells were transplanted subcutaneously in 
immunocompetent mice and tumour growth was measured overtime. In this model, 
ACKR3 ablation reduced significantly the tumour growth although the exact 
mechanism responsible for this phenotypes was not investigated in this study. 
Furthermore, ACKR3 expression was detected using immunohistochemistry  in the 
tumour associated vasculature in human lung adenocarcinoma resections253. The 
antI- ACKR3 antibody that was used for the immunohistochemical analyses in this 
study,  was clone 11G8 that we validated for specificity in Chapter 4.  
Furthermore, in another lung cancer study, the authors assessed the gene 
expression of CXCR3 , CXCR4  and ACKR3 in surgical specimens of 127 non-small 
cell lung cancer (NSCLC) patients who underwent complete tumour resection. They 
observed  a higher CXCR4 and ACKR3 expression in patients with recurrence of 
secondary tumours, compared to the non- recurrence group. These results suggest 
that ACKR3 and CXCR4 may be involved in a more aggressive post-surgical tumour 
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phenotype. In the same study, it was revealed a positive correlation between ACKR3 
mRNA expression and the presence of EGFR mutations, suggesting a positive 
involvement of  ACKR3 in this subset of  lung cancer patients254. 
 
Aims of the study  
 
ACKR3 is a seven-transmembrane spanning receptor that can fine-tune several 
physiological processes including development, tissue repair and homeostatic 
regulation. ACKR3 is also linked to a number of pathological conditions, including 
diabetes and atherosclerosis. ACKR3 was discovered to be a binding receptor for 
CXCL12.  Because of the involvement of the CXCR4/CXCL12 axis in cancer 
progression and metastasis, ACKR3 was also interrogated in the cancer context. 
ACKR3 is upregulated in several types of human cancers but also in the tumour-
associated vasculature.  
Because of the lack of specific ACKR3 antibodies and due to technical limitations and 
differences in experimental approaches, there are a lot of discrepancies in the 
scientific literature regarding ACKR3 expression and role in cancer development and 
progression.    
To this end, the aims of the present study where:   
• to shed more light on the expression of ACKR3 in particular organs in 
which ACKR3 expression is linked with cancer development with a 
particular focus on the lung   
• To validate commercially available ACKR3 antibodies   
• to understand the contribution of ACKR3 to cancer development with 
the help of genome editing technologies    
• to model ACKR3 role in cancer using in silico analyses and in vivo  
murine models   
  
To accomplish these aims, we employed a combination of genome editing 
approaches, fluorescent reporter mice analyses, bioinformatic analyses and 
established in vivo cancer murine models. 
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CHAPTER 2   
Materials and Methods  
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2.1 Microbiological techniques and reagents  
  
2.1.1 E. coli bacteria culture reagents  
 
LB (Luria-Bertani) liquid medium composition and preparation  
Initially, 10 g tryptone, 5 g yeast extract and 10 g NaCl were added to 500 ml of 
water. Subsequently, the ingredients were mixed by shaking or stirring until the 
solutes were dissolved and the final volume of the solution was adjusted to 1 litre by 
adding water. Finally, the solution was sterilised by autoclaving for 20 minutes.  
  
Ampicillin antibiotic 1000x stock preparation  
Ampicillin powder (Sigma) was dissolved in distilled water (or 70 % ethanol) to a 
concentration of 100 mg/mL and filtered using a .22 μm filter before storing at -20°C.  
Final working concentration after addition to the media was determined at 100 μg/ml.  
  
LB (Luria-Bertani) solid medium (agar) preparation   
Initially, 3 g of tryptone, 1.5 g of yeast extract, 3 g NaCl and 4.5 g of agar were 
weighed. Subsequently, distilled water was added to the tryptone, yeast extract and 
NaCl mixture, until it was dissolved. Then, the pH of the solution was adjusted to 7.0, 
agar powder was added, and the mixture was autoclaved. After autoclaving, the LB 
agar was allowed to cool down to 55°C, and ampicillin was added. Finally, the LB-
agar ampicillin was poured into Petri dishes (approximately 10 ml per dish), and the 
agar dishes were left to solidify at room temperature.  
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Solution I for preparation of competent cells   
For solution I preparation, the following ingredients were added in distilled water 
and stirred until the ingredients were dissolved.   
 
Solutes  Final concentration in solution   
KAc  30 mM   
KCl  100 mM  
CaCl2   10 mM  
MnCl2   50 mM  
Glycerol  15% (v/v)  
 
Subsequently, pH was adjusted to 5.8 with addition of acetic acid. Finally, the solution 
was filtered using a .22 μm filter and stored at 4°C.   
  
Solution II for preparation of competent cells  
For solution II preparation, the following ingredients were added in distilled water 
and stirred until the ingredients were dissolved.   
  
Solutes  Final concentration in solution   
KCl  10 mM  
CaCl2   75 mM  
Glycerol  15% (v/v)  
 
Subsequently, pH was adjusted to 6.5 with addition of KOH. Finally, the solution was 
filtered using a .22 μm filter and stored at 4°C.   
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2.1.2 Preparation of competent bacteria  
The E. coli strain XL-1 blue (Agilent) was chosen to propagate plasmid DNA. An LB-
agar plate with no antibiotics was spread with non-transformed XL-1 blue cells and 
colonies were allowed to grow overnight at 37°C. The next day, one of the colonies 
was picked and inoculated in 5 ml of LB medium with no antibiotics for the following 
night at 37°C. The following day, 5 ml of the bacterial culture were sub-cultured in 
100 ml of LB broth with no antibiotics and grown at 37°C until the optical density at 
600 nm reached a value of 0.3-0.4. After chilling 5 minutes on ice, cells were spun 
at 3000 rpm for 10 min at 4°C in 50 ml sterile Falcon tubes. Each pellet was 
resuspended in 20 ml of solution I by gentle pipetting, chilled for 5 minutes and spun 
as previously. Each pellet was then resuspended in 2.2 ml of solution II, by gently 
pipetting up and down and chilled for a further 15 minutes. Finally, cells were 
aliquoted by placing 200 μl per Eppendorf tube, then were snap-frozen in dry ice and 
stored at  -80°C for future use.  
   
 
2.2 Tissue culture  
  
2.2.1 LLC murine cell line  
The Lewis Lung Carcinoma cell line was first isolated from a spontaneous epidermoid 
carcinoma of the lung in C57BL/6 mice in 1954 by Dr Margaret Lewis. It has been an 
important tumour model for cancer therapy, as it has helped in the study of metastasis 
and angiogenesis and has been involved in developing anti-tumour 
chemotherapeutic drugs. LLCs hold an advantage because they were isolated from 
a spontaneous tumour in C57BL/6 mice; thus they are immunologically compatible 
with this strain of mice, so they can be engrafted into immunocompetent C57BL/6 
(both sexes are suitable hosts for engraftment) mice and not be rejected by their 
immune system. Together with the lack of immune-dependent obstacles, being 
syngeneic allowed the study of every aspect of the tumour microenvironment, 
including the role of the resident and recruited immune cells282.  
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2.2.1.1 Maintenance  
LLC cell line was cultured in DMEM medium (Invitrogen) supplemented with 10% 
FBS (Invitrogen), 1% L Glutamine (Invitrogen) and 1% penicillin/ streptomycin 
(Invitrogen), at 37°C in 5% CO2. Cells were passaged by incubating for 5 minutes at 
37°C in trypsin-EDTA 0.5 % when they reached 80% confluency, which usually 
occurred every second or third day due to their extremely high rate of proliferation. 
During passaging, 106 cells were placed in a new T75 cell culture flask.  
  
  
2.2.2 B16F10 murine cell line  
B16 cells were first isolated and maintained from a tumour that developed 
spontaneously behind the ear of a C57BL/6 mouse. The tumour was then resected, 
transplanted, and maintained in vivo. During the 1970’s Dr Isaiah J. Fidler, 
established protocols for the use of the B16 model. Dr Fidler stained B16 cells, with 
125I-5-iodo-2′-deoxyuridine for tracking and implanted the cells into C57BL/6J mice. 
Subsequently, he sacrificed the mice at different time points and measured the B16 
cells in the blood and in different organs. He observed that 99% of the original cell 
population had died within the first day and that only a small population of about 400 
cells had colonised the lung. This study was pioneering because it established a 
metastasis model that was simple, reliable and gave consistent results. It also 
demonstrated that metastasis is regulated by various factors and does not rely only 
on the presence or the number of tumour cells. Only a few cells from the original 
population could enter the circulation, colonise the lung and begin to form a 
tumour283.This cell line was used in female  C57BL/6 mice in our studies. 
  
2.2.2.1 Maintenance  
B16-F10 murine melanoma cell line (ATCC) was cultured in DMEM medium 
(Invitrogen) supplement with 10% FBS (Invitrogen), 1% L Glutamine (Invitrogen) and 
1% penicillin/streptomycin (Invitrogen), at 37°C under 5% CO2. Cells were passaged 
by incubating for 5 minutes at 37°C in trypsin-EDTA 0.5 % when they reached 80% 
confluency, which usually occurred every four days after placing 106 cells in a T75 
cell culture flask.  
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2.2.3 Freezing procedures   
The freezing medium that was used during the freezing process was FBS containing 
10 % DMSO. Usually, an 80% confluent T75 cell culture flask yielded 8-10 x106 cells. 
Usually, 106 cells were resuspended in 1 ml of freezing medium, and stored in 
cryovials at -80°C for 24 hours and then stored in Liquid Nitrogen (−195.79°C) for an 
indefinite period.  
 
2.3 Cell biology  
  
2.3.1 Lipofectamine 2000 transfection  
Lipofectamine (Invitrogen) is a cationic liposome formulation, which can form 
complexes with negatively charged nucleic acids such as DNA or RNA. The resulting 
complexes can easily fuse with the negatively charged plasma membrane of living 
cells, allowing the liposome- nucleic acids complexes to cross into the cytoplasm so 
the nucleic acids can be expressed. To be efficiently expressed the transfected 
product should enter the nucleus; therefore, transfection is recommended on 
subconfluent cells, which are more proliferative and can undergo mitosis.  
  
2.3.1.1 Transfection of B16F10/ LLC cells in six- well plates  
The day before transfection, 3x105 cells per well were seeded in a 6-well plate. The 
following day, in an Eppendorf tube, 2 μg of DNA per transfection reaction was diluted 
in 150 μl of Opti-MEM medium (Invitrogen). In another Eppendorf tube, 8 μl of 
Lipofectamine 2000 was diluted in 150 μl of Opti-MEM medium. Subsequently, the 
contents of the two Eppendorf tubes were combined, mixed for 5 seconds by 
vortexing and incubated for 5 minutes at room temperature to allow the formation of 
complexes. Then, the DNA/ lipofectamine mix was dispensed dropwise into each 
well. After 24 hours, the cells were assessed for the efficiency of the transfection.  
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2.4 Molecular biology  
  
2.4.1 Guide RNA cloning protocol to PX461 vector   
At first, a digestion reaction was set up in an Eppendorf tube. More specifically, 1 μg 
of PX461 plasmid DNA (Addgene), 1 μl of Fast Digest BbsI enzyme (Thermo 
scientific), 2 μl 10X FastDigest Buffer (Thermo scientific), 1 μl Fast AP (Thermo 
scientific) were mixed, and distilled water was added to a final volume of 20 μl. Then, 
the digestion mixture was incubated for 30 min at 37°C. After the incubation, the 
digested plasmid was gel purified using the QIAquick Gel Extraction Kit (Qiagen), 
according to the manufacturers’ protocol. At the next step, each pair of guide RNA 
oligos was phosphorylated and annealed. For this, a reaction was set by adding 1 μl 
of oligo 1 (100mM), 1 μl of oligo 2 (100mM), 1 μl of 10X T4 Ligation Buffer (NEB), 6.5 
μl distilled water and 0.5 μl T4 PNK (NEB) in a PCR tube. The oligos were annealed, 
by placing the reaction in a thermocycler using the following parameters: 37°C for 30 
min 95°C for 5 min and then ramp down to 25°C at 5°C /min. Then ligation reaction 
was set and incubated at room temperature for 10 min. The ligation reaction mix 
contained 1 μl of BbsI digested plasmid from the digestion reaction (50ng), 1 μl of 
phosphorylated and annealed oligo duplex (1:200 dilution), 5 μl of 2X Quickligation 
Buffer (NEB) and X μl of distilled water to a final volume of 11 μl. Finally, the ligation 
reaction was incubated at 37°C for 30 min. At the last step, DH5a bacteria were 
transformed with the ligation reaction.  
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The sequences of the guide RNAs used in this study are listed below: 
 
 Guide RNAs sequence (‘5-3’ 
direction )  
Mouse ACKR3 Forward TACATTTTCATCTTCGTGAT 
Mouse ACKR3 Reverse ATCACGAAGATGAAAATGTA 
Mouse ACKR3 Forward 2 AACAAGAACGTGCTTCTGTA 
Mouse ACKR3 Reverse 2 TACAGAAGCACGTTCTTGTT 
Mouse CXCR4 Forward GGAGCATGACGGACAAGTAC 
Mouse CXCR4 Reverse GTACTTGTCCGTCATGCTCC 
Mouse CXCR4 Forward 2 TCTTCTGGTAACCCATGACC 
Mouse CXCR4 Reverse 2 GGTCATGGGTTACCAGAAGA 
 
The following primer was used for Sanger sequencing to verify successful cloning of 
the guide RNAs: U6 Forward :GAGGGCCTATTTCCCATGATTCC. 
 
  
2.4.2 Bacteria DH5a transformation protocol  
Competent E. coli bacteria (strain DH5a) cells were allowed to thaw on ice. Then the 
cells were gently mixed with a pipet tip and aliquoted by putting 50 μl of cells for each 
transformation into 1.5 ml tubes that have been pre-chilled on ice. Then 1-5 μl DNA 
(1-100ng) was added to the cells, and they were mixed gently by pipetting. Then the 
cells/ DNA mixture was placed on ice for 30 minutes. Afterwards, the bacteria were 
heat-shocked at 42°C for 30- 45 seconds without shaking. Then the tubes were 
placed on ice for 2 minutes. After this, 500 μl of pre-warmed (37°C) LB medium were 
added, and the bacteria were placed in a rocking incubator at 37°C for 1 hour.  
Finally, 100 μl of each transformation was plated on LB plates with the appropriate 
antibiotic for selection, and bacterial colonies were allowed to grow overnight at 37°C.  
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2.4.3 FACS cell sorting and data analysis  
Cas9-EGFP transiently transfected B16F10 and LLC1 cells were trypsinised, 
resuspended in FACS buffer [DPBS 1X without Calcium (Invitrogen) +2% FBS 
(Invitrogen 10270106) +2mM EDTA)] and sorted using a BD FACS Aria TM III sorter.  
  
2.4.4 CRISPR validation  
B16F10 and LLC cells have undergone genome editing processes. After transfection 
with the Cas9/GFP plasmid, cells were subjected to single-cell sorting in 96 well 
plates, and single-cell clones were allowed to grow for 3-4  weeks. When clones 
reached 80% confluency, the genomic DNA was extracted, followed by PCR 
amplification of the gene of interest. Genomic DNA PCR products were analysed and 
pre-screened for their size on an agarose gel. The selected PCR products were TA 
cloned inside pGEM T-Easy vector and sequenced to verify biallelic knockouts.  
   
  
2.4.5 Genomic DNA extraction  
Genomic DNA was extracted using the QuickExtract Solution (Lucigen). Cells were 
placed in a 0.2 mL PCR tube and 100 μl of QuickExtract Solution was added to each 
tube. Then cells were vortexed at 300g for 15 seconds and incubated at 65°C for 10-
15 minutes. Subsequently, cells were vortexed for 15 seconds and incubated at 98°C 
for 2 minutes. After this, the extracted genomic DNA was ready to use for PCR 
amplification or for storage at -20◦C for later use. For CRISPR validation, the genomic 
DNA from different single-cell expanded clones, was PCR amplified using specific 
genomic primers (that span the area of the expected double-strand break).  
The genomic PCR product was run in a 2% w/v agarose gel and the clones of interest 
were interrogated by comparing the size of the PCR band with the PCR band from 
the WT clone that served as a control. Selected PCR products, from the clones of 
interest, were then gel purified and prepared for the subsequent TA cloning step.  
  
2.4.6 Genomic PCR  
The genomic DNA extracted from the cells was amplified using the Q5 High-Fidelity 
2X Master Mix (New England  Biolabs). More specifically 2 μl (50- 100 ng) of genomic 
DNA was added to 25 μl of 2X PCR Master Mix, 2,5 μl of forward and 2,5 μl of reverse 
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primer (final concentration 10 μM) and 18 μl of distilled water. Reactions were run 
with the following programme:  
 
     
 
The primers used for the genomic PCR were the following: 
 
Forward ACKR3 CACTCTTCACCTCTGGCCTAA 
Reverse ACKR3 GCTACTGTGCTTCTCCTGGT 
Forward CXCR4.     TTGGTTCCACTAAAGAGGGCA 
Reverse CXCR4      CCCTTGGAGTGTGACAGCTT 
 
2.4.7 Gel electrophoresis  
PCR products were run on a 2% agarose gel to determine the size. The gel was 
made by dissolving 3g of agarose (Sigma-Aldrich) to 150ml of tris acetate 
ethylenediaminetetraacetic acid (TAE) buffer. Subsequently, 7.5 ml of ethidium 
bromide were added and the solution was poured into a gel electrophoresis tank and 
left to solidify.  Samples were loaded and run for 60 min at 100 volts.  The gel was 
imaged by UV illumination using an Alpha 2200 Digital UV- Visphoto (Alpha Innotech, 
Santa Clara, California).  
 
 
 
Initial Denaturation 98°C 30 seconds 
35 Cycles 98°C 
68 °C 
72°C 
5–10 seconds 
10–30 seconds 
20–30 seconds/kb 
Final Extension 72°C 2 minutes 
Hold 4°C  
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2.4.8 TA cloning  
Genomic PCR amplification products were blunt-ended dsDNA oligonucleotides 
because a high-fidelity DNA polymerase was used. TA cloning protocol required 
single nucleotide 3’ overhang at each strand. At the first step, blunt-ended genomic 
PCR products were incubated with dATP (Ambion), Taq polymerase (New England 
Biolabs) and Taq polymerase buffer at 70°C for 30 min. The pGEM T-Easy (Promega) 
is a linearized vector with a single dTTP 5’ overhang. Subsequently, the pGEM T-
Easy, the genomic PCR products with overhangs added, and DNA ligase (Promega) 
were incubated together for 1 hour at room temperature. After one-hour, competent 
bacteria were transformed with the ligation product.  
  
2.4.9 Genome editing using the D10A Cas9 (nickase) strategy  
Mutant D10A Cas9 encoded in PX461 vector (Addgene) was used for the genome 
editing approaches (Figure 2.1). Mutation of D10A impairs the DSB (double-strand 
break) formation ability of WT Cas9, giving it the ability to generate a single nick on 
the complementary strand. Therefore, to generate a DSB, a pair of nickases, with two 
different guide RNAs is required, reducing the possibility of off-target effects greatly. 
The efficiency of the genome editing is reduced if the distance between the two 
gRNAs is greater than 20 nucleotides.  
One disadvantage of the nickase method is the fact that it is more challenging to find 
a target region in which the two guide RNAs are closely spaced and at the same time 
are located close to the beginning of the gene, to achieve efficient gene disruption. 
The main advantage of the nickase approach is that the genome targeting is 
extremely precise, with a reduced number of off-target effects occurring.   
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Figure 2.1 Diagram of the in PX461 vector that encodes for mutant D10A Cas9 
protein (source Snapgene software)  
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2.5 Flow cytometry  
Flow cytometry is an analytical laser-based cell biology technique, that exploits the 
refracted or emitted light from cells, to count and identify different cell types in a 
heterogeneous fluid mixture. Cells are usually stained with fluorescent antibodies 
against cell markers, that allow the cell type identification so that light is first absorbed 
and then emitted at different wavelengths. Then cells are suspended in a fluid and 
injected into the flow cytometer instrument. The flow cytometer applies fluidics 
pressure to regulate flow rate, ideally allowing one cell at a time through a laser beam 
and the light scattered is characteristic to the cell type. Flow cytometry is a powerful 
method because it allows the rapid and accurate collection of data related to many 
parameters from a heterogeneous fluid mixture containing live cells.  
  
2.5.1 Forward Scatter (FSC)  
Forward Scatter light is refracted by a cell in the flow channel and continues along in 
the light path. The forward scattered light is detected by a sensor in the light path and 
is typically used to identify particle size. The forward scattered light is most commonly 
used to detect the size of the cell. Larger cells will produce more forward scattered 
light than smaller cells, and larger cells will have a stronger forward scatter signal.  
  
2.5.2 Side Scatter (SSC)  
Side-scattered light is usually used to determine the granularity and complexity of the 
cell. Cells with high granularity and a large amount of internal complexity, like 
neutrophils, will produce more side-scattered light, and a higher side-scatter signal 
than cells with a low-granularity and complexity.  
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2.5.3 Flow cytometry analysis  
When acquiring samples in the flow cytometer, FSC and SSC voltages were set to a 
suitable value to make sure that all the cell events were ‘’on scale’’ and included for 
analysis. When analysing flow cytometry data, cells of interest were gated using FSC 
and SSC, cell doublets were discriminated using SSC-A (Side Scatter- Area) and 
SSC-H (Side Scatter- Height) or FSC-A and FSC-H, and live cells were selected 
based on negativity of dead cell dye staining. This gating strategy was applied to all 
the flow cytometry data before proceeding to further gating analyses.  
  
2.5.4 Fluorescent minus one controls (FMO)  
Fluorescence minus one (FMO) controls were used to assess and gate on positive 
staining accuracy. In every antibody panel, an FMO was made for each fluorophore 
of the panel. FMO for an antibody involves staining the cells with a cocktail of 
antibodies that includes all the colours of the panel apart from one. The missing 
fluorophore in each FMO sample would be used to assess any spill-over of 
fluorescence from other channels, while also serving as a negative control, allowing 
clear visualisation of the positive staining.  
  
  
2.5.5 Doublet discrimination  
Doublet exclusion is a critical step in flow cytometry to ensure we include single cells 
and exclude doublets from the subsequent analysis. This can be critical in cell sorting, 
cell cycle analysis. If a doublet containing a fluorescence positive and negative cell 
passes through the laser it will produce a positive signal leading to false positives. 
Doublet exclusion is performed by plotting the height or width against the area for 
forward scatter or side scatter. Doublets will have double the area and width values 
of single cells while the height is roughly the same.  
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2.5.6 Flow cytometry antibodies and viability dyes  
  
Cell marker   Antibody clone   
  
Final  antibody  
dilution   
  
Fluorophore  
CD45   30F11 (Biolegend)   1:200   
  
APC Cy7  
EpCAM   G8.8 (Biolegend)   
  
1:200   
  
  
  
PERCP 5,5  
CD31   
MEC13.3  
(Biolegend)   
1:200   
  
PE, BV650  
Gp38   8.1.1 (Biolegend)   1:200   
  
PE Cy7  
CD140A   APA5 (Biolegend)   
  
1:200   
  
  
  
APC  
ACKR3  
11G8(RnD  
Systems)  
1:100  
  
PE  
  
ACKR3   
10D1(BD 
Biosciences)  
1:100  
  
BV421  
Viability dye  
Viability Dye eFluor 
506  ThermoFisher  1:5000  
  
BV510  
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2.5.7 Live dead viability staining for flow cytometry  
After digestion, cells were isolated  and stained with a viability dye. These dyes are 
commonly used in cellular staining for flow cytometry analysis and are based on the 
reaction of a fluorescent reactive dye with cellular proteins (amines). The viability 
dyes cannot penetrate cell membranes of live cells, so only a few cell surface proteins 
are available to react with the dye, resulting in dim staining. The viability dyes can 
permeate the interrupted membranes of dead cells and stain both the surface and 
interior protein amines, resulting in brighter staining.  
 
The viability staining step is essential for the flow cytometry data analysis since it is 
a common practice to exclude dead cells from the data analysis. This is because 
dead cells have higher autofluorescence and exhibit increased non-specific antibody 
binding, which can lead to false positives284.  
  
2.5.8 ACKR3 antibody intracellular staining for flow cytometry   
Lung cell suspensions after the viability staining step were stained for  extracellular 
markers. More specifically, cells were stained with an antibody cocktail (detailed in 
2.5.6 section) for 20 minutes on ice in the dark in the presence of FcR blocking 
reagent (Miltenyi) according to the manufacturers’ instructions. Subsequently, the 
cells were fixed and permeabilised in 200μl of BD Cytofix/Cytoperm buffer per 
sample. Cells were incubated in this buffer for 20-30 minutes on ice. The fixation step 
before intracellular staining is essential to ensure stability of the antigens. 
Subsequently, the cells were washed in  1ml 1x Perm Wash Buffer per sample (10x 
solution buffer was diluted to 1x using distilled). Cells were centrifuged at 400xg for 5 
minutes.  
At the next step, ACKR3 intracellular staining was performed by diluting the ACKR3 
antibody in 1x Perm Wash Buffer. ACKR3 antibody staining was performed in 
permeabilization buffer to ensure the cells remain permeable. The cells were 
incubated for 20-30 minutes on ice in the dark. After this, the cells were washed  in 
1ml 1x Perm Wash Buffer per sample as previously and  collected by centrifugation 
at 400xg for 5 minutes.  
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2.5.9 Chemokine uptake assay  
Synthetic chemokines directly labelled with a fluorophore provide a useful tool for 
studying chemokine and chemokine receptor interactions285. It has been shown that 
chemical attachment of a fluorophore at the C terminus of a chemokine does not alter 
its biological function. The chemokine uptake assay takes advantage of the use of a 
C-terminally fluorescently-labelled chemokine. The internalization of the labelled 
chemokine is proportional to the presence of the chemokine receptor in question. 
The uptake medium  consists of RPMI 1640 + 0.5% BSA. For the chemokines uptake 
assay we used the mouse CXCL12 C terminus-tagged Alexa Fluorophore 647 
(Almac). 
Briefly, 90 μl of cells were suspended in uptake medium at a concentration of 106 
cells /ml (90,000 cells per well) in a round bottom 96 well plate. Subsequently,10 μl 
of 10x concentrated fluorescent chemokine (final concentration 25nM) were diluted  
in uptake medium and the final diluent was added dropwise to the cells. Then cells 
were incubated at 37 °C for 1 hour. Subsequently, the cells were washed twice with 
uptake medium and were centrifuged at 300g for 5 min at RT. Cells were 
resuspended in 150-200 μl of uptake medium and were analysed using a flow 
cytometer.  
  
  
  
2.5.10 Ki-67 proliferation assay  
Ki-67 is a protein which is located in the nucleus of eukaryotic cells. Fluorescent 
antibodies against Ki-67 are regularly used in order to assess the proliferative 
capability of cells, making it a commonly used biomarker. In our study, the 
proliferation rate of the cells was assessed by flow cytometry. Briefly, the staining 
protocol is the following: 70% ethanol was prepared and chilled overnight at -20°C.  
Cells were trypsinised and centrifuged at 300g for 5 min at 4°C. The cells were then 
washed with FACS buffer and centrifuged at 300g for 5 min at 4°C. Then, if desirable, 
cells were stained for other cell markers. Cells were rewashed with FACS buffer and 
centrifuged at 300g for 5 min at 4°C. Supernatant was discarded, and the cell pellet 
was loosened by vortexing. One drop of ice-cold 70% ethanol was added to the pellet, 
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and the pellet was vortexed. Then, 500 μl of ice-cold ethanol was added to the pellet 
and vortexed. After this, the cells were incubated for 1 hour at -20°C.  
Then the cells were washed and centrifuged at 300g for 5 min at 4°C and 
resuspended in FACS buffer. Then, the anti-Ki-67 antibody was added to the samples 
at 1:220 dilution. Samples were incubated in the dark at RT (room temperature) for 
30 min. After this, the samples were washed and centrifuged at 300g for 5 min at 4°C 
and resuspended in FACS buffer before reading in the flow cytometer.  
  
  
  
2.5.11 Murine lung and trachea tissue dissociation and cell isolation for flow 
cytometry  
Digestion solution  
RPMI (Invitrogen) containing:   
Dispase II (800 μg /ml, Roche)  
Collagenase P (200 μg/ml, Roche)   
DNAse I (100 μg/ml, Roche)  
  
Mice were euthanised by a Schedule 1 procedure. Lungs were perfused by flushing 
the heart through the right ventricle with 20 ml of ice-cold PBS (using a 20 ml syringe 
and an 18G needle) until lungs were cleared of blood. Subsequently, lungs/tracheas 
were removed and placed in a petri dish containing PBS on ice. Afterwards, 
lungs/tracheas were moved to a clean petri dish, other tissues were trimmed off, and 
the lungs were minced using scissors. Then 2.5 ml of digestion solution was added 
per lung/trachea and incubated for 20-30 min at 37°C on a rocking platform. 
Afterwards, lungs were passed through a cell strainer (100 μm), and the separated 
cells were collected in 50 ml Falcon tubes. Then, the cells were centrifuged at 300g 
for 5 minutes. At the next step, red blood cell lysis using ACK lysis solution 
(Invitrogen) was performed for 5 minutes at room temperature, and the reaction was 
stopped by adding DMEM + 5% FBS serum. Cells were centrifuged at 300g for 5 
minutes. If the pellet was not white, the red blood lysis step was repeated one more 
time. After this step, cells were ready for antibody staining. 
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2.6 In vivo techniques  
  
2.6.1 Mice strains  
 
C57BL/6 mice  
C57BL/6, often called” C57” or” black 6”, refers to an inbred strain of mice widely used 
in labs all over the world. Some of the reasons for the success and the widespread 
use of this mouse strain, are the fact that they are easy to breed, they are robust, and 
a lot of congenic strains are available for crossings. The strain C57BL/6 was created 
in 1921 at the Bussey Institute, and its genome was the second whole genome ever 
sequenced286.  
  
C57BL/6-Ackr3tm1Litt /J reporter mice   
The entire exon 2 that encodes for the ACKR3 gene was replaced by the EGFP 
sequence. A 5′ homology arm containing a 5.4-kb genomic fragment containing part 
of intron 1 and 26 bp of exon 2 immediately upstream of the ATG start codon was 
PCR amplified using C57BL/6 genomic DNA as a template, and then cloned in front 
of EGFP coding sequence. A 3′ homology arm containing a 5.2-kb genomic fragment 
including DNA sequence immediately downstream of the stop codon of ACKR3 gene 
was PCR amplified using C57BL/6 genomic DNA and cloned after a neomycin-
resistant gene cassette flanked by Lox P sites. The targeting construct was 
electroporated into albino C57BL/6 embryonic stem (ES) cells.   
The colonies doubly resistant for the aminoglycoside G418 and ganciclovir were 
screened by Southern blot analyses with BsrgI, BamHI, and HindIII digestions for 
homologous recombination. Positive clones were injected into mouse blastocysts. 
Mice were subsequently crossed with EIIa-cre mice to remove the neomycin-resistant 
cassette287.  
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2.6.2 Animal Welfare   
All the mice that were used in the present study were housed in the Biological 
Services Central Research Facility at the University of Glasgow and maintained in 
specific pathogen-free conditions with unrestricted access to food and water. All 
experiments were approved by the University of Glasgow Ethical Review Committee 
and performed under the auspices of a licence from the United Kingdom Home Office.  
  
  
2.6.3 Subcutaneous tumour cell injections  
Wild type female C57BL/6 mice aged 8-9 weeks; back skin was shaved the day 
before injections. Before injection, mice were anaesthetised with isoflurane, then 
2x105 LLCs per mouse were injected directly beneath their dorsal skin. Tumours were 
measured every day from the day the tumour became visible below the skin until their 
largest radius reached the length of 12 mm in compliance with the Home Office 
Procedure Project License (PLL number 70//8377) and with a Procedure Individual 
Licence (PIL number ID34B8D13). At the end of the growth period, mice were 
subjected to a Schedule 1 procedure and pictures of the tumour were taken, and 
tumours were weighed.  
  
2.6.4 Intravenous tumour cells injections 
2x105 B16F10 cells were injected into the tail vein of female C57BL/6 mice aged 8-9 
weeks. Mice were weighed daily (in compliance with the Home Office project animal 
license) after the day of injection. After two weeks from the day of injection, mice were 
subjected to Schedule 1 procedures; lungs were removed and assessed 
macroscopically (counting individual tumour nodules) regarding the tumour burden.  
 More specifically, lungs from different  groups were blinded before counting and 
subsequently were counted by two different individuals and measurements were 
compared to assure an unbiased measurement .  
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2.7 Software  
  
2.7.1 Flow cytometry data analysis  
All data obtained from flow cytometry were analysed using FlowJo software. Samples 
were gated initially on forward and side-scatter parameters to exclude debris, forward 
scatter average against height to exclude doublets and cells negative for viability dye 
to exclude dead cells. Individual stains were gated based on FMO, if available. For 
individual tissues and cell types, standard gating strategies were applied as detailed 
in the results section.  
  
  
2.7.2 Statistical Analysis  
For statistical analysis, Prism (GraphPad) software was used. For all statistical 
analyses in this study, the following methods were used : When two groups were 
compared, an un paired  t-test was applied. For comparison of more than two groups, 
one-way analysis of variance (ANOVA) was applied with Tukey’s or Bonferroni’s  
correction for multiple comparisons. For comparison of groups with data that did not 
follow the normal distribution assumption, the Kruskal-Wallis test was applied. 
Statistical significance was indicated as: *P≤0.05, **P≤0.01, ***P≤0.001, 
****P≤0.0001, ns = P>0.05. Error bars represented the standard deviation of the 
mean.  
Box-and-whisker plot: Whiskers indicate 10th and 90th percentile boxes indicate 25th 
to 75th percentile, and the  horizontal solid line indicates the median. Circles indicate 
the minimum and maximum values.   
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CHAPTER 3   
Characterisation of ACKR3 expression in 
the adult lung   
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3.1 Introduction and aims of the chapter  
  
One of the most critical obstacles when studying GPCRs is the lack of specific 
antibodies due to the high number of GPCRs and the high structural homology among 
GPCR members of the same subfamily. Antibodies against ACKR3 are not an 
exception to this general rule. There are several discrepancies reported in the 
literature regarding ACKR3 expression in different tissues, that are mostly attributed 
to the non- specific nature of the anti ACKR3 antibodies. For example, in lung cancer, 
ACKR3 expression in patients’ biopsies is mostly assessed by immunohistochemistry 
using antibodies that were not validated in ACKR3 KO cell lines or ACKR3 KO mice. 
In murine lung cancer models cells are examined for ACKR3 expression using 
immunohistochemistry and flow cytometry using anti -ACKR3 antibodies. 
To this end, it is very important to validate some of the most commonly used ACKR3 
antibodies in order to be able to critically evaluate the ACKR3 expression in lung 
cancer and other cancers. 
 
To circumvent this problem, other complementary methods are used to assess the 
expression of ACKR3. For in vitro studies, competition binding assays of labelled 
chemokines among others, are usually performed as supplementary methods of 
identification. For in vivo studies, the use of ACKR3 fluorescent reporter animals is a 
reliable approach to characterize ACKR3 expression in different tissues.  
 
To this end, for this study, we used the C57BL/6-Ackr3tm1Litt /J reporter mouse to 
interrogate ACKR3 expression in the resting lung. The Ackr3tm1Litt/J mouse strain 
was generated in the laboratory of Dr Dan Littman in New York University. More 
specifically, the EGFP (enhanced green fluorescent protein) cDNA was knocked into 
the second exon of the gene immediately after the endogenous start codon. This 
mouse strain is maintained in the heterozygous state since the homozygous GFP 
(ACKR3 knockout) mice die postnatally (Figure 3.1)288.  
 
The aforementioned reporter mouse provides a powerful tool to assess ACKR3 
expression in stromal cell subsets, in the resting lung. The main reason for the 
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selection of this particular tissue for analysis is that ACKR3 is overexpressed in lung 
cancer (described in chapter 5). Lung cancer can originate from cell populations that 
reside in the lung. Furthermore, the ACKR3 reporter mouse provides a valuable tool 
to validate  commercially available anti-ACKR3  antibodies.  
   
  
 
  
Figure 3.1 Schematic representation of C57BL/6-Ackr3tm1Litt /J reporter 
mouse strain. This mouse strain is maintained in the heterozygous state since the 
homozygous GFP (ACKR3 knockout) mice die postnatally. The EGFP (enhanced 
green fluorescent protein) cDNA was knocked into the second exon of the gene 
immediately after the endogenous start codon. 
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3.2 Interrogation of ACKR3 expression in the resting lung stroma 
using flow cytometry  
  
For this study, both female and male ACKR3 GFP reporter animals aged 10-12 weeks 
were used to assess expression of ACKR3 in resting lung. More specifically, we 
isolated cells from the lung and stained them with a cocktail of antibodies against cell 
markers that would allow us to discriminate between major stromal cell types, using 
flow cytometry. Four major stromal cell types were interrogated for ACKR3 (GFP) 
expression: lymphatic endothelial cells (LECs), blood endothelial cells (BECs), 
epithelial cells and fibroblasts. An overview of the general gating strategy we applied 
to analyse the flow cytometry data from the lung is presented in Figure 3.2.  
  
 
 
  
Figure 3.2 Stromal cell markers used for flow cytometry gating of the lung  
stromal cell populations.  
 
 
At first, lungs were dissected from the animals, and tissues were minced with a pair 
of scissors and subsequently digested (described in detail in the Materials and 
Cell type   Gating strategy   
Epithelial cells   Live, CD45-,CD31-,EpCam+  
Lymphatic endothelial cells   Live, CD45-,CD31+,Gp38+  
Blood endothelial cells  Live, CD45-,CD31+,Gp38-  
Fibroblasts  Live, CD45-,CD31-,CD140a+  
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Methods, section 2.5.11). After the live/dead staining (described in detail in the 
Materials and Methods, section 2.5.7), we stained the cell isolates with a fluorescent-
tagged antibody cocktail against cell markers characteristic of distinct cell subsets. 
We included appropriate FMO (Fluorescence Minus One) controls for every 
fluorophore that was present in our antibody panel.  
After staining, cells were fixed, and the following day were analysed using a BD LSR 
Fortessa cytometer analyser. Single fluorophore stained beads were used to calibrate 
the cytometer lasers before running the cell samples.  
 
3.3 Interrogation of ACKR3 expression in the resting lung  
  
The first population we interrogated for ACKR3 (GFP) expression in the resting lung 
was epithelial cells. For this purpose, we used the general pan- epithelial marker, 
epithelial cell adhesion molecule (EpCAM). More specifically, in the flow cytometry 
data analysis, at first dead cells were excluded because dead cells often have higher 
autofluorescence and also bind antibodies non-specifically, thus generating artefacts 
in the downstream analyses (detailed in Materials and Methods section 2.5.7).  
To this end, we selected only the live cell population for further analyses, as 
presented in the Figure 3.3 A. Subsequently, we gated the single cells (doublet 
discrimination) as presented in Figure 3.3 B.   
Then we used the CD45 (lymphocyte common antigen) cell marker that is a general 
pan-leukocyte marker. CD45 is a transmembrane protein, a receptor-linked protein 
tyrosine phosphatase that is expressed on all leukocytes and plays a crucial role in 
the function of these cells289.   
We selected the CD45- (non-leukocyte) cell population (Figure 3.3 C) and then 
enriched for the CD31- negative population (Figure 3.3 D). CD31 is a general pan -
endothelial marker. This step is essential since a significant portion of epithelial cells 
is also positive for CD31, possibly due to the highly vascularized nature of the lung 
epithelium and the tight association of endothelial and epithelial cells in the lung290.  
After the CD31 depletion step, we enriched for the EpCAM positive population (Figure 
3.3 E). This population was subsequently interrogated for GFP (ACKR3) expression 
(Figure 3.4).  
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Figure 3.3 Flow cytometry gating strategy to identify epithelial cells in the 
resting lung of the ACKR3 (GFP) reporter mouse.  
Flow cytometry data plots of fibroblasts in the resting lung of the ACKR3(GFP) 
reporter mouse. The gated populations selected for analysis are depicted in red. A) 
Dead cells and cell debris were excluded, then B) single cells were gated (doublet 
discrimination) C) CD45- cells were selected to exclude white blood cells D) CD31- 
cells for endothelial cell exclusion and E) EpCAM+ cells were selected.   
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Figure 3.4 ACKR3 is not expressed in the epithelial cells in the resting lung. A) 
Graph representing the ACKR3/ GFP expressing epithelial cells  from six 
ACKR3/GFP reporter mice. The GFP/ACKR3 expression is presented as % 
percentage of GFP expressing epithelial  to total epithelial  in the resting lung. Error 
bars represent the SD of the mean. B) Representative flow cytometry data plots of 
epithelial from ACKR3 (GFP) and WT mice. One WT mouse served as a negative 
control for the FITCH(GFP) fluorescence.   
.   
 
As observed in figure 3.4, the GFP/ ACKR3 expression in the reporter mice (left plot) 
is almost identical to the GFP expression in the WT control mouse (right plot). This 
observation was consistent among all six GFP/ACKR3 mice examined and compared 
with the wt control mouse and suggests that ACKR3 is not expressed in resting lung 
epithelium. 
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Subsequently, we interrogated the fibroblastic cell population in the lung. Fibroblasts 
are a very heterogeneous cell population and different cell markers, dependent on 
the tissue, are used for the identification of this cell population. In this study, for the 
resting lung analysis, we used the CD140A cell marker. This marker is also known 
as Platelet-Derived Growth Factor Receptor Alpha (PDGFRα).  
For the fibroblasts flow cytometry gating strategy, similar to the epithelial cell gating, 
we enriched for live single cells, CD45- and CD31- (Figure 3.5. A, B, C and D). 
Subsequently, the CD31- population was enriched for CD140A positive cells (Figure 
3.5 E). The fibroblastic CD140A population was examined for GFP (ACKR3) 
expression.   
After our analysis, we interrogated the flow cytometric data from six ACKR3 GFP 
mice, and we observed that on average, a portion of fibroblasts in the resting lung, 
express ACKR3 (Figure 3.6). More specifically, it was observed that around 13-18 % 
of the total fibroblasts expressed GFP/ACKR3 in the resting lung (Figure 3.6A). 
As mentioned previously, CD140a is a general marker for fibroblasts in the lung and 
fibroblasts are a very heterogeneous population. To this end, more cell markers 
should be used to further characterise the fibroblastic subpopulations that express 
ACKR3 and to gain a better understanding about the possible biological roles of 
ACKR3 in these cell populations.  
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Figure 3.5 Fibroblasts gating strategy in the resting lung.   
Flow cytometry data plots of fibroblasts in the resting lung of the ACKR3(GFP) 
reporter mouse. The gated populations for analysis are depicted in red colour. A) Live 
(B) single cells were selected, then C) CD45- cells were gated for immune cells 
exclusion. Subsequently D) CD31- were gated to exclude endothelial cells and E) 
CD140A+ cells were selected. 	  
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Figure 3.6 ACKR3 is expressed in fibroblasts in the resting lung.   
A) Graph representing the ACKR3/ GFP expressing fibroblasts from six ACKR3/GFP 
reporter mice. The GFP/ACKR3 expression is presented as % percentage of GFP 
expressing fibroblasts to total fibroblasts in the resting lung. Error bars represent the 
SD of the mean. B) Representative flow cytometry data plots of fibroblasts from 
ACKR3 (GFP) and WT mice. One WT mouse served as a negative control for the 
FITCH(GFP) fluorescence.   
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The next lung stromal population we analysed was blood endothelial cells (BECs). 
For this subset of cells, we used the general pan- endothelial marker CD31(cluster of 
differentiation 31). CD31 is also known as platelet endothelial cell adhesion molecule 
(PECAM-1) and is expressed in a variety of endothelial cells, including lymphatic 
endothelial cells.  
 
The gating strategy we followed for the identification of the blood endothelial cells, 
included live single cells and CD45- selection (Figure 3.7 A, B,C) and then CD31 
positive cells (Figure 3.7D). At this step of the analysis, in order to exclude lymphatic 
endothelial cells that also express CD31, we used the Gp38 cell marker. Gp38 
protein, also known as podoplanin (PDPN), is a specific lymphatic vessel marker291. 
Regarding this, we selected from the CD31+ cells, the Gp38 negative cells to exclude 
LECs (Figure 3.7E). Finally, the Gp38- cells that consist of the BECs, were 
interrogated for GFP (ACKR3) expression (Figure 3.8). Also, in this case, analysis of 
flow cytometry data from GFP/ACKR3 reporter mice revealed that a significant 
number of BECs in the lung express ACKR3. Data from six GFP reporter mice that 
were compared with one WT control mouse, verified the ACKR3 expression in the 
BECs in the resting lung. More specifically, around 35-45% of BECs express GFP in 
the resting adult lung. 
 
This observation is in accordance with several studies that highlight the expression 
of ACKR3 in blood endothelial cells in several tissues and organs. ACKR3 expression 
has been associated with endothelial cell homeostasis, CD31 redistribution, loss of 
endothelial cell contacts and inhibition of endothelial barrier function. Some studies 
propose that ACKR3 expression in endothelial cells can regulate angiogenesis under 
certain conditions292.  
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Figure 3.7 Blood endothelial cell gating strategy in the resting lung. 
Representative flow cytometry data plots of blood endothelial cells in the resting lung 
of the ACKR3(GFP) reporter mouse. The gated populations for analysis are depicted 
in red colour. A) Live cells were selected, then B) single cells C) CD45- cells were 
gated for immune cells exclusion, D) then CD31+ and E) GP38- cells were selected.   	  	  
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Figure 3.8 ACKR3 is expressed in blood endothelial cells in the resting lung.  
A) Graph showing GFP/ACKR3 expressing blood endothelial cells, as the percentage 
of the total blood endothelial cells. Error bars represent the SD of the mean. B) 
Representative flow cytometry data plots of lymphatic endothelial cells from ACKR3 
(GFP) and WT mice. One WT mouse served as a negative control for the GFP 
fluorescence.   
 
 
 
 
 
The last stromal population we assessed for ACKR3 expression in the lung was 
lymphatic endothelial cells (LECs). As in the previous stromal cell populations, we 
selected live single and CD45- cells (Figure 3.9 A, B, C). Then we enriched for CD31+ 
and Gp38+ cells (Figure 3.9 D, E) that is a specific marker for LECs. A significant 
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portion of this population was ACKR3 positive LECs (Figure 3.10). More specifically, 
after analysing flow cytometry data from 6 GFP / ACKR3 reporter mice, we observed 
that  24-31 % of the total lymphatic endothelial cells express GFP/ACKR3 (Figure 
3.10 A). This observation is reported in the literature, and the critical role of ACKR3 
in lymphatic vessel development has been highlighted in past studies236.  
  
 
 
Figure 3.9 ACKR3 gating strategy in lymphatic endothelial cells in the resting 
lung. Representative flow cytometry data plots of lymphatic endothelial cells in the 
resting lung of the ACKR3(GFP) reporter mouse. The gated populations for analysis 
are depicted in red colour. A) Live cells were selected, then B) single C) CD45- cells 
were gated for immune cell exclusion, then D) CD31+ and E) GP38+ cells were 
selected.  
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Figure 3.10 Lymphatic endothelial cells in resting lung, express ACKR3 A) 
Graph showing comparative GFP/ACKR3 as a percentage of total lymphatic 
endothelial cells. Error bars represent the SD of the mean B) Representative flow 
cytometry data plots of lymphatic endothelial cells  from ACKR3 (GFP) and WT mice.  
One WT mouse served as a negative control for the GFP fluorescence.   
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Finally, we assessed GFP/ACKR3 expression in CD45- non-immune cells (Figure 
3.11) and  CD45+ immune cells (Figure 3.12). Data from six reporter mice revealed 
that ACKR3/GFP positive cells were around 14% (mean value) of the total CD45- 
cells (Figure 3.11A). The same analysis revealed that ACKR3/GFP positive cells 
were around 3.9 % (mean value) of the total CD45+ immune cells (Figure 3.12A).  
  
  
  
Figure 3.11 ACKR3 expression in the non-immune cells in the resting lung.   
A)Graph representing the ACKR3/ GFP expressing CD45- cells  from six 
ACKR3/GFP reporter mice. The GFP/ACKR3 expression is presented as the 
percentage of GFP expressing CD45- cells  of the total CD45- cells  in the resting 
lung. Error bars represent the SD of the mean. B) Representative flow cytometry data 
plots of CD45- cells derived from ACKR3 (GFP) and WT mice .  
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Figure 3.12 ACKR3 expression in leukocytes in the resting lung.   
A) Graph representing the ACKR3/ GFP expressing leukocytes  from six ACKR3/GFP 
reporter mice. The GFP/ACKR3 expression is presented as percentage of GFP 
expressing leukocytes of the total leukocytes in the resting lung. Error bars represent 
the SD of the mean. B) Representative flow cytometry data plots of leukocytes 
derived from ACKR3 (GFP) and WT mice .  
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3.4 Antibody validation using the ACKR3 GFP reporter mouse   
  
As mentioned previously, one of the major challenges in ACKR3 studies, is the lack 
of specific anti-ACKR3 antibodies. After verifying ACKR3 expression in the stromal 
cell subsets in the resting lung, we attempted to assess the specificity and the 
efficiency of commercially available flow cytometry anti-ACKR3 antibodies. More 
specifically, we used two anti-ACKR3 antibodies and stained the same stromal cell 
populations in the lung of the ACKR3/GFP reporter mice. This approach allowed us 
to compare the ACKR3 antibody-stained cell populations with ACKR3/GFP 
fluorescent cells.  
  
  
3.4.1 ACKR3 (10D1) antibody validation  
First, we attempted to validate the anti ACKR3 antibody clone 10D1(BD). For this 
purpose, murine lung tissues from the ACKR3/GFP mice were processed as 
described previously (described in details in Materials and Methods, section 2.5.11) 
and cell isolates were permeabilised and fixed (detailed in Materials and Methods 
2.5.8) before the antibody staining step. The permeabilisation/ fixation step is 
essential for ACKR3 detection in flow cytometry experiments since ACKR3 is known 
to be a constitutively internalising receptor, with only a small portion being present on 
the plasma membrane.   
The flow cytometric comparative analyses between ACKR3 stained cells and 
ACKR3/GFP fluorescent cells revealed the following:  
  
Epithelial cells: We observed that anti-ACKR3 antibody stained a small population of 
around 7,8% of the total epithelial cells (Figures 3.13 B and 3.14A). This observation 
is in contrast to what we observed with the ACKR3/ GFP expression that is negative 
in epithelial cells (Figures 3.13 D and 3.14 A). Furthermore, when we interrogated 
the ACKR3 antibody- stained cell population for GFP expression, we noticed that the 
ACKR3 positively -stained cells were mostly negative for GPF expression with only 
around 7% (median value) of these cells shown to be GFP/ACKR3 positive (Figures 
3.13 C and 3.14 B). Collectively these data indicate that ACKR3 staining with the 
10D1 antibody in epithelial cells was non-specific.   
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Figure 3.13 ACKR3 (10D1) antibody validation in lung epithelial cells of the 
ACKR3/GFP reporter mice.  
Representative flow cytometry data plots of epithelial cells in the resting lung. A) 
Epithelial cells were positive for B) ACKR3 staining but this population was negative 
for C) ACKR3/GFP fluorescence. D) total epithelial cells were mostly negative for 
ACKR3/GFP fluorescence.  
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Figure 3.14 ACKR3 (10D1) antibody validation in epithelial cells of the 
ACKR3/GFP reporter mice.  
A) Comparison between the percentages of total epithelial cells that were positive 
after ACKR3 (10D1) antibody staining and ACKR3/GFP fluorescence. B) Graph 
representing  the percentage of  ACKR3(10D1) positively stained cells that were 
expressing GFP. An unpaired t-test was applied to the groups of ACKR3 (10D1) vs 
GFP samples. Statistical significance is indicated as *P≤0.05, **P≤0.01,***P≤0.001, 
****P≤0.0001, ns = P>0.05.All error bars represent the SD of the mean. 
 
Blood endothelial cells: After staining with anti ACKR3 antibody, we observed that 
only a small population of the total blood endothelial cells around 10% were stained 
with this antibody (Figure 3.15 C). When we interrogated this population for 
ACKR3/GFP expression, we noticed that  around 57% of these cells were expressing 
GFP, but there were still many GFP negative cells (Figures 3.15 D and 3.16 B). These 
observations are significantly different from our previous data that indicate that almost 
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40% of blood endothelial cells in the resting lung are GFP/ACKR3 positive (Figures 
3.8 and 3.15E and 3.16A). These data suggest that ACKR3 antibody staining is 
significantly less efficient but also nonspecific in this cell subset.   
 
Figure 3.15 ACKR3 (10D1) antibody validation in the blood endothelial cells of 
the ACKR3/GFP reporter mice.  
Representative flow cytometry data from blood endothelial cells in the resting lung. 
A,B) CD31+,Gp38- blood endothelial cells were C) positive for a small subset of cells 
after ACKR3 staining and this population was partially positive for D) ACKR3/GFP 
fluorescence. E) The total blood endothelial cell population was strongly positive for  
ACKR3/GFP fluorescence.  
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Figure 3.16 ACKR3 (10D1) antibody validation in blood endothelial cells of the 
ACKR3/GFP reporter mice. A) Comparison between the percentages of total blood 
endothelial cells that were positive after ACKR3 (10D1) antibody staining and 
ACKR3/GFP fluorescence. B) Graph representing  the percentage of  ACKR3 (10D1) 
positively stained cells that were expressing GFP. An unpaired t-test was applied to 
the groups of ACKR3 (10D1) vs GFP cell populations. Statistical significance is 
indicated as: *P≤0.05, **P≤0.01,***P≤0.001, ****P≤0.0001, ns = P>0.05. All error bars 
represent the SD of the mean.  
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Lymphatic endothelial cells: The last stromal cell population we interrogated for 
ACKR3 antibody staining was lymphatic endothelial cells. In this cell population, we 
observed that the ACKR3 antibody staining was very inefficient (Figure 3.17 C) as 
only around 8% of the total lymphatic endothelial cell population was positively 
stained.  This is in contrast with the almost 30% of ACKR3/GFP expression we 
observed previously (Figures 3.10, 3.17E and 3.18A). Furthermore, the ACKR3 
antibody positively stained population is mostly negative for GFP/ACKR3 expression 
since only 27% is GFP positive  (Figures 3.17 D and 3.18B), a fact that indicates the 
antibody’s non-specific binding nature.  
 
Figure 3.17 ACKR3 (10D1) antibody validation in lymphatic endothelial cells of 
the ACKR3/GFP reporter mice. Representative flow cytometry data from lymphatic  
endothelial cells in the resting lung. A,B) CD31+,Gp38+ lymphatic endothelial cells 
were C) positive for a small subset of cells after ACKR3 staining and this population 
was partially positive for D) ACKR3/GFP fluorescence. E) The total lymphatic 
endothelial cell population was greatly positive for ACKR3/GFP fluorescence. 
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Figure 3.18 ACKR3 (10D1) antibody validation in lymphatic endothelial cells of 
the ACKR3/GFP reporter mice. A) Comparison between the percentages of total 
epithelial cells that were positive after ACKR3 (10D1) antibody staining and 
ACKR3/GFP fluorescence. B) Graph representing  the percentage of  ACKR3 (10D1) 
positively stained cells that were expressing GFP. An unpaired t-test was applied to 
the groups of ACKR3 (10D1) vs GFP samples. Statistical significance is indicated as 
*P≤0.05, **P≤0.01,***P≤0.001, ****P≤0.0001, ns = P>0.05. All error bars represent 
the SD of the mean.  
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3.4.2 ACKR3 (11G8) antibody validation  
Subsequently, we followed the same approach to validate the ACKR3 antibody clone 
11G8 (R&D Systems). The comparison between the ACKR3 11G8 antibody staining 
and GFP fluorescence in different lung stromal cell types revealed the following:  
In epithelial cells (Figure 3.19) this ACKR3 antibody did not exhibit positive staining, 
consistent with the negative GFP fluorescence.  
  
  
 
 
Figure 3.19 ACKR3 (11G8) antibody validation in lung epithelial cells of the 
ACKR3/GFP reporter mice. Representative flow cytometry data from epithelial cells 
in the resting lung. A) Epithelial cells were negative for B) ACKR3 staining and total  
epithelial cell population was also negative for C) ACKR3/GFP fluorescence.   
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In lymphatic endothelial cells (Figure 3.20), the ACKR3 11G8 antibody stained 
around 10% of the total lymphatic endothelial cells  which is significantly lower than 
the 30% GFP/ACKR3 expressing lymphatic endothelial cells (Figures 3.20C and  
3.21 A). Furthermore, the ACKR3 staining in this population appeared to be 
unspecific as only around 44% of the antibody-stained positive population was also 
GFP positive (Figures 3.20 D and 3.21 B). These observations suggest that ACKR3 
11G8 antibody stained less efficiently, but also non-specifically, this cell population. 
 
 
Figure 3.20 ACKR3 (11G8) antibody validation in lymphatic endothelial cells of 
the ACKR3/GFP reporter mice. Representative flow cytometry data from lymphatic  
endothelial cells in the resting lung.  
A, B) CD31+,Gp38+ lymphatic endothelial cells were C) positive for a subset of cells 
after ACKR3 staining and this population was partially positive for D) ACKR3/GFP 
fluorescence. E) The total lymphatic endothelial cell population was greatly positive 
for ACKR3/GFP fluorescence. 
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Figure 3.21 ACKR3 (11G8) antibody validation in lymphatic endothelial cells of 
the ACKR3/GFP reporter mice.  
A) Comparison between the percentages of total lymphatic endothelial cells that were 
positive after ACKR3(11G8) antibody staining and ACKR3/GFP fluorescence. B) 
Graph representing the percentage of  ACKR3(11G8) positively stained cells that 
were expressing GFP. An unpaired t-test was applied to the groups of ACKR3 (11G8) 
vs GFP samples. Statistical significance is indicated as: *P≤0.05, **P≤0.01, 
***P≤0.001, ****P≤0.0001, ns = P>0.05. All error bars represent the SD of the mean.  
 
In blood endothelial cells ACKR3 11G8 antibody stained only a small percentage of 
this cell population (Figures 3.22 C and 3.23 A) but the ACKR3 staining was also 
non-specific in this cell population as indicated in Figures 3.22 D and 3.23 B.  More 
specifically, anti- ACKR3 antibody clone 11G8, stained only around 13 % of the total 
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blood endothelial cells compared to around 40% that was GFP/ACKR3 positive as 
indicated by the reporter mice (Figure 3.23 A). Furthermore, when we interrogated 
the anti-ACKR3 11G8 antibody-stained cell population for GFP/ACKR3 expression, 
we observed that around 56 % expressed GFP/ACKR3, that suggests that this 
antibody staining is non-specific (Figure 3.23 B). 
 
 
 
Figure 3.22 ACKR3 (11G8) antibody validation in blood endothelial cells of the 
ACKR3/GFP reporter mice. Representative flow cytometry data from blood  
endothelial cells in the resting lung. A,B) CD31+,Gp38- lymphatic endothelial cells 
were C) positive for a small subset of cells after ACKR3 staining and this population 
was partially positive for D) ACKR3/GFP fluorescence. E) The total blood endothelial 
cell population was greatly positive for ACKR3/GFP fluorescence. 
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Figure 3.23 ACKR3 (11G8) antibody validation in the  blood endothelial cells of 
the ACKR3/GFP reporter mice. A) Comparison between the percentages of total 
blood endothelial cells that were positive after ACKR3(11G8) antibody staining and 
ACKR3/GFP fluorescence. B) Graph representing  the percentage of  ACKR3(11G8) 
positively stained cells that were expressing GFP. An unpaired t-test was applied to 
the groups of ACKR3(11G8) vs GFP samples. Statistical significance is indicated as: 
*P≤0.05, **P≤0.01,***P≤0.001, ****P≤0.0001, ns = P>0.05.All error bars represent the 
SD of the mean. 
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3.5 Interrogation of ACKR3 expression in the resting trachea 
 
In our next step, we tried to assess ACKR3 expression in the trachea in the same 
stromal cell populations that we interrogated in the resting lung. More specifically, 
our cell populations of interest were epithelial cells, blood endothelial cells, lymphatic 
endothelial cells and fibroblasts. We applied the same cell markers gating 
strategy (live, single cells, CD45-, CD31-, EpCAM+) in the flow cytometry data to 
distinguish these cell populations. The first population we analysed was the 
trachea epithelial cells. We observed the existence of a small population of epithelial 
cells in the trachea that express ACKR3. The significance of this finding needs 
further investigation as ACKR3 expression in the resting epithelial tissues has not 
been reported in the literature (Figure 3.24). 
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Figure 3.24 ACKR3 is expressed in epithelial cells in the resting trachea. 
Single parameter histograms of flow cytometric analysis of resting trachea 
epithelial cells. Histogram overlay of flow cytometry data of resting trachea blood 
endothelial cells from WT (depicted in red colour) and ACKR3 (GFP) reporter 
mouse (depicted in blue colour).  WT mouse served as negative control for the GFP 
fluorescence. 
 
 
Subsequently, we analysed the blood endothelial cell population and observed that a 
significant number of cells belonging to this population express ACKR3 (Figure 
3.25). Although there are no previous reports about ACKR3 expression in the trachea, 
ACKR3 has been described to be expressed in endothelial cells in several 
organs and endothelial cell lines and plays an important role in endothelial cells 
homeostasis and angiogenic processes. 
 127 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25 Blood endothelial cells express ACKR3 in the resting trachea. 
Single parameter histograms of flow cytometric analysis of the resting trachea blood 
endothelial cells. Histogram of the overlay of flow cytometry data of resting tracheal 
blood endothelial cells from WT (depicted in red colour) and ACKR3 (GFP) reporter 
mouse (depicted in blue colour). WT mouse served as a negative control for the GFP 
fluorescence. 
 
 
The next population we analysed was lymphatic endothelial cells and we observed 
that a significant number of cells belonging to this population express ACKR3 (Figure 
3.26). This finding is in accordance with the observation that ACKR3 is present in 
lymphatic endothelial cells in several tissues and primary cell isolates. The role of 
ACKR3 in lymphangiogenesis during embryonic development is highlighted in a 
recent study236. 
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Figure 3.26 Lymphatic endothelial cells express ACKR3 in the resting 
trachea. Single parameter histograms of flow cytometric analysis of the resting 
trachea lymphatic endothelial cells. Overlay of the ACKR3 negative cell population 
from WT mice (depicted in red colour) and ACKR3 (GFP) positive population from 
the GFP reporter mouse (depicted in blue colour). WT mouse served as a negative 
control for the GFP fluorescence. 
 
 
 
Finally, we assessed ACKR3 expression in resting tracheal fibroblasts and we also 
verified  ACKR3 expression in this cell population (Figure 3.27 ). Fibroblasts are a 
very heterogeneous cell population and further characterisation is needed to specify 
the fibroblastic subpopulations that express ACKR3. 
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Figure 3.27 Fibroblasts express ACKR3 in resting trachea. Single parameter 
histograms of flow cytometric analysis of the resting trachea fibroblasts. Overlay of 
the ACKR3 negative cell population from WT mice (depicted in red colour) and 
ACKR3 (GFP) positive population from the GFP reporter mouse (depicted in 
blue colour). WT mouse served as a negative control for the GFP fluorescence. 
 
Some of the most important caveats when working with trachea murine tissues are 
the limited amount of starting material and the limited viability after tissues digestion 
and processing for flow cytometry. More specifically, we were able to obtain live cells 
for flow cytometry analyses only from one mouse out of the six ACKR3/ GFP mice 
we processed. This suggests that our tissue digestion protocol needs further 
optimisation and other complimentary methods (such us immunofluorescence) 
should be used to assess the ACKR3 expression in murine trachea tissues. 
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3.6 Summary and discussion of the chapter  
  
In this chapter, we took advantage of an ACKR3 GFP reporter mouse to interrogate 
ACKR3 expression in the adult resting lung and trachea. For this purpose, we 
employed flow cytometry to assess ACKR3 expression in four stromal cell 
populations: LECs, BECs, epithelial cells and fibroblasts. Our analyses revealed that 
a significant portion of LECs, BECs and fibroblasts in the adult resting lung and 
trachea, express ACKR3. According to our study, epithelial cells in the adult resting 
lung do not express ACKR3. Our findings in the context of previously published 
studies are the following:  
 
ACKR3 expression in lymphatic endothelial cells: The role of AKCR3 in lymphatic 
system development has been recently described. More specifically, Klein et al. 
proposed that ACKR3 binds and scavenges ADM hormone and modulates ADM 
mediated lymphangiogenesis. In the same study, ACKR3 KO mice exhibited 
enhanced cardiac lymphangiogenesis. This phenotype is due to increased levels of 
ADM in the plasma and increased ADM-dependent lymphatic endothelial cell 
migration236. Regarding this, a similar developmental role is possible for ACKR3 in 
lymphatics in the lung. It is possible that ACKR3 regulates ADM signalling and 
lymphangiogenesis also in the lung, but this has not been investigated so far in the 
literature or the aforementioned study. In another study, ACKR3 has also been shown 
to be expressed in lymphatic endothelial cells in renal allografts. ACKR3 in lymphatic 
endothelial cells was increased during allograft rejection. It is possible that ACKR3 
through its ligand CXCL12 is involved in lymphatic trafficking of inflammatory 
leukocytes in the area of rejection293,294.  
These studies suggest a similar role for ACKR3 in the lymphatic vessels in the lung. 
Possibly in lung inflammatory conditions, ACKR3 scavenges CXCL11, and CXCL12 
thus regulating the trafficking of leukocytes expressing CXCR4, ACKR3 or CXCR3 to 
the sites of inflammation.  
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ACKR3 expression in blood endothelial cells. Regarding the expression of ACKR3 in 
blood endothelial cells in the lung and trachea, several studies highlight the role of 
ACKR3 in these cells. ACKR3 is expressed by human endothelial cells, including 
HUVECs (human umbilical vein endothelial cells)295 HMVECs296 (human 
microvascular endothelial cells), pulmonary microvascular endothelial cells297, and 
endothelial cells within the central nervous system298. ACKR3 expression in blood 
endothelial cells has been associated with angiogenesis, proliferation and migration 
of endothelial progenitor cells. It has been shown that CXCL12 can induce 
angiogenesis through ACKR3 in primary HUVECs, and this process is Akt 
dependent. Similar angiogenic properties were observed after treating HUVECs with 
TC14012, a synthetic ACKR3 agonist292. In another study, it was shown that ACKR3 
is expressed in human brain microvascular endothelial cells (HBMECs) and regulates 
endothelial cell functions such as proliferation, tube formation, migration and 
adhesion. Transient knockdown of ACKR3 in these cells inhibited the cells’ responses 
after exogenous treatment with CXCL12, despite the presence of CXCR4. In a 
different context, using an experimental  autoimmune encephalomyelitis model 
(EAE), for multiple sclerosis, it has been shown that ACKR3, which scavenges 
CXCL12, regulates leukocyte entry via endothelial barriers into the central nervous 
system (CNS). ACKR3 was upregulated in endothelial barriers during EAE at sites of 
inflammation299.  
 
ACKR3 expression in fibroblasts. During our analyses in chapter 3, we also observed 
ACKR3 expression in fibroblastic cell populations in the lung and trachea tissues. 
Fibroblasts are a very heterogeneous cell population. The use of more specific cell 
markers is necessary for the identification of the different fibroblastic subsets that 
express ACKR3. This characterisation will also allow us to gain a better 
understanding of the possible biological function of ACKR3 in these cell populations. 
In the literature, it has been reported that ACKR3 is endogenously expressed in 
Vascular Smooth Muscle Cells (VSMCs). Furthermore, stimulation of these cells with 
the ACKR3 ligands CXCL11 and CXCL12 led to β-arrestin recruitment but no G 
protein-mediated responses were detected131.  
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Regarding the epithelium, we observed no expression of ACKR3 in epithelial cells in 
the resting lung. There are no previous reports that suggest the presence of ACKR3 
in resting epithelial tissues. In one study, ACKR3 expression is upregulated in lung 
tissue upon LPS stimulation, a fact that implicates ACKR3 expression with 
inflammatory conditions is the lung epithelium. Although the authors presented gene 
expression real-time PCR data to assess the ACKR3  upregulation after 
lipopolysaccharide (LPS) treatment, they used immunofluorescence to assess 
ACKR3 localisation in the lung tissue. More specifically, they used a polyclonal anti 
ACKR3 antibody (sc-107515; Santa Cruz Biotechnology) that has not been validated 
for its specificity. Furthermore, taking into account the anti ACKR3 antibody validation 
data presented in this chapter, and general concerns about the specificity of anti 
ACKR3 antibodies, the findings of this study about ACKR3 expression in the lung 
epithelium should be considered carefully300.  
 
One of the major obstacles in ACKR3 studies is the lack of specific anti ACKR3 
antibodies. Regarding this, we used the ACKR3/GFP reporter mouse to validate the 
anti ACKR3 antibody clones 10D1 and 11G8. Comparison of the ACKR3 antibody 
stained cell populations with the GFP fluorescence revealed that both antibodies 
were less efficient at staining the GFP/ACKR3 positive cells, and they also stained 
non-specifically in certain cell types. Our data are in agreement with the previous 
reports301 about the non-specific nature of ACKR3 antibodies and explained several 
discrepancies in the literature about AKCR3 expression in different tissues.   
  
 
  
  
  
  
  
 133 
CHAPTER 4  
Generation of ACKR3 knock out cell lines 
using CRISPR/Cas technology  
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4. 1 Introduction and aim of the chapter  
  
4.1.1 The CRISPR/Cas system   
CRISPR stands for clustered regularly interspaced short palindromic repeat DNA 
sequences. CRISPR had been noticed initially as an unusual  DNA repeat element in 
prokaryotic organisms before it was recognised as part of the bacterial immune system 
and subsequently it has been exploited as a genome-editing tool. The CRISPR repeats 
are separated by non-repeating DNA sequences in the prokaryotic genome that are 
called spacers. The CRISPR gene-editing technology is based on the Cas9 protein with 
endonuclease activity, that forms complexes with short guide RNAs that can ‘’guide’’ the 
Cas9 with high specificity to the DNA target region of the genome.  
 
Cas9 nuclease is a powerful tool for genome editing, which works by inducing double-
strand breaks (DSBs) at its target site, in turn stimulating two endogenous DNA damage 
repair pathways. The high fidelity homology-directed repair (HDR) pathway, needs a 
homologous template for recombination to repair DSBs. The non-homologous end-
joining (NHEJ) pathway, does not require a template and frequently produces insertions 
or deletions (indels) as a consequence of repair. Exogenous HDR templates can be 
designed and introduced along with Cas9 and sgRNA to promote exact sequence 
alteration at a target locus; however, this process typically occurs only in dividing cells 
and at low efficiency302,303.   
 
The wild-type Cas9 enzyme makes use of two conserved nuclease domains, HNH and 
RuvC, to cleave DNA. A “nickase” mutant (Cas9n) can be generated by alanine 
substitution at crucial catalytic residues. More specifically D10A substitution inactivates 
the RuvC domain while N863A substitution inactivates HNH domain. A pair of nickases, 
appropriately spaced and oriented at the same locus, can effectively generate DSBs with 
high specificity and low off-target activity304.  
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The main aim of this chapter was the generation of ACKR3 and CXCR4 knock out (KO) 
cancer cell lines to define ACKR3 involvement in cancer progression and metastatic 
potential. The KO cell lines generated in this chapter were used in two well-characterised 
and established mouse cancer models in chapter 5 to interrogate ACKR3 contribution in 
cancer in an in vivo setting. Regarding this, we took advantage of CRISPR/Cas9 genome 
editing technology to generate ACKR3 and CXCR4 knock out cell lines. For our studies, 
we generated two ACKR3 and CXCR4 KO B16F10 cell lines and an ACKR3 KO  Lewis 
Lung Carcinoma (LLC) cell line. The workflow of the generation of the KO cell lines 
included: a) transfection of Cas9 GFP plasmid in B16F10/LLC cells, b) single-cell sorting 
of GFP positive cells in 96 well plates, c) clonal expansion and genomic PCR of the gene 
of target and d) KO validation by Sanger sequencing of the genomic PCR products 
(Figure 4.1).  
 
Figure 4.1 Schematic depiction of CRISPR/Cas9 workflow for the generation of KO 
cell lines. The strategy included transfection of Cas9 – GFP plasmid in B16F10/ LLC 
cells, single-cell sorting of the GFP positive cells in 96 well plates, clonal expansion and 
genomic PCR/ Sanger sequencing validation of the clones. 
 
  
Cris p r w o r k flo w 
B16F10/L L C 1 
gPCR c lo n e s / 
San g e r s e q u e n c i n g 
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4.2 Generation of B16F10 ACKR3 and CXCR4 KO cell lines  
  
For the generation on the gene KO cell lines, we employed the CRISPR/Cas9 nickase 
approach. This approach has the advantage that it almost eliminates the possibility of 
off-target effects that is one of the main disadvantages associated with the wild type 
Cas9 nuclease. CRISPR/Cas9 nickase mutants introduce single-strand breaks in DNA 
(nicks) instead of the double-strand breaks created by wild type Cas enzymes. In order 
for the nickase endonucleases to create a double-strand break, the two pairs of gRNAs 
that target opposite strands of the DNA need to be in close proximity (less than 20 base 
pairs). These double nicks create a double-strand break (DSB) that is repaired using the 
error-prone non-homologous end joining (NHEJ) DNA repair pathway (Figure 4.2). One 
of the main disadvantages of using the Cas9 nickases approach is the reduced efficiency 
in generating DSB.  
 
Figure 4.2 Schematic depiction of the CRISPR/ Cas9 nickase mechanism of action 
Cas9 nickase proteins forms different complexes with two gRNAS (gRNA1 and gRNA2) 
that can bind to adjacent genomic target regions (Target 1 and 2) preceding the Cas9 
recognition sequences PAM1 and 2. The nickase/gRNA complexes after binding the 
DNA create double-strand breaks (DBS) that can be repaired using the error-prone non-
homologous end joining (NHEJ) or the high fidelity homology-directed repair (HDR) 
mechanism (source Addgene). 
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To design the guide RNAs, we used the crispr.mit.edu web tool designer (the sequences 
of mouse ACKR3 and mouse CXCR4 guides and plasmids generated for this study are 
presented in Appendices section). For every KO, a pair of nickases are needed, so a 
pair of guide RNAs were designed for each gene KO (Figures 4.3 and 4.4). These 20 bp 
long guide RNAs were cloned into the pSpCas9n(BB)-2A- GFP plasmid vector (PX461 
Addgene) that includes as a selection marker the GFP protein that is attached to the C 
terminal of the Cas9 nickase protein. The GFP tag allows the selection of GFP positive 
cells by flow cytometry.  
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Figure 4.3  Representative image that illustrates the location that  the pair of guides 
RNAs aligns to the exon 2 of the mouse ACKR3 gene. The pair of  guide  RNAs bind 
in close proximity to each other and guide the Cas9 nickase protein to generate a double- 
strand break that can lead to gene disruption. ACKR3 protein amino acids that are 
encoded by their respective codons are depicted in different colours. 
10/7/2019 11:39:28 AMCxcr7 (ENSMUSG00000044337) (12772 bp) (from 90213610-90214465 bp)
https://benchling.com/angie/f/lib_ZfIg2Nbt-cxcr7-mouse-lenti/seq_llXlMHOJ-cxcr7-ensmusg00000044337/edit 8/11
TCCCCAGCACCATGTAACCTTAGCTGGGCTGTGTTTGATTTTCTTTCTTGCAGCCTAAGTTAGTTGTTTTCTTTCCTTTCTTTGTGAAGACATCGAAGAGCAAAAGC
AGGGGTCGTGGTACATTGGAATCGACCCGACACAAACTAAAAGAAAGAACGTCGGATTCAATCAACAAAAGAAAGGAAAGAAACACTTCTGTAGCTTCTCGTTTTCG
Cxcr7
AAAACCCGTGAGCATCCTCAGTGTTGACTGAGACCCGAGGTTTCTCATGATGATCTCTCCTGCTTGCCTTTGCTGTAGGTCACTTGGTCGCTCTCCTCAAGACCATG
TTTTGGGCACTCGTAGGAGTCACAACTGACTCTGGGCTCCAAAGAGTACTACTAGAGAGGACGAACGGAAACGACATCCAGTGAACCAGCGAGAGGAGTTCTGGTAC
M
Cxcr7
Ackr3-001 Exon 2
GATGTGCACTTGTTTGACTATGCAGAGCCTGGCAACTACTCTGACATCAACTGGCCATGTAACAGCAGCGACTGCATTGTGGTGGACACTGTGCAGTGTCCCACCAT
CTACACGTGAACAAACTGATACGTCTCGGACCGTTGATGAGACTGTAGTTGACCGGTACATTGTCGTCGCTGACGTAACACCACCTGTGACACGTCACAGGGTGGTA
D V H L F D Y A E P G N Y S D I N W P C N S S D C I V V D T V Q C P T M
Ackr3-001 Exon 2
Cxcr7
GCCTAACAAGAACGTGCTTCTGTATACCCTCTCCTTCATCTACATTTTCATCTTCGTGATCGGCATGATTGCCAACTCTGTGGTGGTCTGGGTGAATATCCAGGCTA
CGGATTGTTCTTGCACGAAGACATATGGGAGAGGAAGTAGATGTAAAAGTAGAAGCACTAGCCGTACTAACGGTTGAGACACCACCAGACCCACTTATAGGTCCGAT
P N K N V L L Y T L S F I Y I F I F V I G M I A N S V V V W V N I Q A
Ackr3-001 Exon 2
Cxcr7
TACATTTTCATCTTCGTGAT
TTGTTCTTGCACGAAGACAT
AGACCACAGGCTACGACACGCACTGCTACATCTTGAACCTGGCCATTGCAGACCTGTGGGTCGTCATCACCATCCCCGTCTGGGTGGTCAGTCTCGTGCAGCATAAC
TCTGGTGTCCGATGCTGTGCGTGACGATGTAGAACTTGGACCGGTAACGTCTGGACACCCAGCAGTAGTGGTAGGGGCAGACCCACCAGTCAGAGCACGTCGTATTG
K T T G Y D T H C Y I L N L A I A D L W V V I T I P V W V V S L V Q H N
Ackr3-001 Exon 2
Cxcr7
CAGTGGCCCATGGGGGAGCTCACATGCAAGATCACACACCTCATTTTCTCCATCAACCTCTTTGGGAGCATCTTCTTCCTCGCCTGCATGAGCGTGGACCGCTATCT
GTCACCGGGTACCCCCTCGAGTGTACGTTCTAGTGTGTGGAGTAAAAGAGGTAGTTGGAGAAACCCTCGTAGAAGAAGGAGCGGACGTACTCGCACCTGGCGATAGA
Q W P M G E L T C K I T H L I F S I N L F G S I F F L A C M S V D R Y L
Ackr3-001 Exon 2
Cxcr7
CTCCATCACCTACTTCACCGGCACCTCCAGCTATAAGAAGAAGATGGTACGCCGTGTTGTATGCATCTTGGTGTGGCTGCTGGCCTTCTTTGTGTCCCTGCCTGATA
GAGGTAGTGGATGAAGTGGCCGTGGAGGTCGATATTCTTCTTCTACCATGCGGCACAACATACGTAGAACCACACCGACGACCGGAAGAAACACAGGGACGGACTAT
S I T Y F T G T S S Y K K K M V R R V V C I L V W L L A F F V S L P D
Ackr3-001 Exon 2
Cxcr7
CCTACTACCTGAAGACGGTCACATCTGCTTCCAACAATGAGACCTACTGCAGGTCCTTCTACCCCGAGCACAGCATCAAGGAGTGGCTGATCGGCATGGAGCTGGTC
GGATGATGGACTTCTGCCAGTGTAGACGAAGGTTGTTACTCTGGATGACGTCCAGGAAGATGGGGCTCGTGTCGTAGTTCCTCACCGACTAGCCGTACCTCGACCAG
T Y Y L K T V T S A S N N E T Y C R S F Y P E H S I K E W L I G M E L V
Ackr3-001 Exon 2
Cxcr7
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Figure 4.4  Representative image that illustrates the location that the pair of guide 
RNAs aligns to the exon 2 of the mouse CXCR4 gene.  The pair of  guide  RNAs bind 
in close proximity to each other and guide the Cas9 nickase protein to generate a double- 
strand break that can lead to gene disruption. CXCR4 protein amino acids that are 
encoded by their respective codons are depicted in different colours.  
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After verifying the successful cloning of gRNAs through Sanger sequencing, we tried to 
optimise the best transfection conditions for efficient delivery and expression of the CAS9 
GFP plasmid into our cell of interest. To this end, we transfected B16F10 cells when they 
reached 60-70% confluency, using Lipofectamine 2000 since it has been described in 
the literature as effective in transfection of these cells. We harvested the cells at two 
different time points: six hours and overnight (16 hours) but also using different 
Lipofectamine/plasmid DNA ratios.  
 
Subsequently, to assess the transfection efficiency, cells were analysed for GFP 
fluorescence using flow cytometry. Briefly, live cells were selected (Figure 4.5 A), we 
enriched for single cells (doublet cell discrimination) (Figure 4.5 B), and the different 
transfection conditions were evaluated according to GFP fluorescence (Figure 4.5 C). 
We noticed that there was not a significant difference in the transfection efficiencies 
under different conditions, with the only exception being the 3:1 ratio after 6 hours which 
exhibited the lowest efficiency (Figure 4.5 C, D). More specifically, after 6 hours the 3:1 
ratio lead to transfection efficiency of 26.90%, the 4:1 lead to 37.60%, the 5:1 to 38.80% 
and the 6:1 to 45.30% respectively. The transfection efficiencies after overnight 
incubation for the same DNA/ Lipofectamine ratios were 37.60%, 38.90%, 40.70% and 
41.60% (Figure 4.5 D). 
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Figure 4.5 Flow cytometry-based assessment of transfection efficiency in B16F10 
cells. A) B16F10 live B) single cells were selected for the analysis. C,D) Different ratios 
of Lipofectamine 2000 / Cas9 GFP plasmid DNA were evaluated for transfection 
efficiency (GFP positivity) after 6 hours and overnight incubation(16 hours).   
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4.3 B16F10 single-cell sorting of KO cells lines  
  
Regarding the aforementioned, we decided to use the 4:1 Lipofectamine/ DNA ratio and 
incubate the cells overnight with the transfection mixture. The next day we single-cell 
sorted the cells in a 96-flat bottom well plate. Appropriate controls were included for 
setting the GFP positivity during sorting. More specifically, we included two control 
conditions for the B16F10 cells: untransfected and mock-transfected to assess the GFP 
autofluorescence.  
Subsequently, we set the GFP positive gates during sorting. Then we single-cell sorted 
cells that belonged to the GFP positive population, excluding the top 10% of the brightest 
population, as this cell population usually exhibits lower survival rates after sorting. Cells 
were sorted in flat bottom 96 well plates containing DMEM + 20% FBS without antibiotics 
(the presence of antibiotics usually decrease cell survival after single-cell sorting) (Figure 
4.6). We noticed that almost 54% of the transfected cells were GFP positive (Figure 
4.6C).  
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Figure 4.6 Flow cytometry plots from single-cell sorting of B16F10 ACKR3/CXCR7 
KO cells. Cells were sorted 24 hours post-transfection. A) untransfected control i) 
B16F10 live cells were selected ii) gates were set to determine FITCH/GFP positivity B) 
mock-transfected control i) B16F10 live cells were selected and ii) gates were set to 
determine FITCH/GFP positivity. C) ACKR3 EGFP CAS9 transfected cells i) live cells 
were selected ii) FITCH/GFP positive cells were selected. 
B16F10
B16F10 MOCK TRANSFECTED
ACKR3 KO EGFP CAS9 TRANSFECTED
A
B
C
i ii
i ii
i ii
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4.4 Clonal expansion and evaluation of the clones  
  
After single-cell sorting, the clones were incubated and allowed to expand until they 
reached 80-90% confluency. For the B16F10 cell line, this occurred after two weeks. 
During the expansion period, the medium was replaced every 3-4 days. When the cells 
reached the desired confluency, one third of the cells from each well was passaged to 
retain the clones until KO verification and the remaining two-thirds were used for genomic 
DNA extraction (detailed in Materials and Methods, section 2.4.5) and genomic PCR 
products were analysed in a 2% agarose gel electrophoresis (Figures 4.7 and 4.8).  The 
analysis of the genomic PCR products was essential in order be able to identify possible 
KO clones by observing the band pattern and comparing it with the wt control PCR 
bands. This is an efficient alternative approach in cases in which there are not good 
antibodies available to allow for the identification of the gene KO clones at the protein 
level. 
 
 
 
 
 
 
 
 
 
 
  
 145 
 
Figure 4.7 Representative images of genomic PCR products of B16F10 CXCR4 KO 
clones. The first and the last lanes were loaded with DNA ladder 100bp(L). Clones in 
which the genomic PCR products were different in size than the wt were selected for 
further analyses. These differences in PCR products size are an indication of INDELs 
(insertions/ deletions) that occurred after Cas9 cut the genomic DNA. Circled in red are 
some of the clones that were chosen for further analyses. Control PCR product from Wild 
type (wt) B16F10 cells was also included to allow comparison.  
  
  
  
 
  
 146 
We compared the size of the DNA band with the DNA band from the wild type PCR 
product, but also, selected for further analyses clones that had a different number of 
bands than the wt. The differences in the size of the PCR products are a good indication 
that Cas9 cut the genomic DNA, and random insertions/deletions (INDELs) occurred. 
The existence of more than one band in the same clone is a strong indication of 
heterozygosity. For example, in the same clone, maybe one allele has a deletion while 
the other has an insertion or is wt. Furthermore, in biallelic KO clones we mostly observed 
that the gene alleles exhibited different alterations, for example, ACKR3 KO clones 14 
and 15, maybe one allele had one small deletion and the other a large insertion. Despite 
these observations, we expect that KO clones will exhibit the same phenotype in our in 
vivo models in chapter 5. Heterozygous KO clones (1 KO allele and 1 wt) were not tested 
in vivo.  
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Figure 4.8 Representative images of genomic PCR products of B16F10 ACKR3 KO 
clones. The first and the last lanes were loaded with DNA ladder 100 base pair(L). Wild 
type (wt) control PCR product was also included to allow comparison. Clones in which 
the genomic PCR products were different in size than the wt PCR were selected for 
further analyses. These differences in PCR products size are an indication of INDELs 
(insertions/ deletions) that occurred after Cas9 cut the genomic DNA. The existence of 
more than one band in the same clone is a strong indication of heterozygosity. Circled 
in red are some of the clones that were chosen for further analyses.  
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4.5 Generation of LLC ACKR3 KO cell lines  
 
Following the same approach, we generated LLC ACKR3 KO cells. We used the already 
validated in the literature, 4:1 lipofectamine/DNA ratio for the GFP Cas9 transfection and 
incubated the cells overnight. The following day the cells were single cell sorted in flat 
bottom 96 well plates. Untransfected and mock-transfected cells were included as 
controls to determine background fluorescence (Figure 4.9). Almost 17% of the cells 
were Fitch/ GFP positive (Figure 4.9 D).  
 
Figure 4.9 Flow cytometry plots from single-cell sorting of LLC cells for ACKR3 
KO cell line generation. A) Live LLCs (68,3% of the total cell population) were selected. 
B) Untransfected LLC served as a negative GFP control C) Mock transfected served as 
a negative GFP control for gating setting D) LLCs GFP positive cells were selected for 
single-cell sorting. 
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GFP positive single-cell clones were allowed to grow for three weeks until they reached 
80% confluency. At this point, following the same strategy we had for the B16F10 
knockouts generation, we harvested the clones and used some of the cells for genomic 
PCR analysis (Figure 4.10). Clones  that exhibited different band size than the wt product 
were selected for the next step of validation. For example, clones 8,13, 25, 31 among 
others, exhibited smaller size bands the wt and this was a strong indication of the 
occurrence of a deletion in the genomic region that we targeted.  
 
 
Figure 4.10 Representative images of genomic PCR products of LLC ACKR3 KO 
clones. The first and the last lanes were loaded with DNA ladder 100 base pair(L). Wild 
type (wt) control PCR product was also included to allow comparison. Clones that 
exhibited different size than the wt were selected for further analyses. These differences 
in PCR products size are an indication of INDELs (insertions/ deletions) that occurred 
after Cas9 cut the genomic DNA. The existence of multiple bands in the same clone is a 
strong indication of heterozygosity.  
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Subsequently, the clones we selected from the genomic PCR validation step were further 
validated using an Alexa 647 -CXCL12 uptake assay (detailed described in Materials 
and Methods, section 2.5.9). From the literature, we know that LLCs do not express 
CXCR4, a fact that allows us to use this functional assay as a readout to identify ACKR3 
null clones253. Cas9 wt  clones were also used as controls. After the uptake assay, the 
clones were analysed in a flow cytometer to measure fluorescence..All the mean 
fluorescence intensities of the clones were normalised against the control clone Cas10 
(Figure 4.11). The clones that showed the lowest fluorescence – lowest uptake of 
CXCL12- were further validated by Sanger sequencing to confirm the biallelic knockout 
(Figure 4.12).  
 
Figure 4.11 Chemokine uptake assay of Alexa 647 CXCL12 in LLC ACKR3 KO 
clones. The median fluorescence intensity (MFI) of every clone was compared to Cas10 
clone. The data were obtained from three independent experiments. An one-way 
ANOVA test with multiple comparisons and a Bonferroni corrections was applied  
between every ACKR3 KO clone and Cas10 WT clone. Statistical significance is 
indicated as: *P≤0.05, **P≤0.01, 
***P≤0.001, ****P≤0.0001, ns = P>0.05. All error bars represent the SD of the mean.  
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 Chemokines are considered to be ‘’sticky’’ proteins and they can stick to plastic surfaces 
and bind non-specifically to the plasma membrane of the cells. Regarding this, the 
chemokine uptake assay has a high background that make the interpretation of the 
results challenging. In this case, complementary methods should be used to verify the 
results of this assay. 
 
The genomic DNA PCR products of the selected clones were cloned into the pGEM easy 
vector and verified by Sanger sequencing for the existence of a biallelic knockout. Protein 
sequences of the KO clones were aligned with the wt sequence using the Clustal online 
algorithm to verify efficient disruption of the protein product. (Figures 4.12, 4.13 and 
4.14).  
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Figure 4.12 Representative Clustal protein alignment sequence of the LLC murine 
ACKR3 31 KO clone generated by CRISPR/Cas genome editing technology. The 
protein sequence of the KO clone was aligned with the wt sequence using the Clustal 
online algorithm to verify efficient disruption of the protein product. The ACKR3 wt was 
aligned with the sequences  of the two alleles (A1 and A2) of the ACKR3 31 KO clone 
that verified the biallelic KO of the ACKR3 gene.  
  
9/28/19, 12(31 AM
Page 1 of 1https://www.ebi.ac.uk/Tools/services/rest/clustalo/result/clustalo-I20190928-052728-0783-44085229-p2m/aln-clustal_num
CLUSTAL O(1.2.4) multiple sequence alignment
CLONE31A2      MDVHLFDYAEPGNYSDINWPCNSSDCIVVDTVQCPTMPNKNVLLYTLSFIYIFIFVIGMI 60
ACKR3WT        MDVHLFDYAEPGNYSDINWPCNSSDCIVVDTVQCPTMPNKNVLLYTLSFIYIFIFVIGMI 60
CLONE31A1      MDVHLFDYAEPGNYSDINWPCNSSDCIVVDTVQCPTMPNKNVLLYTLSFIYIFIFVIGMI 60
               ************************************************************
CLONE31A2      A----------------------------------------------------------- 61
ACKR3WT        ANSVVVWVNIQAKTTGYDTHCYILNLAIADLWVVITIPVWVVSLVQHNQWPMGELTCKIT 120
CLONE31A1      ANSVVA*----------------------------------------------------- 66
               *                                                           
CLONE31A2      --------------------------TYVTGTSSYKKKMVRRVVCILVWLLAFFVSLPDT 95
ACKR3WT        HLIFSINLFGSIFFLACMSVDRYLSITYFTGTSSYKKKMVRRVVCILVWLLAFFVSLPDT 180
CLONE31A1      ------------------------------------------------------------ 66
                                                                           
CLONE31A2      YYLKTVTSASNNETYCRSFYPEHSIKEWLIGM---------------------------- 127
ACKR3WT        YYLKTVTSASNNETYCRSFYPEHSIKEWLIGMELVSVILGFAVPFTIIAIFYFLLARAMS 240
CLONE31A1      ------------------------------------------------------------ 66
                                                                           
CLONE31A2      ------------------------------------------------------------ 127
ACKR3WT        ASGDQEKHSSRKIIFSYVVVFLVCWLPYHFVVLLDIFSILHYIPFTCQLENVLFTALHVT 300
CLONE31A1      ------------------------------------------------------------ 66
                                                                           
CLONE31A2      ------------------------------------------------------------ 127
ACKR3WT        QCLSLVHCCVNPVLYSFINRNYRYELMKAFIFKYSAKTGLTKLIDASRVSETEYSALEQN 360
CLONE31A1      ------------------------------------------------------------ 66
                                                                           
CLONE31A2      -- 127
ACKR3WT        TK 362
CLONE31A1      -- 66
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Figure 4.13 Representative Clustal protein alignment sequence of the B16F10 
CXCR4 32 KO clone generated by CRISPR/Cas genome editing technology. Protein 
sequences of the 32 CXCR4 KO clone were aligned with the wt sequence using the 
Clustal online algorithm to verify efficient disruption of the protein product. In the second 
row, the CXCR4 wt  sequence is depicted and in the first and third row the sequences of 
the two alleles (A1 and A2) of the 32 CXCR4 KO clone that verified the biallelic KO.  
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Figure 4.14 Representative Clustal protein alignment sequence of the B16F10 
ACKR3 10 KO clone generated by CRISPR/Cas genome editing technology. Protein 
sequences of the  ACKR3 KO clone 10 were aligned with the ACKR3 WT sequence 
using the Clustal online algorithm to verify efficient disruption of the protein product. In 
the first row, the ACKR3 WT sequence is depicted and in the second and third row the 
sequences of the two alleles (A1 and A2) of the ACKR3  KO clone 10 that verified the 
biallelic KO.  
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Subsequently, we evaluated if the cells derived from single-cell clones were proliferating 
equally in vitro. This step is essential to understand if the ACKR3 KO clones had a 
proliferation  defect or advantage compared  to Cas9 controls. It is also useful to 
understand if the clones belonging to the same group proliferate at the same rate. Clones 
that could show serious defects in proliferation and if this phenotype is not consistent 
within the same group had to be eliminated from downstream application since the 
phenotype is probably a problem related to damage during sorting or single-cell 
expansion and not an ACKR3-dependent phenotype. To characterise the clones 
regarding their proliferation rate, we used a flow cytometry-based assay KI67 staining 
(described in detail in Materials and Methods, section 2.5.10). The cells, after staining 
with the KI67 antibody, were analysed using a flow cytometer to measure fluorescence 
intensity. Cas9 control clones (cells deriving from transfection with Cas9 with no guides 
RNAs) were included to compare the proliferation rate. The fluorescence intensity was 
normalised against the control clone Cas10. Most of the clones exhibited the same 
proliferation rate, equal to the Cas9  control clones (Figure 4.15).  
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Figure 4.15 Ki67 flow cytometry-based proliferation assay in LLC ACKR3 KO 
clones. The median fluorescence intensity (MFI) of every clone was normalized to Cas7 
control clone. All ACKR3 KO clones exhibited comparable proliferation rates with the 
Cas9 controls. The data were obtained from three independent experiments. An one-
way ANOVA test with multiple comparisons and a Bonferroni correction was applied  
between every ACKR3 KO clone and Cas10 WT clone.  *P≤0.05, **P≤0.01,***P≤0.001, 
****P≤0.0001, ns = P>0.05. All error bars represent the SD of the mean. 
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4.6 Summary and discussion of the chapter  
  
In chapter 4, we employed CRISPR/Cas genome editing technology, to generate single 
gene knock out cell lines, null for ACKR3 or CXCR4. The purpose of this approach was 
to use these KO cell lines in chapter 5 in vivo to model ACKR3 and CXCR4 involvement 
in cancer. Our strategy included the use of the double nickase approach that significantly 
reduces off-target effects.  
We chose B16F10 murine melanoma cells, a very well established and characterised 
cell line, to study the contribution of ACKR3 to the early events of metastasis (seeding) 
in the lung. For this purpose, we generated two different B16F10 knock out cell lines. 
More specifically, we generated B16F10 CXCR4 null cells and B16F10 ACKR3 null cells.  
 
Subsequently, we generated Lewis Lung Carcinoma (LLC) ACKR3 null cells. We chose 
this cell line because it is commonly used in research for tumour development studies, 
but also because ACKR3 is significantly upregulated in human lung cancer. Even though 
it is widely used in cancer studies, the LLC cell line is not fully characterised regarding 
the mutation burden in crucial oncogenes. To this end, it is challenging to classify this 
cell line as Lung Adenocarcinoma, the Lung Squamous Carcinoma or the mixed 
(Adenosquamous) lung cancer subtype. Despite this, this cell line is a useful tool in 
tumour development and tumour growth studies.  
During the process of generating ACKR3 and CXCR4 knockout cell lines, one obstacle 
we needed to overcome was the lack of specific antibodies for ACKR3 but also for 
CXCR4. Usually, the validation of knockout cell lines requires verification at the protein 
level that the targeted gene of interest does not lead to the expression of any protein 
product. The use of unspecific antibodies while validating knockout cells, can lead to 
false results as knockout cells can appear to still be expressing the targeted protein.  
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To overcome this issue, other complementary assays were used when it is possible and 
finally verify the knockout cell clones using Sanger sequencing. In our case, we used 
Alexa 647 labelled CXCL12 chemokine uptake assay286 and Sanger sequencing to 
validate the ACKR3 knockout in LLCs. In the B16F10 cell line, the validation of both 
ACKR3 and CXCR4 knock out cell lines was carried out using only Sanger sequencing 
of the genomic DNA of a single cell-derived clone. In B16F10 cells, labelled CXCL12 
chemokine uptake assay could not be applied for the validation of ACKR3 and CXCR4 
knockout cells since this cell line expresses both ACKR3 and CXCR4 and both receptors 
can bind and internalise CXCL12305,306.  
Collectively our experimental approach in this chapter provides a useful guideline for 
generating and validating a CRISPR/Cas-mediated gene KO when antibodies against 
the gene of interest are not available.  
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CHAPTER 5  
The role of ACKR3 in cancer  
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5.1 Introduction and aims of the chapter  
 
The aims of this chapter were: A) to use the information deposited in publicly available 
cancer databases to get information about ACKR3 expression in different types of human 
cancers. Furthermore, in these databases we can get information about the mutational 
burden (if any) of ACKR3 in different types of cancer B) to assess the role ACKR3  in 
cancer development using in vivo mouse models. Two well established and 
characterised mouse models where used. First, the B16F10 melanoma model was used 
to understand the early steps of metastasis. Subsequently we used the LLC 
subcutaneous model to determine any involvement of ACKR3 in tumour growth. For both 
models, we used the knockout cell lines that were generated in chapter 4.  
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5.2 Analysis of publicly available datasets for ACKR3 expression in  
cancer  
 
In the era of “Big Data”, it is vital for the research community and the general public to 
be able to access data of high interest like patient data, data from clinical trials and 
genomic data. Data collection and curation can originate from different sources such as 
individual researchers/ research groups, charities/philanthropies, organisations and 
national projects. Data can range from a limited number of sample datasets to fully 
integrated data produced by high throughput technology platforms and thousands of 
samples.  
In any case, there is a need to be general agreement on the way that data are collected, 
curated and stored before they are made available to the scientific community and the 
public.  
To date, there are several publicly available databases with data related to major human 
diseases like cancer, diabetes and autoimmune diseases.  
For the purpose of this study, we exploited the publicly available information deposited 
in these databases to query the expression of ACKR3 gene in different types of human 
cancer.  
  
  
5.2.1 Oncomine platform  
Oncomine platform is an RNA sequencing and DNA microarray web-based database 
that contains a significant amount of data regarding gene expression analyses from 
several studies in the context of cancer. Oncomine database contains gene expression 
datasets from individual cancer studies but also the Cancer Genome Atlas Project (also 
described in this chapter). This platform, apart from being a useful database, also 
provides an easy to use software that allows gene differential expression analyses 
comparing the most significant types of cancer with their respective healthy tissues. 
Furthermore, in Oncomine, there is much information from a variety of cancer subtypes 
and clinical-based and pathology-based analyses307.  
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In our first analysis, we assessed ACKR3 expression using the Oncomine platform. We 
found that ACKR3 expression was seen to be upregulated in two different lung cancer 
studies. More specifically, in the first study (Bhattacharjee Lung) 308, ACKR3 gene 
expression was about 6,4 fold upregulated when 21 human lung squamous cell 
carcinoma specimens were compared to 17 healthy lung specimens as shown by the 
log2 difference of the median of the two groups (Figure 5.1A). In another study309, 
ACKR3 was also upregulated in lung squamous carcinoma 4-fold when 5 human lung 
squamous cell carcinoma specimens were compared with 5 healthy lung specimens  
(Figure 5.1B).   
 A  B 
 
 
Figure 5.1 ACKR3 gene expression in lung cancer based on two different studies 
obtained from the Oncomine platform. A) ACKR3 is upregulated 6.4 fold in 21 human 
lung squamous carcinoma specimens compared to 17 human healthy lung specimens  
in the Bhattacharjee lung study and B) ACKR3 is  4 fold upregulated in the Wachi lung 
study that compared 5 human lung squamous carcinoma specimens compared to 5 
healthy lung specimens. Box-and-whisker plot: Whiskers indicate the 10th and the  90th 
percentile, boxes indicate the 25th to 75th percentile, and horizontal solid lines indicate 
the median. Circles indicate the minimum and maximum values.  
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5.2.2 The Cancer Genome Atlas (TCGA)  
Nowadays, technological advances have led to an explosion of oncogenic analyses and 
generation of a significant amount of data that uncover the complexity involved in gene 
expression patterns in cancer. The Cancer Genome Atlas (TCGA) is a project/ initiative 
that started in 2005, was funded by US government, and had as a goal to identify and 
catalogue genomic and gene expression data from major different human cancers. The 
project was overviewed by the National Cancer Institute (NCI) and the National Human 
Genome Research Institute (NHGRI). The project started with a pilot period study in three 
types of cancer: glioblastoma, lung and ovarian. The information collected in the TCGA 
includes gene expression profile, Single Nucleotide Polymorphisms (SNPs), DNA 
methylation, miRNA profiling and exon sequencing of more than 1000 genomes310.  
 
In cancer, often mutations in genes can lead to loss of function of the gene or lead to 
altered function of the gene protein product. These alterations in genes may cause the 
aberrant growth of cancer cells. Mutations in genes that become oncogenes can be 
inherited or caused by exposure to substances and other environmental conditions. For 
the purposes of this study, we exploited the data deposited in the TCGA database to 
assess if ACKR3 is frequently mutated in different types of human cancers. Our analysis 
of exome sequencing data deposited in TCGA revealed that there is no positive 
correlation between mutations in the ACKR3 gene and tumourigenesis.  
 
Subsequently, we interrogated the ACKR3 gene expression in different types of human 
cancers using data from the TCGA database (Figures 5.2- 5.8). The RNA Seq counts 
were deposited in the form of RSEM log2 (RNA-Seq by Expectation Maximisation). We 
downloaded and analysed these data using Graph Pad Prism software. More 
specifically, unpaired two-tailed t-test was applied to the groups of control vs tumours 
samples. When we compared the gene expression data  expression from cancer patients 
(tumour versus healthy tissue) we observed that ACKR3 gene is significantly upregulated 
in several types of human cancers.   
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More specifically, ACKR3 was upregulated in glioblastoma (GBM), glioma (GBMLGG), 
lung squamous carcinoma (LUSC), Head-Neck Squamous Cell Carcinoma (HNSC) and 
Pan-Kidney cohort (KIPAN)   among others. For the purposes of the present study, we 
decided to focus our analysis on lung cancer subsets. In lung squamous carcinoma 
(LUSC), gene expression of ACKR3  is upregulated 3.62 fold in tumour versus control 
samples (Figure 5.4 B).  
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Figure 5.2 ACKR3 expression in different human cancers as obtained from the 
TCGA database. Tumour samples are depicted with red colour and healthy control 
samples with blue. ACKR3 is A)  upregulated 0.99 fold in 306 Cervical squamous cell 
carcinoma and endocervical adenocarcinoma (CESC) patients versus 3 healthy control 
samples, B) downregulated 0.501 fold in 498 Prostate Adenocarcinoma (PRAD) patients 
versus 52 healthy control samples C)  upregulated 2.67 fold in 891 Pan-Kidney cohort 
(KIPAN) patients versus 129 healthy control samples. An unpaired two-tailed t-test was 
applied to the groups of control vs tumour samples. The expression is depicted in the 
form of RSEM (log2). Statistical significance is indicated as *P≤0.05, **P≤0.01, 
***P≤0.001, ****P≤0.0001, ns = P>0.05. All error bars represent the SD of the mean. 
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Figure 5.3 ACKR3 expression in different human cancers as obtained from the 
TCGA database. Tumour samples are depicted with red colour and healthy control 
samples with blue. ACKR3 is A) downregulated 0.601 fold in 415 Stomach 
Adenocarcinoma (STAD) patients versus 35 healthy control samples, B)  downregulated 
0.553 fold in 517 Lung Adenocarcinoma (LUAD) patients versus 59 healthy control 
samples, C)  upregulated 4.27 fold in 166 Glioblastoma Multiforme (GBM) patients 
versus 5 healthy control samples. An unpaired two-tailed t-test was applied to the groups 
of control vs tumour samples. The expression is depicted in the form of RSEM (log2). 
Statistical significance is indicated as: *P≤0.05, **P≤0.01,***P≤0.001, ****P≤0.0001, ns 
= P>0.05. All error bars represent the SD of the mean. 
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Figure 5.4 ACKR3 expression in different human cancers as obtained from the 
TCGA database. Tumour samples are depicted with red colour and healthy control 
samples with blue. ACKR3 is A) downregulated 0.324 fold in 408 Urothelial Bladder 
Carcinoma (BLCA) patients versus 19 healthy control samples, B)  upregulated 3.62 fold 
in 501 Lung Squamous Carcinoma (LUSC) patients versus 51 healthy control samples, 
C)  upregulated 3.21 fold in 696 Glioma (GBMLGG) patients versus 5 healthy control 
samples. An unpaired two-tailed t-test was applied to the groups of control vs tumour 
samples. The expression is depicted in the form of RSEM (log2). Statistical significance 
is indicated as: *P≤0.05, **P≤0.01,***P≤0.001, ****P≤0.0001, ns = P>0.05.All error bars 
represent the SD of the mean. 
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Figure 5.5 ACKR3 expression in different human cancers as obtained from the 
TCGA database. Tumour samples are depicted with red colour and healthy control 
samples with blue. ACKR3 is A) downregulated 0.933 fold in 179 Pancreatic 
adenocarcinoma (PAAD) patients versus 4 healthy control samples, B)  upregulated 1.96 
fold in 522 Head-Neck Squamous Cell Carcinoma (HNSC) patients versus 44 healthy 
control samples, C) downregulated 0.438 fold in 509 Thyroid Cancer (THYCA) patients 
versus 59 healthy control samples. An unpaired two-tailed t-test was applied to the 
groups of control vs tumour samples. The expression is depicted in the form of RSEM 
(log2). Statistical significance is indicated as: *P≤0.05, **P≤0.01, ***P≤0.001, 
****P≤0.0001, ns = P>0.05.All error bars represent the SD of the mean. 
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Figure 5.6 ACKR3 expression in different human cancers as obtained from the 
TCGA database. Tumour samples are depicted with red colour and healthy control 
samples with blue. ACKR3 is A) downregulated 0.782 fold in 546 Uterine Corpus 
Endometrial Carcinoma (UCEC) patients versus 35 healthy control samples, B)  
downregulated 0.547 fold in 66 Kidney Chromophobe (KICH) patients versus 25 healthy 
control samples, C)upregulated 2.34 fold in 184 Pheochromocytoma and Paraganglioma 
(PCPG) patients versus 3 healthy control samples An unpaired two-tailed t-test was 
applied to the groups of control vs tumour samples. The expression is depicted in the 
form of RSEM (log2). Statistical significance is indicated as: *P≤0.05, 
**P≤0.01,***P≤0.001, ****P≤0.0001, ns = P>0.05.All error bars represent the SD of the 
mean. 
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Figure 5.7 ACKR3 expression in different human cancers as obtained from the 
TCGA database. Tumour samples are depicted with red colour and healthy control 
samples with blue. ACKR3 is A) downregulated 0.503 fold in 167 Rectum 
Adenocarcinoma (READ) patients versus 10 control samples, B) downregulated  0.656 
fold in 291 Kidney renal papillary cell carcinoma (KIRP) patients versus 32 healthy 
control samples, C) upregulated 1.47 fold in 36 Cholangiocarcinoma (CHOL) patients  
versus 9 healthy control samples. An unpaired two-tailed t-test was applied to the groups 
of control vs tumour samples. The expression is depicted in the form of RSEM (log2).  
Statistical significance is indicated as *P≤0.05, **P≤0.01,***P≤0.001, ****P≤0.0001, ns = 
P>0.05.All error bars represent the SD of the mean. 
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Figure 5.8 ACKR3 expression in different human cancers as obtained from the 
TCGA database. Tumour samples are depicted with red colour and healthy control 
samples with blue. ACKR3 is  A) downregulated 0.896  fold in 373 Liver Hepatocellular 
Carcinoma (LIHC) patients versus 50 control samples. B) upregulated 2.03 fold in 185 
ACKR3 Esophageal Carcinoma (ESCA) patients  versus 11 control samples. C) 
downregulated 0.694 fold in 600 Stomach and Esophageal carcinoma (STES) patients 
versus 46 control samples An unpaired two-tailed t-test was applied to the groups of 
control vs tumour samples. The expression is depicted in the form of RSEM (log2). 
Statistical significance is indicated as: *P≤0.05, **P≤0.01,***P≤0.001, ****P≤0.0001, ns 
= P>0.05.All error bars represent the SD of the mean. 
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Figure 5.9 ACKR3 expression in different human cancers as obtained from the 
TCGA database.  Schematic summary of Figures 5.2 – 5.8. Tumour samples are 
depicted with red colour and healthy control samples with blue. 
The expression is depicted in the form of RSEM (log2). An unpaired two-tailed t-test 
was applied to the groups of control vs tumour samples. Statistical significance is 
indicated as: *P≤0.05, **P≤0.01,***P≤0.001, ****P≤0.0001, ns = P>0.05.All error bars 
represent the SD of the mean. 
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5.3 ACKR3 involvement at the early stages of metastasis in the lung  
  
To investigate if ACKR3 is involved in the early stages of the metastatic process in the 
lung, we used the established pseudometastatic B16F10 melanoma mouse model.  
The role of CXCR4 in cancer metastasis has been extensively investigated in the 
literature and its roles in secondary metastatic site colonization already established. In 
this model, we already know from the literature that CXCR4 silencing impairs the 
metastasis/ colonization of the tumour cells in the lung. We also know that this phenotype 
is CXCL12- dependent, as the use of CXCL12 antagonists phenocopied the CXCR4 
knockdown311,312.  
 
To understand the role of ACKR3 in this model, we used the ACKR3 B16F10 KO clone 
10 that we generated in chapter 4. We also included the CXCR4 KO B16F10 clone 32, 
that could serve as a control of a known phenotype in this model. We injected 2x105 
B16F10 cells into the tail vein of 7-8 week old female C57BL/6 mice. After two weeks, 
mice were sacrificed according to Schedule 1 procedures, lungs were removed and were 
examined macroscopically and microscopically. Every lung was assessed for tumour 
burden by counting all tumour nodules.  
 
We observed a reduction in the number of pulmonary tumour nodules in the ACKR3 KO 
group compared to the wt ones. More specifically, in the ACKR3 KO group, we observed 
a reduction from the mean value of 230 nodules observed in the WT group, to around 
100 nodules. The CXCR4 KO group exhibited less tumour burden than both the wt and 
the ACKR3 KO group. The mean number of nodules per lung in the CXCR4 KO group 
was around 50 (Figure 5.10). Our observation in the CXCR4 KO group is in agreement 
with what others observed in the model, using other techniques (siRNA/shRNA 
knockdown)313.This ACKR3 phenotype has not been described before, but there is 
controversy in the literature about the ability of ACKR3 to drive chemotaxis thus 
metastasis. Further investigation is needed to clarify if this phenotype is CXCR4 driven 
or if other mechanisms contribute.  
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Figure 5.10 ACKR3 KO reduces the pulmonary metastatic nodules in the B16F10 
melanoma metastatic model. ACKR3 knockout B16F10 cells exhibit reduced metastasis, 
as assessed by the number of tumour nodules counted in the lung two weeks’ post-injection. 
CXCR4 knockout B16F10 cells served as a control of a known phenotype in this model. 
Groups of mice were blinded and subsequently the tumours were counted by two individuals 
to ensure an unbiased counting. Non-parametric Kruskal Wallis test was applied for multiple 
comparisons. Both KO groups (ACKR3 KO and CXCR4 KO were compared against the 
control (wt) group. Statistical significance is indicated as: *P≤0.05, **P≤0.01,***P≤0.001, 
****P≤0.0001, ns = P>0.05. All error bars represent the SD of the mean. 
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 5.4 ACKR3 role in tumour growth  
 
Finally, to assess the role of ACKR3 in tumour growth, we used the LLC ACKR3 KO 
clone 31 that we generated in chapter 4 in a subcutaneous mouse model. Briefly, 2x105 
LLC cells were injected subcutaneously in the flank of 7-8 week old female C57BL/6 
mice. On day nine after injection, tumours became palpable, and we could start the 
measurements. Tumours were measured every second day, and on day eighteen, when 
they reached the largest acceptable size, the protocol was terminated according to the 
Home Office Project Licence regulations (Figure 5.11). On day eighteen, tumours were 
resected, weighed and pictures taken.  
 
In this model, we observed that ACKR3 null LLC cells have significantly impaired tumour 
growth. This phenotype has also been observed in a previous study, where ACKR3 was 
silenced using siRNAs. In the same study it was demonstrated that LLC cells do not 
express CXCR4 in vitro, but it needs to be determined if the expression of CXCR4 
increases in vivo in these cells253. This will allow us to clarify if the ACKR3 null phenotype 
is CXCR4-driven or if there are other mechanisms involved that drive this phenotype.  
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Figure 5.11 ACKR3 absence impairs the tumour growth in an LLC subcutaneous 
mouse model. A) ACKR3 KO LLC exhibited a significant reduction in tumour growth 
after 18 days. One-way analysis of variance (ANOVA) was applied with Tukey’s 
correction for multiple comparisons. B) Tumour weight on day 18, was also significantly 
reduced in the ACKR3 KO group. Paired t student’s test was applied.  C) Images of wt 
(upper row) tumours and ACKR3 KO (lower row) on day 18. Statistical significance is 
indicated as, *P≤0.05, **P≤0.01,***P≤0.001, ****P≤0.0001, ns = P>0.05.All error bars 
represent the SD of the mean. 
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5.5 Summary and discussion of the chapter   
  
In chapter 5, we exploited information from the publicly available cancer databases such 
as TCGA, but also from the Oncomine software, to interrogate the ACKR3 expression in 
different types of human cancers. In the analysis of the data obtained from the TCGA, 
we identified several types of human cancers in which ACKR3 is upregulated including 
glioblastoma (GBM), glioma (GBMLGG) and lung squamous carcinoma (LUSC) among 
others. Subsequently, we used the knockout cell lines that we generated in chapter four, 
to investigate the role of ACKR3 in tumour growth but also in the ‘’seeding step’’ during 
metastasis in the lung.  
 
To this end, B16F10 ACKR3 and CXCR4 KO cells were injected into the tail vein of 
C57BL/6J mice, and after two weeks we assessed tumour burden in the lung. We 
observed that the CXCR4 KO cell group exhibited significantly reduced tumour burden 
in the lung – a phenotype that is previously described in the literature.  
ACKR3 KO B16F10 cell group phenocopied the CXCR4 KO, but the tumour burden was 
higher than the one observed in the CXCR4 KO group. This phenotype indicates a role 
for ACKR3 in the ‘’seeding’’ initial step of metastasis in the lung. Furthermore, if this 
phenotype is CXCR4 dependent or there are other mechanisms involved needs to be 
further investigated.  
 
Finally, we used the LLC subcutaneous tumour model to assess ACKR3 involvement in 
tumour growth. Indeed, we observed a significant reduction in tumour size and weight 
when we implanted LLC ACKR3 null cells in the flank of C57BL/6 mice. This phenotype 
was observed before in a study, where LLCs were knocked down using siRNAs. Our 
study verifies this phenotype, but the mechanism that ACKR3 uses to control tumour 
growth in this model requires further investigation. In our study, the lack of ACKR3 
expression in the tumour cells possibly leads to an increase in the concentration of the 
ACKR3 ligands within the tumour microenvironment.  Since all the in vivo experiments 
were performed on a C57BL/6J mouse strain background, this excludes the involvement 
of CXCL11 (C57BL/6J mice do not express CXCL11) 314in the ACKR3 null phenotype. 
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This fact allows us to suggest a CXCL11-independent mechanism for the observed 
phenotypes in these murine models.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 179 
CHAPTER 6   
Discussion  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
  
 
 
 180 
6.1 Main findings of the study   
  
In the present study, we investigated the involvement of ACKR3 in cancer progression 
and metastatic potential. In the literature, there is a substantial body of evidence that 
indicates that ACKR3 is upregulated in several types of cancers but also the tumour-
associated vasculature. To this end, at first, we tried to query cancer gene expression 
databases to understand in which types of human cancers ACKR3 expression is 
significantly altered. Our analyses revealed that ACKR3 is upregulated in several types 
of human cancer including squamous cell lung carcinoma, among others. Taking into 
consideration these initial findings from patient data, we decided to focus on ACKR3 role 
in lung cancer.   
 
One significant obstacle we encountered in this study is the lack of specific ACKR3 
antibodies. In the present study we validated, for the first time, two commercially 
available anti ACKR3 antibodies using an ACKR3 GFP reporter mouse. Our flow 
cytometry-based validation revealed that both antibodies were non-specific when tested 
in lung stromal cell populations of the ACKR3 reporter mouse. This observation led us to 
conclude that more complementary methods should be used for ACKR3 detection. The 
use of the ACKR3/ GFP reporter mouse allowed us to characterise the expression of 
ACKR3 in stromal cells in the resting lung and trachea. This approach helped identify  
ACKR3 positive cells in three stromal cell types: blood endothelial cells, lymphatic 
endothelial cells and fibroblasts. Although our finding is in accordance with several 
reports in the literature, further characterisation of the GFP/ACKR3 positive populations 
to ensure that the reporter mouse model accurately reflects biology would be useful. 
Probably a real-time PCR in GFP positive sorted populations could further verify ACKR3 
expression in these cell types.  
 
Finally, we employed CRISPR/Cas9 genome editing to generate ACKR3 null cancer cell 
lines to model cancer progression and metastatic potential of  ACKR3 deficient tumours. 
We noticed a significant reduction in both tumour growth and tumour cell colonisation in 
the lung. Our observations are in broad agreement with other studies in the literature.  
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In the context of cancer, tumour endothelial cells support tumour growth by supplying the 
tumour with nutrients, but also by affecting the immune cell infiltration and stromal 
composition of the tumour. In the scientific literature, there are several studies that 
demonstrate that ACKR3 is upregulated in the tumour vasculature. Taking into 
consideration all the endothelial cell functions that ACKR3 regulates, there is the 
possibility that ACKR3 promotes tumour angiogenesis but also the recruitment of 
immune cells that promote tumour growth, such as tumour-associated macrophages 
(TAMs) and tumour associated neutrophils (TANs)315.  
 
Within the tumour microenvironment, hypoxic conditions induce NF kappa B- mediated 
CXCL8 expression in vascular endothelial cells, which results in angiogenesis in breast 
and colon cancer. It has been shown, that CXCL8 induces upregulation of ACKR3, which 
is likely involved in endothelial progenitor cell mediated angiogenesis316.  
Furthermore, tumour associated endothelial cells secrete CXCL12 that promotes 
ACKR3-mediated angiogenesis via ERK1/2 phosphorylation via an autocrine/paracrine 
loop. It is also reported that vascular endothelial growth factor (VEGF) stimulation 
upregulates ACKR3 expression in endothelial cells. VEGF is stimulated by hypoxia that 
is characteristic of tumours and ACKR3 is also stimulated by hypoxia-inducible factor 
(HIF1a). Regarding this, it is likely that once hypoxic conditions are established within 
the tumour, ACKR3 expression by tumour endothelial cells is induced by both HIF1a and 
VEGF. After this, ACKR3 plays a decisive role in tumour-associated angiogenesis and 
subsequent tumour growth317 . 
 
In the cancer literature, there are no studies that can give us information about the 
expression levels of ACKR3 in the lymphatic system or in cancer-associated fibroblasts 
(CAFs), but it would be interesting to assess if there is any alteration in the levels of 
expression in these cells. After our observations about the expression of ACKR3 in the 
resting lung we generated ACKR3 and CXCR4 null murine cancer cell lines using 
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CRISPR/Cas9  genome editing technology to model ACKR3 involvement in lung cancer 
progression but also in the initial seeding steps in cancer metastasis in the lung. We 
observed a role for ACKR3 in both mouse models we employed in chapter 5.   
  
In lung cancer, ACKR3 has been reported to promote tumour development by increasing 
tumour cell proliferation and inhibiting apoptosis. More specifically, in lung cancer, TGF-
β increased ACKR3 expression, and this was correlated with a poor prognosis. In breast 
and prostate cancer, ACKR3 was reported to form heterodimers with EGFR and promote 
tumour cell proliferation in a ligand-independent way318. Finally, in renal cancer, ACKR3 
expression promoted tumour growth by activating the mTOR pathway and ACKR3 
expression was correlated with a poor clinical outcome319.  
 
One of the ligands that ACKR3 scavenges, and which has been associated with tumour 
progression, is CXCL12. ACKR3 is mainly a scavenger receptor for CXCL12, and there 
is the possibility that, by regulating the levels of CXCL12 in the microenvironment, 
ACKR3 assists CXCR4-mediated signalling by preventing CXCR4 saturation. In our 
models, the lack of ACKR3 could cause an increase in the levels of CXCL12 in the 
extracellular milieu. The CXCL12-CXCR4 signalling has been associated with dendritic 
cell trafficking into tumours but also with tumour cell proliferation320. In ovarian cancer 
cells, CXCL12 and hypoxia-induced VEGF synergise to induce neoangiogenesis and 
endothelial cell survival321. 
 
CXCR4 has also been shown to induce proliferation in glioblastoma tumour cells. In 
another study, it was shown that a proliferative phenotype in glioma cells could be 
induced by CXCL12, and that it is mediated through ERK and AKT signalling cascades. 
CXCL12 can also increase proliferation in ovarian cancer cells and prostate 
cancer322,323. In small cell lung cancer (SCLC) cell lines, CXCR4 is almost ubiquitously 
expressed in different cell lines, and CXCL12 can induce proliferation, cell adhesion and 
morphological changes in these cells324. In preclinical models, pharmacological 
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inhibition of CXCR4-CXCL12 signalling using anti-CXCL12 antibodies abrogated tumour 
extravasation and metastasis and reduced tumour growth325,326. Some studies have 
shown that expression of ACKR3 is associated with increased proliferation and adhesion 
properties  in the context of cancer327,328,229.  
  
In prostate cancer, CXCL8 leads to upregulation of ACKR3 that causes a more 
proliferative phenotype in these cells. More specifically transient siRNA silencing of 
ACKR3 in PC-3 and LNCaP human prostate cancer cell lines reduced by more than 50% 
the proliferation rate. The downregulation of ACKR3 blocked the cell cycle and caused 
cell cycle arrest in the G1 phase. Furthermore, exogenous administration of ACKR3 
ligands CXCL11 and CXCL12 did not increase the proliferative ability of those cells. This 
indicates that the ACKR3 driven proliferative phenotype is independent of the ACKR3 
ligands. Instead, the authors proposed that ACKR3 interacts with EGFR (estrogen 
growth factor receptor) and leads to ERK mediated proliferation261.  
 
In a recent clinical study, it has been proposed that ACKR3 is upregulated in prostate 
cancer patients that exhibit resistance after treatment with enzalutamide, a new 
androgen receptor antagonist. These groups of patients exhibited higher levels of 
MAPK/ERK activation. This enzalutamide-resistant phenotype was attributed to elevated 
levels of ACKR3, and is β arrestin/MAPK-dependent but ACKR3 ligand- independent. In 
this study, ACKR3 could serve as a clinical biomarker in this group of patients. 
Furthermore, treatment with MAPK/ ERK inhibitors improved the therapeutic outcome of 
enzalutamide in this resistant group of patients. This study is another example of ACKR3 
providing a survival advantage to tumour cells330.  
 
In a breast cancer study, the authors took advantage of an in vivo bioluminescence 
imaging assay to monitor ACKR3 scavenging of its ligand CXCL12 that was secreted 
within the tumour microenvironment. Furthermore, they used orthotopic human breast 
cancer xenografts, and demonstrated that ACKR3 scavenges CXCL12 and reduces its 
bioavailability within the tumour. They also demonstrated through staining of primary 
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human breast cancers that CXCR4 and ACKR3 are frequently expressed on different 
cell populations within the same tumour331.  
 
Tumour xenografts of human mammary fibroblasts secreting CXCL12, exhibited 
increased proliferation and spontaneous metastasis of CXCR4 positive cancer cells 
when a separate population of cancer cells expressing ACKR3 was present. Finally, the 
use of a CXCL12 inhibitor in orthotopic tumours decreased the ACKR3+ cancer cells’ 
effect on the growth of CXCR4+ cancer cells332,333.  
  
While the role of ACKR3 in promoting cancer growth is well established, the role of 
ACKR3 in the metastatic process is controversial. Cell migration and invasion that lead 
to metastasis require degradation of basement membrane extracellular matrix proteins 
by matrix metalloproteinases (MMPs). ACKR3 expression is associated with the 
secretion of MMP2, MMP3 and MMP9. ACKR3 overexpression is also linked with 
mesenchymal to epithelial transition, which is associated with metastasis. ACKR3 
promotes metastasis in a breast cancer model as well as in hepatocellular carcinoma 
through upregulation of osteopontin334. In a lymphoma model, ACKR3 regulated 
CXCR4-mediated transendothelial migration of tumour cells335.   
 
In contrast, other studies propose a different role for ACKR3 in metastasis. More 
specifically, one study proposed that ACKR3 inhibits breast tumour metastasis by 
decreasing CXCR4-mediated production of metalloproteinase-12 and matrix 
degradation268. In rhabdomyosarcomas, ACKR3 expression was associated with a 
reduced metastatic phenotype336.   
 
Collectively, these paradigms highlight the pleiotropic mechanisms that ACKR3 uses to 
regulate the tumour growth and metastatic potential in different types of cancer. In the 
cancer setting, ACKR3 is working together with other receptors such as CXCR4 and 
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EGFR and can regulate the cell cycle, thus proliferation, metastasis of CXCR4+ cells, 
angiogenesis and cell adhesion207,337. 
 
Apart from the very well described CXCL12-depended mechanism that regulate tumour 
growth and metastasis the other less characterised ACKR3 ligands could play a role in 
the ACKR3 depended  phenotypes observed in this study.  
For example MIF ligand  is a positive regulator for tumour growth in the  Lewis Lung 
carcinoma subcutaneous model. More specifically, the authors reported a significant 
reduction in tumour growth after subcutaneous injection in MIF-1 KO mice or in a mutant 
mouse strain of MIF( Mif P1G mice) that abolishes the MIF topoisomerase enzymatic 
activity. This observation was phenocopied when using a MIF topoisomerase inhibitor in 
the same mouse model. This study could provide a mechanistic explanation in our 
ACKR3 KO  observation in Lewis Lung carcinoma mouse model in chapter 5338. 
 
Furthermore, adrenomedullin, has also being implicated in tumour growth. More 
specifically in vivo administration of an anti- adrenomedullin antibody in a prostate 
tumour xenograft  model abrogated tumour growth. Immunohistochemistry analyses of 
αAM-treated tumours revealed reduced tumour vascularisation, with included a 
reduction in both of blood and  lymphatic endothelial cells339. 
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6.2 Future directions  
  
Based on some interesting initial observations in this study, there are several future 
experimental directions to shed more light on the mechanisms that ACKR3 uses to 
control cancer development.  
Initially, one crucial limitation when working with C57BL/6 mice, is the fact that this mouse 
strain is lacking the expression of a functional CXCL11 protein. CXCL11 is one of the 
two main ligands of ACKR3. The absence of CXCL11 from our in vivo studies presents 
a major disadvantage that the experiments performed on the C57BL/6 genetic 
background, do not fully resemble the human microenvironment. One solution to this 
problem is the use of a different mouse strain that expressed CXCL11, such as the 
DBA/2 or BDF1 mouse strains.  
 
Another important set of experiments will include the use of the ACKR3 LLC KO cell line 
in an orthotopic lung cancer mouse model. Several orthotropic lung cancer mouse 
models have been established in the literature that includes, the intrathoracic injection of 
lung cancer cell lines in the lung with the help of an ultrasound or non-invasive 
approaches with the use of a catheter. The orthotopic cancer mouse models are always 
preferable as they better resemble the microenvironment of the organ where the cancer 
develops340,334.  
 
To understand if the ACKR3 phenotype in our in vivo cancer models is immune system-
driven, the use of immunodeficient mice would be a powerful tool. More specifically, the 
ACKR3 null cancer cells exhibit the same phenotype after being transplanted in 
immunodeficient mice, this would be a strong indication that the ACKR3 KO phenotype 
is immune system independent. On the other hand, if the phenotype resembles the wt 
phenotype, we can consider evaluating the different immune cell subsets that could 
possibly be involved in this process. It is also important to characterise the 
cytokine/chemokine differences between the wt and the ACKR3 null tumours, using 
ELISA or Luminex assays. The use of ACKR3 inhibitors targeting the tumours would also 
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be a useful tool to assess if this approach will generate similar phenotypes like the ones, 
we observed using the ACKR3 null cells.  
  
Another important step would be the visualisation of ACKR3 in human biopsies from lung 
cancer patients. Although there are already several studies that evaluate the expression 
of ACKR3 in cancer biopsies using standard immunohistochemistry methods, the use of 
controversial ACKR3 antibodies in these studies should be taken into account when 
interpreting the results. One more expensive and laborious, but also more suitable, 
method in this case is the visualisation of the ACKR3 mRNA using RNA in situ 
hybridisation approaches (RNA ISH).  
 
Finally, the use of spontaneous lung cancer models will allow us to evaluate the 
expression of ACKR3 in the tumour nodules. These mouse models could also be a useful 
tool to identify expression of ACKR3 in certain cell populations that are considered the 
‘’cells of origin’’ in the lung cancer research field. Several studies have identified small 
stem cell populations residing in the lung but also in the trachea epithelium and that are 
considered to have cancer stem cell properties. These cancer stem cells can differentiate 
into all the cell types of the tumour. One obstacle in the use of spontaneous cancer 
mouse models in the lung cancer field is the lack of mouse models that accurately 
recapitulate patient histology for every lung cancer subtype. Also, we should consider 
that the existing murine cancer models usually have a long latency, that raises the cost 
related to animal care.  
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6.3 Concluding Remarks  
  
ACKR3 acts both as a signalling receptor through β arrestin and as a scavenger receptor 
regulating the equilibrium of its ligands in the extracellular milieu.  
Pharmacological targeting of ACKR3 seems a promising approach in several 
pathological conditions, including cancer. ACKR3 inhibitors have already attracted 
attention and exhibited some promising results in glioblastoma cancer mouse models267.  
Specific ACKR3 agonists or antagonists, depending on the pathophysiological context, 
need to be generated to improve the clinical outcome. One important challenge in these 
efforts is the lack of specificity since ACKR3 belongs to the GPCR family, and there are 
members with high homology with ACKR3. Another critical challenge is the fact that new 
ligands of ACKR3 are being discovered, so we need to fully understand and characterise 
the ACKR3 interactome to appreciate its contribution in different biological settings, 
including the pathophysiological conditions.  
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Schematic representation of the first CRISPR CAS 9 nickase plasmid (pX461 Addgene 
plasmid) targeting the mouse ACKR3(CXCR7) gene. Guide RNAs were cloned 
immediately after the U6 promoter.  
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Sequence illustration that indicates where the first pair of guide RNAs (forward and 
reverse) were cloned in the (pX461 Addgene plasmid).  
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Schematic representation of the second CRISPR CAS 9 nickase plasmid (pX461 
Addgene plasmid) targeting the mouse ACKR3(CXCR7) gene. Guide RNAs were cloned 
immediately after the U6 promoter.  
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10/7/2019 3:21:08 PM(from 1-1177 bp)
https://benchling.com/angie/f/lib_fWqmtNJd-training/seq_LEDFSr1k-cxcr7-ensmusg00000044337-assembly-2/edit 1/8
Cxcr7 (ENSMUSG00000044337) Assembly 2 (9292 bp)
gagggcctatttcccatgattccttcatatttgcatatacgatacaaggctgttagagagataattggaattaatttgactgtaaacacaaagatattagtacaaaa
ctcccggataaagggtactaaggaagtataaacgtatatgctatgttccgacaatctctctattaaccttaattaaactgacatttgtgtttctataatcatgtttt
Human U6 Promoter
tacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaagtatttcgatttct
atgcactgcatctttcattattaaagaacccatcaaacgtcaaaattttaatacaaaattttacctgatagtatacgaatggcattgaactttcataaagctaaaga
Human U6 Promoter
tggctttatatatcttGTGGAAAGGACGAAACACCGTACAGAAGCACGTTCTTGTTgttttagagctaGAAAtagcaagttaaaataaggctagtccgttatcaact
accgaaatatatagaaCACCTTTCCTGCTTTGTGGCATGTCTTCGTGCAAGAACAAcaaaatctcgatCTTTatcgttcaattttattccgatcaggcaatagttga
chimeric guide RNA scaffoldHuman U6 Promoter Guide
CACCGTACAGAAGCACGTTCTTGTT
CATGTCTTCGTGCAAGAACAAcaaa
tgaaaaagtggcaccgagtcggtgcTTTTTTgttttagagctagaaatagcaagttaaaataaggctagtccgtTTTTagcgcgtgcgccaattctgcagacaaatg
actttttcaccgtggctcagccacgAAAAAAcaaaatctcgatctttatcgttcaattttattccgatcaggcaAAAAtcgcgcacgcggttaagacgtctgtttac
chimeric ...scaffold
gctctagaggtacccgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaatagtaacgccaatagggactttcca
cgagatctccatgggcaatgtattgaatgccatttaccgggcggaccgactggcgggttgctgggggcgggtaactgcagttatcattgcggttatccctgaaaggt
CBh
ttgacgtcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggc
aactgcagttacccacctcataaatgccatttgacgggtgaaccgtcatgtagttcacatagtatacggttcatgcgggggataactgcagttactgccatttaccg
CBh
ccgcctggcattGtgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtcgaggtgagccccacgttc
ggcggaccgtaaCacgggtcatgtactggaataccctgaaaggatgaaccgtcatgtagatgcataatcagtagcgataatggtaccagctccactcggggtgcaag
CBh
tgcttcactctccccatctcccccccctccccacccccaattttgtatttatttattttttaattattttgtgcagcgatgggggcggggggggggggggggcgcgc
acgaagtgagaggggtagaggggggggaggggtgggggttaaaacataaataaataaaaaattaataaaacacgtcgctacccccgccccccccccccccccgcgcg
CBh
gccaggcggggcggggcggggcgaggggcggggcggggcgaggcggagaggtgcggcggcagccaatcagagcggcgcgctccgaaagtttccttttatggcgaggc
cggtccgccccgccccgccccgctccccgccccgccccgctccgcctctccacgccgccgtcggttagtctcgccgcgcgaggctttcaaaggaaaataccgctccg
CBh
ggcggcggcggcggccctataaaaagcgaagcgcgcggcgggcgggagtcgctgcgacgctgccttcgccccgtgccccgctccgccgccgcctcgcgccgcccgcc
ccgccgccgccgccgggatatttttcgcttcgcgcgccgcccgccctcagcgacgctgcgacggaagcggggcacggggcgaggcggcggcggagcgcggcgggcgg
CBh
ccggctctgactgaccgcgttactcccacaggtgagcgggcgggacggcccttctcctccgggctgtaattagctgagcaagaggtaagggtttaagggatggttgg
ggccgagactgactggcgcaatgagggtgtccactcgcccgccctgccgggaagaggaggcccgacattaatcgactcgttctccattcccaaattccctaccaacc
CBh
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Sequence illustration that indicates where the second pair of ACKR3 guide RNAs 
(forward and reverse) were cloned in the (pX461 Addgene plasmid).  
  
  
  
 
Schematic representation of the first CRISPR CAS 9 nickase plasmid (pX461 Addgene 
plasmid) targeting the mouse CXCR4 gene. The guide RNAs were cloned immediately 
after the U6 promoter.  
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Sequence illustration that indicates the location that the first pair of CXCR4 guide RNAs 
(forward and reverse) was cloned in the (pX461 Addgene plasmid).  
10/7/2019 9:56:56 PM(from 1-1284 bp)
https://benchling.com/angie/f/lib_fWqmtNJd-training/seq_eDP5Bvoe-cxcr4-ensmusg00000045382-assembly-1/edit 1/7
Cxcr4 (ENSMUSG00000045382) Assembly 1 (9291 bp)
gagggcctatttcccatgattccttcatatttgcatatacgatacaaggctgttagagagataattggaattaatttgactgtaaacacaaagatattagtacaaaa
ctcccggataaagggtactaaggaagtataaacgtatatgctatgttccgacaatctctctattaaccttaattaaactgacatttgtgtttctataatcatgtttt
Human U6 Promoter
tacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaagtatttcgatttct
atgcactgcatctttcattattaaagaacccatcaaacgtcaaaattttaatacaaaattttacctgatagtatacgaatggcattgaactttcataaagctaaaga
Human U6 Promoter
tggctttatatatcttGTGGAAAGGACGAAACACCGGAGCATGACGGACAAGTACgttttagagctaGAAAtagcaagttaaaataaggctagtccgttatcaactt
accgaaatatatagaaCACCTTTCCTGCTTTGTGGCCTCGTACTGCCTGTTCATGcaaaatctcgatCTTTatcgttcaattttattccgatcaggcaatagttgaa
chimeric guide RNA scaffoldHuman U6 Promoter Guide
CACCGGAGCATGACGGACAAGTAC
CCTCGTACTGCCTGTTCATGcaaa
gaaaaagtggcaccgagtcggtgcTTTTTTgttttagagctagaaatagcaagttaaaataaggctagtccgtTTTTagcgcgtgcgccaattctgcagacaaatgg
ctttttcaccgtggctcagccacgAAAAAAcaaaatctcgatctttatcgttcaattttattccgatcaggcaAAAAtcgcgcacgcggttaagacgtctgtttacc
chimeric ...scaffold
ctctagaggtacccgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaatagtaacgccaatagggactttccat
gagatctccatgggcaatgtattgaatgccatttaccgggcggaccgactggcgggttgctgggggcgggtaactgcagttatcattgcggttatccctgaaaggta
CBh
tgacgtcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcc
actgcagttacccacctcataaatgccatttgacgggtgaaccgtcatgtagttcacatagtatacggttcatgcgggggataactgcagttactgccatttaccgg
CBh
cgcctggcattGtgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtcgaggtgagccccacgttct
gcggaccgtaaCacgggtcatgtactggaataccctgaaaggatgaaccgtcatgtagatgcataatcagtagcgataatggtaccagctccactcggggtgcaaga
CBh
gcttcactctccccatctcccccccctccccacccccaattttgtatttatttattttttaattattttgtgcagcgatgggggcggggggggggggggggcgcgcg
cgaagtgagaggggtagaggggggggaggggtgggggttaaaacataaataaataaaaaattaataaaacacgtcgctacccccgccccccccccccccccgcgcgc
CBh
ccaggcggggcggggcggggcgaggggcggggcggggcgaggcggagaggtgcggcggcagccaatcagagcggcgcgctccgaaagtttccttttatggcgaggcg
ggtccgccccgccccgccccgctccccgccccgccccgctccgcctctccacgccgccgtcggttagtctcgccgcgcgaggctttcaaaggaaaataccgctccgc
CBh
gcggcggcggcggccctataaaaagcgaagcgcgcggcgggcgggagtcgctgcgacgctgccttcgccccgtgccccgctccgccgccgcctcgcgccgcccgccc
cgccgccgccgccgggatatttttcgcttcgcgcgccgcccgccctcagcgacgctgcgacggaagcggggcacggggcgaggcggcggcggagcgcggcgggcggg
CBh
cggctctgactgaccgcgttactcccacaggtgagcgggcgggacggcccttctcctccgggctgtaattagctgagcaagaggtaagggtttaagggatggttggt
gccgagactgactggcgcaatgagggtgtccactcgcccgccctgccgggaagaggaggcccgacattaatcgactcgttctccattcccaaattccctaccaacca
CBh
tggtggggtattaatgtttaattacctggagcacctgcctgaaatcactttttttcaggttGGaccggtgccaccATGGACTATAAGGACCACGACGGAGACTACAA
accaccccataattacaaattaatggacctcgtggacggactttagtgaaaaaaagtccaaCCtggccacggtggTACCTGATATTCCTGGTGCTGCCTCTGATGTT
CBh 3xFLAG
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Schematic representation of the second CRISPR CAS 9 nickase plasmid (pX461 
Addgene plasmid) targeting the mouse CXCR4 gene. The guide RNAs were cloned 
immediately after the U6 promoter.  
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Sequence illustration that indicates the location that  the second pair of  CXCR4 guide 
RNAs (forward and reverse) was cloned in the pX461 plasmid (Addgene).  
 
 
10/7/2019 10:03:00 PM(from 1-1177 bp)
https://benchling.com/angie/f/lib_fWqmtNJd-training/seq_1xJpTR9m-cxcr4-ensmusg00000045382-assembly-2/edit 1/8
Cxcr4 (ENSMUSG00000045382) Assembly 2 (9292 bp)
gagggcctatttcccatgattccttcatatttgcatatacgatacaaggctgttagagagataattggaattaatttgactgtaaacacaaagatattagtacaaaa
ctcccggataaagggtactaaggaagtataaacgtatatgctatgttccgacaatctctctattaaccttaattaaactgacatttgtgtttctataatcatgtttt
Human U6 Promoter
tacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaagtatttcgatttct
atgcactgcatctttcattattaaagaacccatcaaacgtcaaaattttaatacaaaattttacctgatagtatacgaatggcattgaactttcataaagctaaaga
Human U6 Promoter
tggctttatatatcttGTGGAAAGGACGAAACACCGTCTTCTGGTAACCCATGACCgttttagagctaGAAAtagcaagttaaaataaggctagtccgttatcaact
accgaaatatatagaaCACCTTTCCTGCTTTGTGGCAGAAGACCATTGGGTACTGGcaaaatctcgatCTTTatcgttcaattttattccgatcaggcaatagttga
chimeric guide RNA scaffoldHuman U6 Promoter Guide
CACCGTCTTCTGGTAACCCATGACC
CAGAAGACCATTGGGTACTGGcaaa
tgaaaaagtggcaccgagtcggtgcTTTTTTgttttagagctagaaatagcaagttaaaataaggctagtccgtTTTTagcgcgtgcgccaattctgcagacaaatg
actttttcaccgtggctcagccacgAAAAAAcaaaatctcgatctttatcgttcaattttattccgatcaggcaAAAAtcgcgcacgcggttaagacgtctgtttac
chimeric ...scaffold
gctctagaggtacccgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaatagtaacgccaatagggactttcca
cgagatctccatgggcaatgtattgaatgccatttaccgggcggaccgactggcgggttgctgggggcgggtaactgcagttatcattgcggttatccctgaaaggt
CBh
ttgacgtcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggc
aactgcagttacccacctcataaatgccatttgacgggtgaaccgtcatgtagttcacatagtatacggttcatgcgggggataactgcagttactgccatttaccg
CBh
ccgcctggcattGtgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtcgaggtgagccccacgttc
ggcggaccgtaaCacgggtcatgtactggaataccctgaaaggatgaaccgtcatgtagatgcataatcagtagcgataatggtaccagctccactcggggtgcaag
CBh
tgcttcactctccccatctcccccccctccccacccccaattttgtatttatttattttttaattattttgtgcagcgatgggggcggggggggggggggggcgcgc
acgaagtgagaggggtagaggggggggaggggtgggggttaaaacataaataaataaaaaattaataaaacacgtcgctacccccgccccccccccccccccgcgcg
CBh
gccaggcggggcggggcggggcgaggggcggggcggggcgaggcggagaggtgcggcggcagccaatcagagcggcgcgctccgaaagtttccttttatggcgaggc
cggtccgccccgccccgccccgctccccgccccgccccgctccgcctctccacgccgccgtcggttagtctcgccgcgcgaggctttcaaaggaaaataccgctccg
CBh
ggcggcggcggcggccctataaaaagcgaagcgcgcggcgggcgggagtcgctgcgacgctgccttcgccccgtgccccgctccgccgccgcctcgcgccgcccgcc
ccgccgccgccgccgggatatttttcgcttcgcgcgccgcccgccctcagcgacgctgcgacggaagcggggcacggggcgaggcggcggcggagcgcggcgggcgg
CBh
ccggctctgactgaccgcgttactcccacaggtgagcgggcgggacggcccttctcctccgggctgtaattagctgagcaagaggtaagggtttaagggatggttgg
ggccgagactgactggcgcaatgagggtgtccactcgcccgccctgccgggaagaggaggcccgacattaatcgactcgttctccattcccaaattccctaccaacc
CBh
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